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General Introduction
This thesis deals with the physiology, growth and application strategy of Akkermansia
muciniphila (Figure 1). This intestinal bacterium lives in the colon of most humans and 
mammals, and degrades the mucus that is produced by the specialised epithelial goblet cells 
of the host. A. muciniphila is highly specialised in degrading mucus, hence the species name 
muciniphila, which loosely translates as ‘loving mucin’. The genus name Akkermansia
derives from Dr. Antoon Akkermans, who was leading the Microbial Ecology group of the 
Laboratory of Microbiology at Wageningen University at the time A. muciniphila was 
isolated and published (Derrien, et al., 2004). Here an introduction is provided into the role 
of the intestinal microbiota in health and disease with specific attention for A. muciniphila,
its properties and impact. In addition, an overview is provided of approaches on how to grow 
and deliver this intestinal microbe for their application in model animals or human studies. 
Figure 1. Image of A. muciniphila obtained by scanning electron microscopy (Image by Laura Huuskonen). 
The role of the faecal microbiota in health and disease
The human colon can be considered as a very densely populated bioreactor. The density of 
microbial cells can reach 1011 cells per gram of faeces for members of the Bacteria and 1010
General Introduction 
9
cells per gram of faeces for that of Archaea. The amount of eukaryotic cells is approximately 
100-1000 fold lower than bacteria and includes protozoa, fungi and multicellular helminths 
(Berg, 1996, Sender, et al., 2016, Hugon, et al., 2017). It is estimated that the amount of 
bacteria is similar to the amount of cells in an average human body (Sender, et al., 2016).
The number of cultured microbial species from the gut has been reviewed and found to reach 
over 1000 (Rajilic-Stojanovic and de Vos, 2014). This number will rapidly increase by the 
recent isolation of hundreds of new candidate species by high throughput methods (Browne, 
et al., 2016, Lagier, et al., 2016). The number of prokaryotic species in the gut based on 
systematic mining of 16S rRNA gene libraries was recently estimated to amount to 
approximately 2500 (Ritari, et al., 2015). This would suggest that over half of the bacterial 
gut species have already been cultured. The intestine of a single adult has been estimated to 
contain at least 500 different bacterial species (Sears, 2005, Steinhoff, 2005). The presence 
and absence of species is influenced by many different factors, including diet, age, host 
genomics, use of antibiotics and the environment in general (Greenhalgh, et al., 2016).
Colonisation in early life is influenced by the delivery mode, diet and the environment of the 
baby, including the presence of siblings (Martin, et al., 2016). Early colonizers are mainly 
species of Bifidobacteria, Bacteroides and Lactobacillus. This early life event has a lasting 
influence on the immune system (Gensollen, et al., 2016).
Correlations between gut microbial species composition and a variety of disorders have been 
described and include many gut-related diseases (Joossens, et al., 2011, Marchesi, et al., 
2016), metabolic diseases (Vrieze, et al., 2010) and more recently also brain-related diseases, 
such as autism and schizophrenia (Dinan, et al., 2013, Zhou and Foster, 2015). However, the 
causal relationships between changes in the microbiota and the onset and subsequent stages 
of associated diseases have rarely been addressed (de Vos and de Vos, 2012).
Even though it is debatable what a healthy microbiota composition is (Clemente, et al., 2012),
it is possible to treat diseases using faecal microbiota transplantations (FMT), as was already 
described in scientific literature in 1958 (Eiseman, et al., 1958). Earlier practices of FMT in 
humans have been documented in the Chinese Djongji dynasty in the fourth century (de Vos, 
2013, Zhang, et al., 2013a). This treatment has demonstrated exceptional good results in case 
of recurrent Clostridium difficile infection, showing a therapeutic effect in 90% of the 
recipients (van Nood, et al., 2013). FMT has also been tested for other diseases and 
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syndromes, including inflammatory bowel disease (IBD), diabetes and metabolic syndrome, 
but with lower success rates (Gupta, et al., 2016). Upon FMT, the microbiota of the recipient 
changes, resulting in a mixture of donor and recipient derived strains (Li, et al., 2016).
Initially, it resembles the microbial composition of the donor, but it deviates to an alternative 
but usually stable composition of either predominantly recipient strains or a mixture of donor 
and recipient strains (Weingarden, et al., 2015, Li, et al., 2016). The application of FMT and 
the relations found between changes in the microbiota and diseases calls for mechanistic 
insights, which can only be obtained with the study of cultured microbes. Therefore, it is 
important to obtain cultured representatives of all species, and preferably even strains, as will 
be discussed below (Hugon, et al., 2017) (Figure 2). 
It was shown in mouse models that changes or interventions in the microbial composition 
may have influences on host metabolism and psychology (Dinan, et al., 2013, Plovier, et al., 
2017). In addition, alterations and interventions in the gut ecosystem may cause diseases, as 
was discovered in the Nobel Prize winning case of Helicobacter pylori, which can cause 
ulcerative colitis (Marshall and Warren, 1984, Ahmed, 2005). The influence of bacteria on 
host health can differ between strains, as was shown for the influence of F. prausnitizii in 
mice (Rossi, et al., 2015, Song, et al., 2016) and the well-described differences between 
probiotic strains in human (Hill, et al., 2014). So, to study the causal relationships between 
bacterial species and compositions in general, we need to culture not only all species, but 
preferably multiple strains per species.
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Figure 2. Correlations between bacterial relative abundances and metabolic status can be observed. Cultured 
representatives of species negatively correlating with disease should be obtained for intervention studies to study 
the causality. 
The niche of Akkermansia muciniphila in the colon
The high number species described to be present in the microbiota live in complex microbial-
ecologic networks with high competition for nutrients, usually from our diet. There are 
different ecosystems along the length of the colon, including the caecum, the crypts, the 
mucus layer and the ascending, transverse and descending colon (Donaldson, et al., 2016).
Along the length of the colon, there is a gradient of compounds that are indigestible for 
humans, but for which the bacteria compete. Therefore, it is important for species to fully 
utilize the potential of the niche they live in. 
An important niche in the colon that is largely independent of our diet is the mucus layer 
(Figure 3A). It serves as a barrier between the host and the intestinal microbiota, thereby 
protecting the host, facilitates the flux of digest in the intestine, and provides nutrients to
mucolytic bacteria. Studies in mouse and recently also human have shown that the mucus 
layer can be divided into two separate layers, namely the firm mucus layer and the loose 
mucus layer (Johansson, et al., 2011, Johansson, et al., 2014). The loose mucus layer is the 
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result of proteolytic cleavage of the mucins that form the firm mucus layer (Figure 3B). The 
mucus dependency of A. muciniphila locates this bacterium close to the host in the loose 
mucus layer, leaving only the firm mucus layer as a border between host and bacteria. The 
mucus layer in the colon measures up to several hundred micrometers, which protects the 
host against invading bacteria and thereby infections (Hansson, 2012). A. muciniphila is 
commonly found throughout the colonic mucus layer, but has also been found to be present 
in ileum mucosal biopsies (Wang, et al., 2005). The close proximity to the host could result 
in direct influences of human metabolic processes on the growth of A. muciniphila. Firstly, 
the host requires oxygen for cells to grow. The oxygen diffuses through the mucus layer into 
the colon (Figure 3A). This poses challenges and opportunities for a bacterium characterized 
as strictly anaerobic, such as A. muciniphila. Secondly, the host mucus provides nearly all 
the nutrients that are required by A. muciniphila. This results in a nutrient availability that is 
mainly dependent on host mucin secretion, and not host dietary intake. The presence of 
mucus throughout the intestine (Donaldson, et al., 2016) would allow colonisation by A. 
muciniphila also in the small intestine. The main constituent of mucus is mucin (Figure 3C). 
This glycosylated protein consists of a threonine, proline and serine-rich peptide backbone, 
which is abundantly decorated with O-linked glycans (Figure 3D). Both the glycan and amino 
acids from the peptide backbone are used by A. muciniphila. The uptake of L-threonine by 
A. muciniphila and other mucolytic bacteria during growth in mice was demonstrated by the 
incorporation of stable isotope (13C and 15N) labelled L-threonine into the bacterial cell. The 
labelled L-threonine was dosed intravenously and rapidly incorporated in intestinal mucus as 
this is the fastest dividing tissue in the body, after which bacteria were visualised with 
fluorescent in situ hybridisation and high-resolution secondary ion mass spectrometry 
imaging. It was shown that A. muciniphila effectively incorporated host-protein derived 
amino acids in vivo (Berry, et al., 2013).
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Figure 3. The niche of A. muciniphila. (A) Specialized goblet cells secrete mucus that covers the intestinal cells to 
form the loose and firm mucus layer. Moreover, an oxygen gradient is formed between the epithelial cell and the 
anaerobic intestinal lumen. A. muciniphila resides in this mucus layer and metabolises the mucus to produce and 
export acetate and propionate. Sugars released by mucinases facilitate the production of butyrate by other bacteria 
(adapted from (Belzer and de Vos, 2012). (B) The firm mucus layer is composed of linked mucin molecules. 
Proteolytic cleavages opens this structure to form the loose mucus layer, image from (Johansson, et al., 2011). (C) 
One mucin molecule is comprised of a C-terminal region and N-terminal region that enclose cysteine rich domains 
and PTS-domains. The cysteine rich domains form sulphur bridges and the PTS domains are heavily O-linked 
glycosylated (picture after (Johansson, et al., 2011). (D) Composition of O-linked glycans attached to proline or 
serine residues in the PTS domain of the mucin molecule (Johansson, et al., 2011).
The mucosal glycans contain a plethora of sugars residues that differ between the types of
mucin. The colonic mucin MUC2 contains mannose, N-acetylglucosamine (GlcNAc), N-
acetylgalactosamine (GalNAc), galactose and fucose. In addition to the sugars, a glycan can 
be capped by sulphate and sialic acid residues (Johansson, et al., 2011).
The genome of A. muciniphila ATCC BAA-835 is a circular genome of 2.7 Mbp coding for 
2,176 protein coding genes, of which 65% was assigned a putative function (van Passel, et 
al., 2011). A total of 61 genes was annotated to be potentially involved in mucus degradation, 
including glycosyl hydrolases, sialidases, proteases and sulfatases. This number was later 
expanded to 78 putative mucus-degrading enzymes (Ouwerkerk, 2016a). A. muciniphila is 
predicted to encode 11 sulfatase and 2 sialidase genes that could be capable of desulfonating 
and detaching the sialic acid residues from the mucus molecules. A. muciniphila cell extract 
shows sulfatase activity on purified hog gastric mucus (Derrien, et al., 2004). The 
desulfonation and detachment of sialic acids of mucins makes the glycan groups accessible 
for A. muciniphila (van Passel, et al., 2011, Tailford, et al., 2015).
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The degradation of mucosal glycans is not only important for the growth of the mucolytic 
bacteria, but also releases sugars that can be used by other colonic residents (Derrien, et al., 
2004). It was proposed that the released sugars combined with acetate produced by A. 
muciniphila stimulate growth of butyrate producing-bacteria and thereby also the butyrate 
production (Belzer and de Vos, 2012). This hypothesis was strengthened after the addition 
of mucus to the in vitro intestinal model SHIME, resulting in the M-SHIME model (Van den 
Abbeele, et al., 2013). The amount of butyrate producing bacteria was increased by the 
addition of mucus. This interaction was studied in more detail by co-culturing A. muciniphila
with different butyrate-producing bacteria. This showed that medium containing mucus 
supported the production of butyrate by co-cultures, while either of the species in pure culture 
on the same medium did not result in butyrate production (Belzer et al., 2017).
This example of interactions between species shows that gut ecology is difficult to predict. 
Even when we focus on the ecology of only one niche within the colon, it is still difficult to 
mechanistically understand what the implications of changes are. In addition, for each 
species, there are many strains, which vary between individuals. Each strain could have a 
different influence on the host (Rossi, et al., 2015), so it is important to understand the 
differentiation between strains of one species, and investigate the role of a strain in its niche. 
Strains and species of the family Akkermansiaceae 
A. muciniphila was the first cultured representative of the Verrucomicrobiae phylum from 
the intestinal microbiota and is found throughout lifetime in the colon in humans (Collado, 
et al., 2007, Derrien, et al., 2008). In mammals it is the only cultured species, although DNA 
sequences have been found that could be assigned to species of the Spartobacteria family in 
otters (Ouwerkerk, 2016a). One different species has been isolated from a python and termed 
Akkermansia glycaniphila (Ouwerkerk, et al., 2016b, Ouwerkerk, et al., 2017b). The 16S 
rRNA gene of A. glycaniphila is only 94.4% similar to that of A. muciniphila, and its genome 
shares 79.7% similarity with that of A. muciniphila. The growth substrates are like those of 
A. muciniphila. In a recent study, a total of 22 A. muciniphila strains were isolated from faecal 
samples of Chinese adults, which could be grouped in 12 different clusters based on the 
enterobacterial repetitive intergenic consensus DNA fingerprinting method (Guo, et al., 
2016). Different strains of A. muciniphila were also isolated from many mammals. Many 
strains are derived from mice, but isolates have also been obtained from horse, pig, echidna, 
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apes and elephant (Lagkouvardos, et al., 2016, Ouwerkerk, 2016a). The phylogenetic 
differentiation of the strains does not follow the phylogeny of the mammals, indicating that 
the bacteria colonized the gut after the mammals diversified (Derrien, et al., 2010, 
Ouwerkerk, 2016a).
The isolated A. muciniphila species seem to be very conserved among all mammals, 
including humans. The average genomic nucleotide identity between human isolates is 97.6% 
and only small differences in genomic organization were observed, including an inversion 
and two rearrangements (Ouwerkerk, 2016a). Mammalian isolated show a somewhat higher 
dissimilarity of up to 93.9% genomic nucleotide identity (Ouwerkerk, 2016a). All strains 
showed highly similar annotations for genes involved in mucus degradation, with a maximum 
of 3 out of 78 mucus degrading enzymes possibly missing in the chimpanzee isolates. 
Considering the high similarity between all strains, we focus for the remainder of this thesis 
only on the type strain A. muciniphila strain ATCC BAA-835T.
The physiology of Akkermansia muciniphila strain ATCC BAA-835T
A. muciniphila is an oval shaped Gram-negative bacterium, and the only cultured 
representative of the Verrucromicrobiae in the human gut. The typical size of A. muciniphila
cells is 0.5-1 µm, and the cells appear as either single cells or as diplococci (Derrien, et al., 
2004). Like many anaerobic members of the microbiota, A. muciniphila was described as a 
fermentative bacterium that produces short chain fatty acids (SCFA). The definition of 
fermentation requires the anaerobic degradation of substrates, in which the substrate 
functions as both electron acceptor and electron donor. When oxygen is used for respiration 
as well, a bacterium cannot be considered to be fully fermentative. For respiration, a 
functional electron transport pathway is required, which transports electrons released from 
sugar degradation, via NADH and membrane-associated quinones to a cytochrome. The 
cytochrome finally reduces oxygen to water (Willey, 2008).
The substrates used for fermentative degradation can be derived from colonic mucus, since 
A. muciniphila is capable of utilizing mucus as sole carbon, nitrogen and energy source 
(Derrien, et al., 2004). Predictions on the degradation of monosaccharides released from 
mucins were done by the interpretation of a genome-scale metabolic model (GEM) obtained 
for A. muciniphila (Ottman, et al., 2017a).
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In short, a GEM is a collection of all reactions that are the result of genome annotation. With 
the addition of model constrains, localisation of the reaction, estimated energy requirements 
and the determination of biomass composition, the information can be used for a 
stoichiometric model of metabolism (Baart and Martens, 2012). The model for A. 
muciniphila allowed the prediction on consumption rates of sugars and production rates of 
SCFAs (Ottman, et al., 2017a). The model accurately predicted the degradation of galactose, 
fucose and GlcNAc, but did not predict the degradation of GalNAc or the conversion of 
oxygen (Figure 4).
Figure 4. Metabolic overview of A. muciniphila. The overview shows the degradation of mucin (top right) and 
mucosal sugars. The degradation of GalNAc and reduction of oxygen are indicated with a question mark, indicating 
gaps in the model. Image adapted from (Ottman, et al., 2017a).
The biomass objective function in this model includes all building blocks of the cell (Feist 
and Palsson, 2010). Combined with the reactions to make these building blocks and the sugar 
consumption rates, it can also be predicted what the growth rate of the bacterium is. Finally, 
by summarizing all requirements, it can be predicted what components are essential for 
growth, which can be used in the definition of a minimal growth medium. 
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The first interpretation of the A. muciniphila model for the composition of a defined medium, 
showed that L-threonine is essential for growth. This was caused by the absence of a pathway 
for the synthesis of this amino acid. Moreover, it was predicted that the addition of simple 
sugars would be sufficient to support growth. These predictions were partly confirmed by 
growth experiments, in which it was shown that A. muciniphila can degrade many sugars, 
including glucose, GlcNAc, GalNAc and fucose. Additionally, it was shown that the addition 
of L-threonine increased growth rate and yield (Ottman, et al., 2017a). Still, the addition of 
undefined components such as large amounts of casein tryptone and mucus, or the use of rich 
media such as Columbia broth or brain- heart infusion (BHI) broth was needed to obtain 
growth (Derrien, et al., 2004, Ottman, et al., 2017a). These additions resulted in media with 
undefined composition that could not fully confirm the predictions obtained from the GEM 
and hence necessitated the development of a minimal medium. 
Besides the metabolic capacities of A. muciniphila, it also has some other features that 
influence its physiology or application. A. muciniphila has been found to be sensitive to 
several antibiotics, including penicillins, macrolides and tetracyclines, but resistant to some 
others, including fluoroquinoles, aminoglycosides and glycopeptides (Ouwerkerk, 2016a).
However, inspection of the genome sequence did not reveal antibiotic resistance genes that 
are linked to known genetically transferrable elements (Gomez-Gallego, et al., 2016). 
Recently, another A. muciniphila strain was shown to be resistant to fluoroquinol and 
glycopeptide antibiotics, such as vancomycin and ofloxacin, in the context a broad-spectrum 
antibiotic isolation procedure on Columbia agar blood plates (Dubourg, et al., 2017).
Akkermansia in health and disease
The relative abundance of gut bacteria has been the main mode of studying the effect of 
health, disease, genetics and diet on the microbiota composition. In many of these studies, a 
high relative abundance of A. muciniphila has been associated with health or negatively 
correlated with a disease. For example, in patients suffering acute appendicitis, a negative 
correlation was found for the abundance of A. muciniphila (Swidsinski, et al., 2011). Many 
other negative correlations have been found between the relative abundance of A. muciniphila
and a dozen of diseases, including obesity, type 2 diabetes, metabolic syndrome and colonic 
inflammations and autism in a small-cohort study (Wang, et al., 2011) (see Table 1 for an 
overview and references). 
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Besides the metabolic capacities of A. muciniphila, it also has some other features that 
influence its physiology or application. A. muciniphila has been found to be sensitive to 
several antibiotics, including penicillins, macrolides and tetracyclines, but resistant to some 
others, including fluoroquinoles, aminoglycosides and glycopeptides (Ouwerkerk, 2016a).
However, inspection of the genome sequence did not reveal antibiotic resistance genes that 
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Recently, another A. muciniphila strain was shown to be resistant to fluoroquinol and 
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Akkermansia in health and disease
The relative abundance of gut bacteria has been the main mode of studying the effect of 
health, disease, genetics and diet on the microbiota composition. In many of these studies, a 
high relative abundance of A. muciniphila has been associated with health or negatively 
correlated with a disease. For example, in patients suffering acute appendicitis, a negative 
correlation was found for the abundance of A. muciniphila (Swidsinski, et al., 2011). Many 
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overview and references). 
Chapter 1. 
18
Table 1. Studies (observational or interventional) related to metabolic disorder and intestinal disorder 
in which a differential Akkermansia abundance was observed. Updated from (Derrien, et al., 2017).
Target
population
Study 
(observational 
or 
intervention)
Groups 
(number 
of 
individual
s)
Microbiot
a analysis 
approach
Samples 
analysed 
time
Akkermansia population References
Obese 
women Observational
Obese 
women 
(n = 53)
Whole 
shotgun 
metagenom
ic
Stool
Negatively associated with 
markers for insulin resistance 
or dyslipidaemia
(Brahe, et al., 
2015)
One time 
point
Elite athletes Observational
Elite 
athletes 
high BMI 
(n = 40)
16S rRNA 
sequencing Stool
Higher proportions in 
athletes and in low
(Clarke, et al., 
2014)
Healthy 
males Low 
BMI ≤25 
(n = 23)
One time 
point BMI control group
Healthy 
males high 
BMI 
(n = 23)
Infants of 
overweight 
and normal-
weight 
mothers
Observational Lean (n = 16) qPCR Stool
Decreased prevalence in 
infants of normal-weight 
mothers and of mothers with 
normal weight gain during 
pregnancy
(Collado, et 
al., 2010)
Overweigh
t mothers 
(n = 26)
FISH-FCM Infants (1, 6 months)
Infants (1, 
6 months)
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Lean and 
overweight 
lactating 
women
Observational
Lean 
women 
(n = 34)
qPCR
Breast milk 
(after 
delivery, 1 
and 6 
months 
later)
Trend towards increased 
prevalence in breast milk (1 
month after delivery) from 
overweight mothers
(Collado, et 
al., 2012)
Overweigh
t women 
(n = 22)
Overweight 
and obese 
adults
6-week calorie 
restriction 
(CR) and 6-
week follow up
Overweigh
t (n = 11) qPCR Stool
At baseline, A. muciniphila
MGS was inversely related to 
fasting glucose, waist-to-hip 
ratio, and subcutaneous 
adipocyte diameter. Subjects 
with higher level of A. 
muciniphila at baseline had 
greater improvement in 
insulin sensitivity markers 
and other clinical parameters 
after CR
(Dao, et al., 
2016)
Obese 
(n = 38)
Metageno
mic
Baseline 
(T0)
After CR 
(T = 6 
weeks)
After 
weight 
stabilisatio
n (T = 12 
weeks)
Lean, 
overweight 
and obese 
adults
Observational Lean (n = 10)
16S rRNA 
sequencing Stool
Akkermansia negatively 
correlated with BMI
(Escobar, et 
al., 2014)
Overweigh
t (n = 10)
One time 
point
Obese 
(n = 10)
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Lean, 
overweight 
and obese 
children(4–5 
years)
Observational Lean (n = 20)
qPCR, T-
RFLP Stool
Decrease in 
obese/overweight children
(Karlsson, et 
al., 2012)
Overweigh
t, obese 
(n = 20)
One time 
point
Obese 
women
8-week of 
impact of 4 g 
of Ephedra 
sinica 
extract/day
Obese 
women
(n = 7)
16S rRNA 
sequencing Stool
Positive association 
of Akkermansia with weight 
loss
(Kim, et al., 
2014)
2 
samples/su
bject 
(before and 
after 
Ephedra 
sinica 
extract 
intake)
T2D and 
healthy 
individuals
Observational T2D (n = 71)
Whole 
shotgun 
metagenom
ic
Stool Increase in T2D (Qin, et al., 2012)
Healthy 
controls 
(n = 74)
One time 
point
Overweight 
individuals
1-week fasting 
program and 6-
week probiotic 
intervention
Overweigh
t adults 
(n = 13)
qPCR Stool Increase between T1 and T3 (Remely, et al., 2015)
Before 
fasting 
(T1)
During 
fasting 
(T2)
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After 6-
week 
probiotic 
interventio
n (T3)
Obese 
individuals
16-week 
weight 
reduction diet
Obese 
individuals 
(n = 33)
qPCR Stool Increase after weight reduction
(Remely, et 
al., 2015)
Before, 
during and 
after 
interventio
n
Normal 
weight and 
overweight 
pregnant 
women (24 
weeks)
Observational
Normal 
weight 
(n = 34)
qPCR Stool
No difference between 
normal and overweight 
Decrease in excessive weight 
gain
(Santacruz, et 
al., 2010)
Overweigh
t (n = 16)
One time 
point
Adult 
women Observational
Lean 
(n = 17) qPCR Stool
Trend to increase prevalence 
in lean individuals
(T, et al., 
2013)
Obese 
(n = 50)
One time 
point
Lean, 
morbidly 
obese post-
gastric-
bypass 
surgery 
human 
subjects
Gastric bypass
Normal 
weight 
(n = 3)
16S rRNA 
sequencing Stool
Increase after bariatric 
surgery
(Zhang, et al., 
2009)
Morbidly 
obese(n =
3)
One time 
point Low in obese
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Post-
gastric-
bypass 
surgery 
(n = 3)
Normal 
glucose 
tolerance
(NGT), 
Prediabetes 
(PD) and 
newly 
diagnosed 
T2D subjects
Observational NGT (n = 44)
16S rRNA 
sequencing Stool
Decrease in Pre-DM and 
T2D
(Zhang, et al., 
2013b)
Pre-DM 
(n = 64)
One time 
point
T2D 
(n = 13)
Diabetics 
with and 
without 
metformin 
medication
Observational
T2D no 
metformin 
(n=14)
16S rRNA 
sequencing Stool
Higher in T2D with 
metformin compared to other 
groups
(de la Cuesta-
Zuluaga, et 
al., 2017)
T2D with 
metformin 
(n=14)
One time 
point
matched 
controls 
(n=84)
T2D patients
4 month 
double-blinded 
intervention 
with metformin
Metformin 
(n=22)
Whole 
shotgun 
metagenom
ic
Stool Higher in metformin treatment
(Wu, et al., 
2017)
Placebo 
(n=18)
Before and 
after 
interventio
n
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Alcoholic 
steatohepatiti
s (ASH) 
patients
Observational ASH (n=21)
16S rRNA 
sequencing Stool Decrease with ASH severity
(Grander, et 
al., 2017)
Severe 
ASH 
(n=15)
One time 
point
Non-obese healthy 
individuals (n=16)
Overweight 
men and 
women
12-week 
double-blinded 
polyphenol 
intervention
Obese 
males 
(n=18)
qPCR Stool not affected (Most, et al., 2017)
Obese 
females 
(n=19)
Before and 
after 
interventio
n
Crohn's 
disease 
patients
Cross over 
dietary 
intervention
Crohn's 
disease 
patients 
(n=9)
qPCR Stool
Increased abundance on 
Australian (higher 
FODMAP) diet
(Halmos, et 
al., 2016)
Pooled samples of each stage (habitual 
diet, low FODMAP, high FODMAP)
Monozygotic 
twins with 
subclinical 
metabolic 
disorders
Observational
Twins 
(n=40 
individuals
)
Whole 
shotgun 
metagenom
ic
Stool, two 
time points
Negatively correlated with 
BMI, insulin levels and 
fasting blood sugar
(Yassour, et 
al., 2016)
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patients
Observational ASH (n=21)
16S rRNA 
sequencing Stool Decrease with ASH severity
(Grander, et 
al., 2017)
Severe 
ASH 
(n=15)
One time 
point
Non-obese healthy 
individuals (n=16)
Overweight 
men and 
women
12-week 
double-blinded 
polyphenol 
intervention
Obese 
males 
(n=18)
qPCR Stool not affected (Most, et al., 2017)
Obese 
females 
(n=19)
Before and 
after 
interventio
n
Crohn's 
disease 
patients
Cross over 
dietary 
intervention
Crohn's 
disease 
patients 
(n=9)
qPCR Stool
Increased abundance on 
Australian (higher 
FODMAP) diet
(Halmos, et 
al., 2016)
Pooled samples of each stage (habitual 
diet, low FODMAP, high FODMAP)
Monozygotic 
twins with 
subclinical 
metabolic 
disorders
Observational
Twins 
(n=40 
individuals
)
Whole 
shotgun 
metagenom
ic
Stool, two 
time points
Negatively correlated with 
BMI, insulin levels and 
fasting blood sugar
(Yassour, et 
al., 2016)
Chapter 1. 
24
However, also the opposite has been observed, where a high A. muciniphila relative 
abundance was found to be correlated with overweight and colorectal cancer in humans and 
allergic diarrhoea in mice (Collado, et al., 2010, Sonoyama, et al., 2010, Weir, et al., 2013, 
Wang, et al., 2017). The increase of A. muciniphila in colorectal cancer patients could be 
induced by the low caloric intake of these patients. A low caloric intake is generally 
associated with a higher abundance of A. muciniphila due to its independence of host diet. 
Recently, A. muciniphila has also been co-isolated from a blood culture with Enterococcus 
faecium and E. coli in a woman with severe diarrhoea (Dubourg, et al., 2017). This suggests 
that A. muciniphila can survive in the blood stream in severe cases of intestinal barrier 
disruption. The studies in which correlations are described, both positive and negative, 
indicate that A. muciniphila has a profound influence on human health.
To move from case reports and correlations to causalities and mechanistic insight, live cells 
of A. muciniphila were administered to mice fed a high fat diet. The mice receiving the live 
but not the autoclaved bacteria showed a decrease in body weight gain when compared to the 
control group (Everard, et al., 2013). In follow-up studies it was shown that the same or an 
even stronger effect can be achieved by pasteurizing the cells before administration. Finally, 
a purified outer membrane protein was administered to the mice that mimicked the effect of 
a whole cell supplement (Plovier, et al., 2017). Additionally, it was shown in vitro that an A. 
muciniphila outer membrane complex could modulate the immune response. The effect was 
traced back to a single pili-associated protein encoded by the DNA at locus Amuc_1100 
(Ottman, et al., 2017b). Such mechanistic studies are needed for the definition and final use 
of therapeutic microbes.
Growing therapeutic microbes
Probiotics have been marketed worldwide, with different regulations imposed for marketing 
in the European Union, Japan, Canada and the USA. Regulations for marketing probiotics 
differ from safety regulations only in the USA, to scientifically proven functionality in the 
European Union (Kumar, et al., 2015). The value of the probiotic market is still increasing 
worldwide (Solanki, et al., 2013, Grand-View-Research, 2016). Most probiotic strains are 
lactic acid bacteria or Bifidobacteria or combinations thereof. E. coli Nissle and S. boulardii
are also marketed as probiotics (Table 2). In the past decade, the interest for the interaction 
between human health and the microbiota has led to the discovery of potential therapeutic 
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bacteria. Note that these bacteria are not termed probiotics, because their use or intended use 
is to treat or prevent diseases and disorders, although they could be employed as next 
generation probiotics. These bacteria are not within the same families as the original 
probiotics, but include various intestinal anaerobes (Table 2). Like some of the previously 
marketed Lactobacilli and Bifidobacteria (Talwalkar and Kailasapathy, 2003, Talwalkar and 
Kailasapathy, 2004), all these gut-derived bacteria are anaerobic and thus mostly very 
sensitive to the exposure to oxygen. This poses great challenges for growing these bacteria, 
upscaling to large scale cultivation and maintaining viability of the bacteria up to delivery in 
the colon. 
Small-scale laboratory cultures have been obtained for all species described in Table 2. In 
case of F. prausnitzii, a minimal medium was defined based on the metabolic map of the 
microbe, in which undefined compounds such as yeast extract and casitone were replaced by 
defined compounds, mainly amino acids (Heinken, et al., 2014). This modification of the 
medium reduced the growth rate from 0.32 h-1 to 0.13 h-1. A defined medium was also used 
to grow and study Intesnimonas butyriciproducens, exposing a new pathway for butyrate 
production with the degradation of fructoselysin. The growth rate on this Amadori product 
as sole carbon source was 0.04 h-1, and when supplemented with acetate 0.06 h-1. When lysine 
is used as carbon source, the growth speed was 0.1 h−1 (Bui, et al., 2015).
Such a defined medium has not been obtained for A. muciniphila before, even though it has 
been used as supplement or treatment in multiple studies. For this purpose it was grown on 
multiple complex media, including mucus based medium (Ouwerkerk, et al., 2017a),
tryptone-based medium, BHI medium (Derrien, et al., 2004, Ottman, 2017), and on solid 
chocolate agar (Grander, et al., 2017).
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Table 2. Potential next generation probiotics or therapeutic microbes, which are isolated from human. 
Adapted from (O'Toole, et al., 2017).
Organism Disease target Level of evidence Study 
type
Reference
Bacteroides 
xylanisolvens DSM 
23694
Cancer
Medium: safety in 
humans has been 
established while 
levels of TFα-
specific IgM have 
been shown to be 
elevated in 
humans
Human (Ulsemer, et al., 2016)
Bacteroides ovatus D-6 Cancer
Low to medium: 
increases levels of 
murine TFα-
specific IgM and 
IgG
Preclinica
l in mice (Ulsemer, et al., 2013)
Bacteroides dorei D8 Heart disease Low: depletion of cholesterol in vitro
Preclinica
l in vitro (Gerard, et al., 2007)
Bacteroides fragilis
ZY-312
Clearance of 
infectious agents
Low: data only in 
vitro
Preclinica
l in vitro (Deng, et al., 2016)
Bacteroides 
acidifaciens JCM 
10556(T)
Clearance of 
infectious agents
Low to medium: 
increases IgA 
levels in the large 
intestine of 
gnotobiotic mice
Preclinica
l in mice (Yanagibashi, et al., 2013)
Clostridium butyricum
MIYAIRI 588
Multiple targets 
including cancer, 
inflammation and 
infectious agents
Low to medium: 
evidence gathered 
for claims in 
human and 
animals trials
Human
(Hosomi, et al., 1982, 
Kobashi, et al., 1983, 
Takeda, et al., 1983, 
Kuroiwa, et al., 1990, 
Murayama, et al., 1995, 
Seki, et al., 2003, 
Takahashi, et al., 2004, 
Shimbo, et al., 2005, 
Kohiruimaki, et al., 2008, 
Nakanishi and Tanaka, 
2010, Woo, et al., 2011, 
Sato, et al., 2012, Seo, et 
al., 2013, Shinnoh, et al., 
2013, Weng, et al., 2015, 
Chen, et al., 2016, Isa, et 
al., 2016, Yasueda, et al., 
2016)
Faecalibacterium 
prausnitzii
Mainly IBD but 
also asthma, 
eczema and type 
2 diabetes
Low to medium: 
mainly focused 
animal models of 
colitis and in 
associative studies
Preclinica
l in mice 
and in 
vitro
(Rossi, et al., 2015, 
Simonyte Sjodin, et al., 
2016, Song, et al., 2016)
Eubacterium hallii
L2-7 Type 2 diabetes
Medium: 
correlations in 
human FMT and 
animal-based 
efficacy
Preclinica
l in mice (Udayappan, et al., 2016)
Akkermansia 
muciniphila MucT
Metabolic 
disorders, 
obesity, type 2 
diabetes
Medium: 
Correlations in 
human and animal 
based efficacy
Human 
phase 1 
and 
preclinical 
in mice
(Everard, et al., 2013, 
Plovier, et al., 2017)
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Intestinimonas 
butyriciproducens
AF211
reduction of 
Advanced 
Glycation 
Endproducts 
(AGEs) in people 
with Metabolic 
syndrome and 
type 2 diabetes
Very low: based 
on butyrate 
production only
Ongoing 
preclinical 
in mice
(Bui, et al., 2015)
Caelus Health BV
Formulation of therapeutic microbes
A final challenge in using anaerobic bacteria as therapeutic microbes or probiotics is the 
downstream processing and subsequent formulation of the product. Many of the conventional 
marketed probiotics are formulated in yoghurt or similar dairy drinks. For most therapeutic 
microbes, these formulations are too acidic and the diffusion of oxygen would be too high 
for survival. Additionally, free suspension of bacteria in dairy products provides no 
protection against gastro-intestinal conditions, such as the high acidity in the stomach, high 
oxygen concentrations in the upper intestinal tract and exposure to bile. 
The formulation of probiotics has influence on the efficacy of the bacteria (Govender, et al., 
2014, Sanders, et al., 2014), so the same can be assumed for therapeutic microbes. Therefore, 
it is very important to not only study the physiology and host-microbe interaction of 
therapeutic microbes, but also find a way to deliver the cells in an appropriate way. The 
possibilities to deliver viable bacteria depend on the resistance of these bacteria against 
processing techniques. Techniques that are currently employed to deliver the bacteria include 
lyophilisation and different encapsulation methods. The encapsulation methods aim at
protecting the bacteria, while lyophilisation inactivates the bacteria. Protection in double 
emulsion systems, by extrusion and encapsulation in starch has been employed successfully 
to protect probiotic bacteria (Mattila-Sandholm, et al., 2002, Pimentel-Gonzalez, et al., 2009, 
Solanki, et al., 2013, Govender, et al., 2014).
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Aim and thesis outline
The introduction above describes the complexity of the gut microbiota and the potential role 
of A. muciniphila in this ecosystem. The application of molecular tools, such as 16S rRNA 
amplicon sequencing as well as metagenomic insight, has been important in describing the 
species abundance in the gut and supporting a correlation between the abundance of specific 
bacteria, their genes and diseases (Le Chatelier, et al., 2013). However, correlations are not 
sufficient to provide causal relationships or a mechanistically understanding that precedes 
the identification of potential therapeutic agents for the use of intervention studies and the 
cure of diseases. Hence, it is the aim of the present study to identify and solve some of the 
physiological, growth and delivery bottlenecks that limit application studies of A.
muciniphila. The studies are essential to determine causality and identify mechanistic 
explanations for host-microbe interactions. To obtain causal relationships and test 
hypothesized mechanisms, it is important to be able to culture bacteria and study their 
possible phenotypes. In chapter 2 we describe the use of GEMs to predict possible growth 
media, phenotypes and species interactions. 
The use of GEMs as discussed in chapter 2 has been applied in chapter 3, in which we 
describe the development of a minimal medium to grow A. muciniphila. This resulted in a 
further refining of the GEM of A. muciniphila.
The development of the minimal medium directly resulted in the optimization of a food-grade 
growth medium for therapeutic applications, as described in chapter 4. We studied the 
influence of this growth medium on gene expression and cell morphology of A. muciniphila.
Finally, we compared the efficacy of cells grown on this newly developed medium with cells 
grown on the previously tested mucus medium in preclinical mice trials. 
The niche of A. muciniphila is reflected in its known physiology and genetics, by its arsenal 
of mucus degrading enzymes and ability to utilize the mucosal sugars. The mucus lining the 
epithelial cells does not prevent oxygen form diffusing into the gut. This results in recurrent 
oxygen exposure to A. muciniphila. It is expected that this is not beneficial for strictly 
anaerobic bacteria. We investigated the influence of low oxygen concentrations on A.
muciniphila, and showed that A. muciniphila is capable of respiring oxygen as presented in 
chapter 5. 
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To deliver viable A. muciniphila to the host, we employed a double emulsion system as will 
be discussed in chapter 6. The protective capabilities of a double water-in-oil-in-water 
emulsion was tested in an in vitro gastric system. 
Finally, the relevance of the findings described in this thesis will be discussed in chapter 7,
with a future perspective about the possible applications of A. muciniphila as a therapeutic 
microbe. 
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Abstract
The human gut is colonized with a myriad of microbes, with substantial interpersonal 
variation. This complex ecosystem is an integral part of the gastrointestinal tract and plays a 
major role in the maintenance of homeostasis. Its dysfunction has been correlated to a wide 
array of diseases, but the understanding of causal mechanisms is hampered by the limited 
amount of cultured microbes, poor understanding of phenotypes, and the limited knowledge 
about interspecies interactions. Genome-scale metabolic models (GEMs) have been used in 
many different fields, ranging from metabolic engineering to the prediction of interspecies 
interactions. We provide showcase examples for the application of GEMs for gut microbes 
and focus on (i) the prediction of minimal, synthetic or defined media, (ii) the prediction of 
possible functions and phenotypes, and (iii) the prediction of interspecies interactions. All 
three applications are key in understanding the role of individual species in the gut ecosystem 
as well as the role of the microbiota as a whole. Using GEMs in the described fashions has 
led to designs of minimal growth media, an increased understanding of microbial phenotypes 
and their influence on the host immune system, and dietary interventions to improve human 
health. Ultimately, an increased understanding of the gut ecosystem will enable targeted 
interventions in gut microbial composition to restore homeostasis and appropriate host-
microbe crosstalk. 
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Understanding the gut microbiome 
The human gut is colonized since birth with complex microbial communities, mainly 
consisting of bacteria with millions of unique genes that show substantial interpersonal 
variation in adult life (Qin, et al., 2010). This complex ecosystem – the gut microbiome– is 
an integral part of the gastrointestinal tract (GIT) and is intrinsically involved in the 
maintenance of body homeostasis. Aberrations in the microbial composition have been 
correlated to a wide array of diseases, ranging from obesity to diabetes, and from 
inflammatory bowel disease to autism (Flint, et al., 2012, Zhou and Foster, 2015). These 
correlations have spawned interest in developing strategies to improve human health by 
rationally steering this composition and thereby the function of the gut microbiome (El-
Semman, et al., 2014, Kelly, et al., 2014). This  approach has been greatly stimulated by the 
success of transplantations of faecal microbiota, which showed that ‘bugs-can-beat-drugs’ in 
fighting recurrent Clostridium difficile infections (van Nood, et al., 2013). However, 
rationally steering microbiome composition and function requires a thorough understanding 
of the causal mechanisms underpinning these correlations. Thus far, this understanding has 
been hampered by (i) the gap between the number cultured gut bacteria and sequenced gut 
bacteria, (ii) the poor phenotypic characterization of the majority of gut microbes, and (iii) 
the limited understanding of the interactions of microbes with each other as well as their host. 
As in other areas of research, the deployment of descriptive and predictive mathematical 
models has the potential to provide insights that ultimately enable to overcome these 
limitations. In this review we will discuss the use of genome-scale constraint-based metabolic 
models for an increased understanding of the gut microbiome and its role in gut homeostasis 
and (dys)function.
GEnome-scale metabolic Models (GEMs) in gut microbiota research
GEMs are mathematical representations of the knowledge on an organism’s metabolic 
capacity and have been previously applied in bacterial systems for a variety of purposes, 
including the design of cultivation media, phenotypic characterizations, metabolic 
engineering, drug discovery, and to study interspecies interactions. For an overview of 
common GEM applications we would like to refer to these reviews (Feist and Palsson, 2008, 
Oberhardt, et al., 2009).
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Strong developments in both GEMs and gut microbiome research are bound to facilitate 
moving from correlation studies to gaining mechanistic insights. GEMs can integrate 
knowledge on the metabolism of one or more gut microbes and predict how this metabolic 
system functions in different niches in the gut. The gut environment includes nutrient 
gradients both along the length of the GIT, as well as along the mucosal gradient and villi, 
and have strong effects on the microbial function (Espey, 2013, Ridlon, et al., 2014). GEMs 
provide a valuable framework for the integrated study of gut function as they enable the 
generation of testable hypotheses that can lead to novel insights into causal relationships 
between the gut microbiome and human health. Considerable progress in these relations has 
been obtained with the short chain fatty acids (SCFAs) that are produced as main bacterial 
metabolites in the colon, as illustrated for butyrate, an established functional compound 
(Hamer, et al., 2008, Smith, et al., 2013). The impact of SCFAs on metabolic health has been 
reviewed recently (Puddu, et al., 2014).  In a model system it was found that acetate is 
secreted by Bifidobacterium adolescentis L2-32, taken up by Faecalibacterium prausnitzii
A2-165 and used to produce butyrate from sugar. This enabled the prediction of F. prausnitzii 
acetate requirements for butyrate production and how this relates to its low abundance in 
cases of Crohn’s disease (El-Semman, et al., 2014), showing how an observed correlation 
can possibly be explained mechanistically using GEMs. 
In the remainder of this review we will discuss the use of GEMs in gut microbiota research 
and how GEMs can advance gut research towards the understanding of gut homeostasis and 
(dys)function. We will focus on the metabolic reactions of the microbes in the gut, on their 
growth, on their interactions and on the metabolites produced. These are either primary 
products of microbial metabolism or breakdown products of our diets or host compounds, 
having a plethora of functions, ranging from SCFAs that fuel enterocytes and have specific 
signalling and immune functions, to vitamins and other host growth-promoting compounds 
(Zoetendal and de Vos, 2014). Most of these metabolites cannot be easily detected in the 
human GIT as these are taken up by the host and processed in the liver. Since GEMs 
stochiometrically represent all metabolic reactions in a microbe or microbial community, 
such models enable to estimate the production of these transient metabolites, estimate their 
distributions within the global metabolic network and provide hypotheses for the metabolic 
interactions among gut microbes and of those with their host. Moreover, GEMs are 
instrumental in optimizing growth of GIT microbes in laboratory conditions and hence are 
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relevant for the production of biomolecules that are involved in host signalling, such as TLR 
ligands or specific functional proteins (Ottman, 2015, Quevrain, et al., 2016). First, we briefly 
describe the process of genome-scale metabolic reconstruction and its implications for 
network modelling. Secondly, we describe applications of GEMs for gut microbiome 
research that enable: (i) selecting minimal and defined growth media for previously cultured 
as well as not yet cultured gut microbes, (ii) predicting growth and phenotypes of gut 
microbes and their influence on health and disease, and (iii) modelling co-cultures and 
multispecies interactions of gut microbes and the human host (Figure 1). 
Figure 1. Simplified overview of the use of GEM to increase understanding of the metabolic interactions in the  gut 
microbiome. Individual species require metabolites (squares) to grow. These metabolites can be predicted by GEMs, 
which results in medium and growth (rate) prediction (i, top). The possible solution the bacteria use to metabolize 
these metabolites can change under different conditions (ii, middle), which leads to altered interactions between 
bacteria (iii, bottom)
Genome-scale metabolic reconstruction and network modelling
The basis of GEM construction is the genome annotation of the microbe of interest since this
predicts the enzymes a microbe encodes, and thereby provides a list of chemical reactions 
the microbe can perform. This list of chemical reactions forms the draft metabolic model, 
which is often far from complete (Thiele and Palsson, 2010). Typically, there are missing 
reactions due to incorrect, missing, or low-quality annotations, even for well-studied 
organisms (Orth and Palsson, 2012). Moreover, our knowledge of the biochemical pathways 
is often insufficient, with unknown conversions still being discovered (Bui, et al., 2015).
These missing reactions – also called gaps – severely limit the possibilities for GEM analyses, 
as parts of the metabolic network are not connected. Therefore, gap-filling algorithms are 
used to predict the presence of additional reactions that can be obtained from reaction 
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databases such as KEGG (Kanehisa, et al., 2014) or Metacyc (Caspi, et al., 2014) and to 
connect disconnected parts of the network (Orth and Palsson, 2010, Thiele and Palsson, 
2010). Thereby, these algorithms provide hypotheses on enzymes that were missed in the 
genome annotation. In some cases, a corresponding gene, not initially annotated as such, is 
identified and the genome annotation is improved. In the remaining cases, the reactions 
become ‘orphan reactions’, e.g., reactions that are thought to occur in the microbe based on 
existing pathways of other microbes but that have not been linked to any genes. The addition 
of orphan reactions might lead to erroneous model predictions, but is often essential to obtain
a functioning GEM and facilitates targeted gene identification (Orth and Palsson, 2010, 
Thiele and Palsson, 2010). Model construction and gap-filling algorithms have been 
extensively described elsewhere (Orth and Palsson, 2010, Thiele and Palsson, 2010, O’Brien, 
et al., 2015).
After gap-filling, GEMs are expected to be able to sustain in silico growth of the modelled 
organism. Growth is modelled as the formation of biomass in a complex organism-specific 
reaction involving a large number of biomass precursors such as DNA, RNA, proteins, lipids, 
ATP, NADPH, and various small molecules. The use of biomass precursors in bacterial 
GEMs has recently been thoroughly explored resulting in a shortlist of universally essential, 
as well as organism-specific biomass precursors (Xavier, et al., 2017).  If all of these 
precursors can be formed in the right ratios the GEM predicts that growth is possible. The 
most common way to predict growth phenotypes is through Flux Balance Analysis (FBA) 
(Orth, et al., 2010). FBA determines an optimal flux distribution for the production of 
biomass components while adhering to several types of constraints: (i) mass-balance 
constraints; the production and consumption of intracellular metabolites cancels out, (ii) 
thermodynamic feasibility constraints; reactions can only operate in thermodynamically 
feasible directions, and (iii) capacity constraints; fluxes through reactions are bounded to 
biologically feasible ranges. Capacity constraints are also used to define the medium 
conditions by directly defining which metabolites can be imported. Thereby, GEMs can be 
easily modified to simulate growth phenotypes in a wide range of different experimental 
conditions.
GEMs are typically evaluated by comparing predicted growth phenotypes for both wild type 
and mutant strains to the available experimental data. This experimental data usually consists 
More than just a gut feeling
45
of growth measurements for a large number of media containing different carbon, nitrogen, 
phosphorus and sulphur sources. For the comparison, both the experimental data and the 
GEM predictions are discretized to the two states ‘growth’ and ‘no growth’. This binary 
discretization leads to two different types of inconsistencies: (i) growth predicted by the GEM 
but not experimentally found, and (ii) growth that is experimentally validated but not 
predicted by the GEM. In the first case, the GEM overestimates the microbe’s abilities, 
suggesting it may include reactions that the microbe cannot perform. In contrast, the other 
case suggests that the GEM is missing reactions. This comparison can thus be used to 
evaluate both the annotation and the gap-filling process that underlie the GEM construction. 
For example, if the removal of a single reaction from the GEM results in a large improvement 
of GEM predictions, this suggests that this reaction was erroneously added and should be 
considered for removal. This process of using experimental data to find incorrect GEM 
predictions and subsequently making changes to the GEM has also been combined into 
algorithms, such as GrowMatch (Kumar and Maranas, 2009), that will make a minimal 
number of changes to a GEM while maximizing its coherence to experimental data.
The established manual GEM reconstruction process ultimately results in high-quality 
GEMs, but is extremely time-consuming (Thiele and Palsson, 2010). The advent of high 
throughput sequencing and concurrent rapid increase in available biological data warrants a 
faster approach, which is provided by the RAVEN toolbox (Agren, et al., 2013) and the 
ModelSEED approach (Henry, et al., 2010). In both cases, the process of genome annotation, 
draft GEM construction and gap-filling has been fully automated, although extensive manual 
curation remains necessary to sustain a high quality (Henry, et al., 2010, Agren, et al., 2013).
This curation process has recently been streamlined for gut microbes specifically as part of 
the AGORA metabolic GEM resource (Magnusdottir, et al., 2017). A distinguishing feature 
of the AGORA GEM resource is the semi-automatic curation of ModelSEED GEMs where 
corrections that are manually applied to a single GEM are propagated to the GEMs of other 
gut microbes. This semi-automatic curation both speeds up the curation process and finally 
results in more uniform and higher quality GEMs.
Use of GEMs to design defined culture media
The basis of classic microbiology is the ability to culture bacteria in a pure culture on a well-
defined medium. Such a well-defined medium is required for detailed metabolic analyses, 
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Use of GEMs to design defined culture media
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defined medium. Such a well-defined medium is required for detailed metabolic analyses, 
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growth optimization and finally also in a feedback loop with the GEM itself to optimize the 
metabolic model. Moreover, well-defined media devoid of animal-derived compounds will 
be needed when intestinal microbes that are therapeutically effective are to be cultured and 
used in therapeutic settings. An example is the recently developed medium for Akkermansia 
muciniphila that was used for a human safety study [61]. Finally, obtaining pure cultures is 
essential for intervention studies to investigate host-microbe interactions and to use the 
beneficial bacteria as potential therapeutic microbes. Pure cultures have been successfully 
obtained for over 1000 different gut species (Rajilic-Stojanovic and de Vos, 2014), which 
was recently expanded by high throughput culturing approaches (Lagier, et al., 2016, 
Abdallah, et al., 2017). However, as it has been predicted that there are at least two to three 
times more different gut species, a significant number of gut microbes remain uncultured and 
inaccessible for study in isolation (Ritari, et al., 2015). A number of known not-yet cultured 
candidates  have been listed in a ‘most wanted’ list (Fodor, et al., 2012), which highlights the 
need for culturing of gut microbes. Among these targets are Oscillospira spp. that are 
receiving considerable attention (Mackie, et al., 2003, Cuiv, et al., 2015, Konikoff and 
Gophna, 2016). A major issue in the culturing of these microbes is the lack of suitable growth 
media. Growth media are often based on the ecosystem a microbe naturally occurs in, but the 
gut is extremely complex with many different nutrients, highly variable nutrient levels, and 
many interspecies interactions. Here we first describe the challenges in the use of GEMs for 
the design of defined media, and then how GEMs have been successfully used for the design 
of defined media and how similar approaches can be used to design suitable defined media 
for not-yet cultured bacteria. 
There are three main challenges in the use of GEMs for the design of defined growth media: 
(i) The in silico biomass composition is an influential aspect of the GEM as it defines all 
metabolites required for growth (Xavier, et al., 2017) . The omission of even a single 
metabolite in this composition can prevent the GEM from predicting an essential media 
supplement. However, the biomass composition cannot be fully determined in silico and 
relies on the availability of organism-specific experimental data. As this is not available for 
many gut microbes, automatic model generation procedures rely on heuristics to estimate the 
biomass components that are required for each organism (Henry, et al., 2010, Magnusdottir, 
et al., 2017). We highly recommend evaluating a given biomass composition generated from 
automatically generated GEMs according to the guidelines recently set out in a thorough 
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evaluation of biomass compositions (Xavier, et al., 2017) prior to gap-filling and media 
design. (ii) The gap-filling step in GEM construction typically relies on the introduction of 
known biochemical reactions to complement the metabolic network of the modelled microbe 
(Orth and Palsson, 2010). In particular, reactions are often added such that the GEM predicts 
in silico growth in a pre-defined medium, which is not directly suitable if no chemically 
defined medium is known for the microbe or if the microbe uses not previously characterized 
reactions. Hence, all gap-filling reactions should be carefully individually inspected and 
corresponding genes need to be identified to support the procedure. (iii) GEMs do not capture 
the non-linear link between concentrations of medium components and the speed with which 
microbes can import them. Hence, GEM-based medium design is limited to predicting which 
compounds need to be present and cannot be used to determine optimal concentrations.
Despite these challenges, GEMs have proven to be useful in the design of chemically defined 
growth media , as has been shown for the lactic acid bacterium Lactobacillus plantarum
WCFS1 (Teusink, et al., 2005). Lactic acid bacteria are important in many industrial food 
processes and some are marketed as probiotics (Teusink and Smid, 2006). Therefore, the 
GEMs of lactic acid bacteria are used to study their metabolic capabilities and behavior in 
fermentation processes (Teusink, et al., 2006, Wegkamp, et al., 2010), as well as their 
probiotic functions (Saulnier, et al., 2011, dos Santos, et al., 2013). The GEM of 
Lactobacillus plantarum WCFS1 was automatically constructed based on its genome 
sequence and subsequently extensively manually curated (Kleerebezem, et al., 2003, 
Teusink, et al., 2005). The GEM was then used to predict the essentiality of 36 compounds 
in a chemically defined growth medium. The GEM predictions were correct for 29/36 (81%) 
of the compounds, but were incorrect for the vitamins folate, thiamine, and vitamin B6, as 
well as for the amino acids arginine, glutamate, isoleucine, and tryptophan. The incorrect 
predictions pinpointed errors in both the GEM construction process and in the experimental 
procedures, and also pinpointed distinct metabolic features of L. plantarum WCFS1, for 
example: (i) The incomplete folate biosynthesis pathway in the GEM was in part due to a 
missing EC number for a correctly annotated gene, as well as no reactions in Metacyc for 
another EC number. (ii) The GEM lacked a complete isoleucine biosynthesis pathway, but 
growth was observed in the isoleucine omission experiment. This turned out to be a result of 
isoleucine contamination in the other amino acids. (iii) A missing reaction for thiamine 
biosynthesis was assigned to a gene involved in molybdopterin biosynthesis. In 
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Enterobacteria these reactions are carried out by two paralogs, but it appears that both 
reactions are carried out by a single enzyme in L. plantarum (Teusink, et al., 2005). These 
results clearly illustrate how a GEM-driven systematic evaluation of medium compositions 
can increase the understanding of a microbe’s metabolism. 
A GEM of a different lactic acid bacterium, Lactococcus lactis IL1403, was constructed and 
used to remove all non-essential metabolites from a rich medium in order to design a minimal 
medium for physiological studies (Oliveira, et al., 2005). This exercise in medium design not 
only resulted in a minimal medium, but also allowed for careful comparisons between in 
silico predictions and experimental data to understand their differences. The GEM predicted 
that arginine, methionine and valine are essential for growth, and that either glutamate or 
glutamine is required additionally. However, recent single amino acid omission experiments 
have led to the conclusion that arginine, asparagine, histidine, methionine, serine, isoleucine, 
leucine, and valine are essential medium components for L. lactis, and that glutamate and 
glutamine are not (Aller, et al., 2014). At first glance this might incorrectly seem like poor 
performance by the GEM. However, the agreements and disagreements between predictions 
and experiments can be summarized in three points: (i) they agree on the essentiality of 
arginine, methionine, valine and the non-essentiality of the ten amino acids not previously 
mentioned, (ii) they do not evaluate glutamate and glutamine in the same manner - the GEM 
predicts that one of them is required, whereas the experiment indicates that either one can be 
omitted, but that glutamine cannot be omitted if the concentration of glutamate is additionally 
reduced to 10% of the normal concentration - and (iii) they disagree on the essentiality of 
asparagine, histidine, isoleucine, leucine, and serine, but also disagree on the meaning of 
‘essential’. In the L. lactis IL1403 GEM a compound was essential if its omission reduced 
the specific growth rate below 0.01/h. In the omission experiment a compound was 
considered essential if the final OD dropped below 40% of the final OD in the rich medium. 
This introduces a certain level of ambiguity and, for example, if the experimental threshold 
would instead be at 20%, asparagine and serine would not have been considered essential. 
The ability to culture pathogens and probiotics is important to study them in isolation and to 
determine their role in the gut microbiome. Therefore, a GEM was used to design a minimal 
growth medium for Staphylococcus aureus N315, a pathogen that frequently infects 
hospitalized patients (Becker and Palsson, 2005). The GEM predicted that several amino 
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acids were essential, but in vivo experiments indicated otherwise. Later on, an updated GEM 
predicted that S. aureus N315 has no intrinsic auxotrophies for amino acids, but that some 
particular isolates do require some amino acids (Heinemann, et al., 2005). This discrepancy
between the updated GEM and the experimental results for the isolates was explained by the 
repression of amino acid synthesizing genes. The repression could be relieved by 
progressively eliminating the amino acids from the medium, supporting the GEM prediction 
that S. aureus can indeed synthesize these amino acids. This study showed how a GEM can 
aid in omitting nutrients from a known defined medium. 
These three case studies show that GEMs are a good starting point for designing minimal 
media. In fact, the ability of GEMs to design growth media was recently emphasized by the 
development of the Minimal Environmental TOol (MENTO) (Zarecki, et al., 2014). MENTO 
predicts the minimal medium requirements for an organism based on its GEM, and was used 
to study broad nutritional trends in over 2500 automatically generated ModelSEED (Henry, 
et al., 2010) models. For three well-characterized organisms, the predictions based on the 
ModelSEED models were also compared to the predictions based on manually curated 
models. The comparison indicated that the ModelSEED models are more pessimistic growth 
predictors, but have a similar accuracy (Zarecki, et al., 2014). Nonetheless, the authors 
indicate that while the ModelSEED models are suitable for studying broad nutritional trends, 
one should be careful in interpreting results for any specific organism. A ModelSEED model 
thus requires manual curation before using it to predict suitable minimal growth media.
Such a manually curated ModelSEED GEM was recently used for minimal medium design 
for F. prausnitzii, a prevalent and potential beneficial gut microbe that is commonly grown 
on the chemically undefined YCFAG medium (Heinken, et al., 2014). The automatically 
generated ModelSEED GEM was first manually curated such that it correctly captured the 
known biochemistry and physiology of F. prausnitzii. This curation involved changing the 
biomass reaction, updating reaction directionalities, adding species-specific pathways, and 
filling gaps. The curated GEM was then used to predict a chemically defined growth medium 
called CDM1. CDM1 did, however, not facilitate in vitro growth and was subsequently 
supplemented with additional nutrients to form an extended medium CDM2, which did 
facilitate in vitro growth. The researchers then used LC-MS to identify what metabolites in 
CDM2 are net consumed, and what metabolites are net produced. The metabolite 
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consumption and production data was then used to improve the GEM and the corresponding 
genome annotation. Ultimately, the researchers were able to design a refined and chemically 
defined medium CDM3 that facilitated both in silico and in vitro growth, albeit that growth 
was still rather poor and unreliable (Heinken, et al., 2014).
The requirement for manual curation of ModelSEED (Henry, et al., 2010) GEMs prior to 
media design has been substantially reduced due to the presence of 773 semi-automatically 
curated GEMs of relevant gut microbes (Rajilic-Stojanovic and de Vos, 2014, Bauer, et al., 
2015) in the AGORA GEM resource (Magnusdottir, et al., 2017). These GEMs have been 
curated collectively such that any issues addressed in one GEM are also directly addressed 
in others. Although further microbe-specific manual curation may still be required for many 
microbes, some AGORA GEMs may also be directly suitable for media design. As a 
showcase, the AGORA GEM of Bacteroides caccae ATCC 34185 was successfully used to 
design the first chemically defined medium supporting in vitro growth for this gut microbe 
(Magnusdottir, et al., 2017).
Metagenomic studies (Nielsen, et al., 2014) and single-cell genomics (Lasken, 2012, 
Kolinko, et al., 2015) of gut bacteria have already yielded genomes that could be used to 
create draft GEMs. However, the available biochemical information to turn draft GEMs into 
functional GEMs for uncultured bacteria is limited. To gain more insight in secreted 
metabolites and available nutrients in the gut, imaging mass spectrometry can be applied 
(Rath, et al., 2012). These uptake and secretion patterns can be incorporated into GEMs. We 
encourage the use of GEMs to predict minimal or defined media on which the microbes of 
interest can be cultured. Combined with additional ecological and genomic markers, such as 
temperature, antibiotic resistance and spore formation, it should be possible to culture more 
bacterial species (Figure 2). The next steps are in predicting how varying environments result 
in different phenotypes.
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Figure 2. Suggested cultivation strategy. The initial cultivation strategy of a microbe can be optimised by thorough 
analysis of its genome and isolation conditions. The genome contains information on metabolic pathways, as 
represented in GEMs, that inform on auxotrophies and suitable carbon, nitrogen, and sulphur sources. In addition, 
the genome annotation can reveal additional considerations such as antibiotic or bile resistance, or the ability to form 
spores. The isolation condition of a microbe, for example the human gut, provides information on suitable 
environmental conditions such as temperature, pH, and ion strength. 
Phenotype prediction
Most microbes have versatile and complex metabolic pathways. Often, many alternative 
pathways are available for the conversion of the available substrate to all biomass 
components. GEMs can be used to explore all possible phenotypes for a wild type or mutant 
strain in a given environment. In addition, GEMs can be used to interpret experimental data 
that is difficult to directly connect to metabolic rates, such as transcriptomics and proteomics 
data. GEMs, which are ultimately based on genotypes, are thus a means to explore possible 
phenotypes in a wide range of different experimental conditions. The ability to predict how 
different microbial phenotypes result from different environments can ultimately have 
consequences for human health. For example, GEMs may be able to identify the conditions 
under which conditional pathogens become pathogenic (Oberhardt, et al., 2008), or, in 
contrast, when therapeutic bacteria or probiotics may convey their beneficial properties 
(Ventura, et al., 2009, Saulnier, et al., 2011).
A main challenge in the use of GEMs for the prediction of phenotypes of gut microbes is that 
these models are –traditionally – restricted to metabolic activities. They do not explicitly 
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include regulation nor the synthesis of mRNAs or individual proteins. Hence, GEMs can 
accurately predict growth phenotypes that are related to the optimal conversion of substrates 
to biomass components (Lewis, et al., 2010), but do not directly predict the synthesis of 
secondary metabolites and proteins involved in, crucial processes such as microbe-microbe 
signalling, microbe-host communication (Guo, et al., 2017, Plovier, et al., 2017) and 
inflammation (Quevrain, et al., 2016). Such predictions rely on the integration of ~omics data 
or regulatory networks, as highlighted by several of the following examples.
GEM-driven exploration of the metabolic capacities of pathogens has been explanatory for 
pathogenic phenotypes. For example, a GEM was used to predict virulence of Salmonella in 
a mouse model system. The GEM describes a very versatile metabolism that enables 
Salmonella to utilize 31 host nutrients, allowing it to grow fast within the host cell. The GEM 
predicted the pathogenicity of phenotypes and was accurate in 92% of the cases (Steeb, et 
al., 2013). In addition, it was found that the metabolic capabilities of Salmonella show 
similarities in host dependency for growth substrates and biosynthesis to other pathogens. 
Like Salmonella, other pathogens are also capable of degrading purine nucleosides, 
pyrimidine nucleosides, fatty acids, glycerol, arginine, N-acetylglucosamine, glucose and 
gluconate. Similarly, it was hypothesized that comparisons of metabolic patterns between 
Pseudomonas aeruginosa and non-pathogenic relatives could yield insight into opportunistic 
pathogenic phenotypes of this species (Oberhardt, et al., 2008), as has later been done 
successfully for Burkholderia species (Bartell, et al., 2014). The metabolic model for the 
pathogenic P. aeruginosa also showed a versatile metabolic pattern and accounted for 
virulence inducing pathways, such as exopolysaccharide alginate synthesis (Ramsey and 
Wozniak, 2005).
In more recent research, highly quantitative proteomics and metabolic measurements were 
used to impose pH-dependent constraints on the GEM of Enterococcus faecalis, a human gut 
pathogen (Großeholz, et al., 2016). The pH-dependent constrained GEM accurately predicted 
growth rate, proton pump activity by ATPase and a metabolic shift from mixed acid 
fermentation to homolactic fermentation. However, discrepancies were found between 
expression of lactate dehydrogenase and lactate production, which emphasized that 
constrains based on solely proteomic measurements are not sufficient for an accurate 
phenotype prediction. 
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Transcriptomics and proteomics experiments aim to discover what an organism is doing, but 
the data is often difficult to analyse because there are no one-to-one relationships between 
expression levels, protein quantities, enzyme activities, and fluxes (Hoppe, 2012, Rocca, et 
al., 2015). GEMs can aid in elucidating the metabolic activities from these data by visualising 
the data on a metabolic map or by predicting metabolic fluxes (Machado and Herrgård, 2014, 
Weaver, et al., 2014, King, et al., 2015, Zhang, et al., 2017). For example, transcriptomics 
data of two strains of Lactobacillus reuteri, with potentially opposite effects on the human 
immune system, were analysed by visualising the data on two GEMs. The analysis revealed 
that both strains produce vitamins, essential amino acids, and mucosal binding proteins, but 
that they differed in their production of potential inducers of tumour necrosis factor (Saulnier, 
et al., 2011). The prediction of metabolic fluxes from ~omics data relies on the concept that, 
on average, gene expression levels are a proxy for fluxes. The GEM then predicts a flux 
distribution that matches the trends in the expression data, while accounting for mass balance, 
thermodynamics, and capacity constraints. Several such methods have been developed in the 
last few years, and have been extensively summarised and evaluated recently (Machado and 
Herrgård, 2014). The evaluation did not result in a clear best-performing method, and none 
of the methods actually outperforms parsimonious FBA (Lewis, et al., 2010), which does not 
require any ~omics data as input. However, the evaluation conditions were limited to minimal 
media where the optimization of the conversion of substrates to biomass seems a suitable 
growth strategy. It remains to be seen how these various methods compare when microbes 
actively synthesize secondary metabolites in situ or in rich media.
A different approach to find out what an organism is doing, rather than what it can do, is by 
combining GEMs with other models, such as regulatory networks (Chandrasekaran and 
Price, 2013, Faria, et al., 2014, Kim and Reed, 2014). The regulatory networks of well-
studied species such as E. coli, M. tuberculosis and M. genitalium have been elucidated and 
incorporated in metabolic models (Chandrasekaran and Price, 2010, Karr, et al., 2012, 
Carrera, et al., 2014, Kim and Lun, 2014). Based on these model organisms, attempts have 
been made to automate the incorporation of regulatory networks into GEMs (Novichkov, et 
al., 2013), also especially aiming at less well-characterized species (Chandrasekaran and 
Price, 2010). These models incorporate the influence of environmental factors on the 
behaviour of the modelled organism, which may be extremely relevant for microbes residing 
in a dynamic environment such as the human gut. 
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include regulation nor the synthesis of mRNAs or individual proteins. Hence, GEMs can 
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These examples show how GEMs can be used to explore possible phenotypes, and to predict 
actual phenotypes based on ~omics data or regulatory models. However, we highlight the 
need for a thorough evaluation on methods for the integration of ~omics data and regulatory 
networks with GEMs to predict the phenotypes of gut bacteria in vitro and ultimately in vivo.
This will be an important stepping-stone in predicting the role of bacteria under different 
gastrointestinal conditions, on which also other microbial species have a big influence. 
GEM predictions on interspecies interactions
Within the gut microbiome there are numerous microbial interactions and networks. Three 
types of simple multispecies interactions have been described and modelled before: 
mutualism, commensalism, competition and neutralism (Klitgord and Segre, 2010, Freilich, 
et al., 2011, McCloskey, et al., 2013). GIT-colonizing microbial species often depend on each 
other for growth signals and substrates or compete for the metabolites, thus this ecosystem is 
ideal for the modelling of interspecies interactions and using interspecies interactions 
predictions to gain a mechanistic insight into this ecosystem (Borenstein, 2012, Ji and 
Nielsen, 2015). Interactions between microbes have been modelled on different phylogenetic 
levels, ranging from strains (Tzamali, et al., 2011) to species (Salimi, et al., 2010, Sun, et al., 
2010) and ecosystem communities (Levy and Borenstein, 2013). The challenges in 
multispecies modelling are briefly described below, followed by examples of successful 
GEM-based multispecies modelling approaches that are also summarized in Figure 3. 
Figure 3. Modes of interspecies interactions as modelled before. Pairwise interactions only account for two species 
to share metabolites. Multispecies models allow sharing of metabolites  between more than two species. Microbiota-
host interaction models lump all the microbial species into one meta-model and model the interaction with the host. 
Microbe-microbe and microbiota-host interactions are multilevel models that take into account microbial 
interactions and interactions with the host.
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Multispecies modelling using GEMs is complicated through the aforementioned phenotype 
prediction challenge regarding secondary metabolites, but also by two other challenges: (i) 
The vast majority of GEM analysis methods rely on a steady-state assumption, but microbial 
interactions via signalling molecules are inherently dynamic. (ii) Flux prediction methods are 
based on computational optimization with regards to a single metabolic goal, usually the 
maximization of biomass production; a reasonable goal for an individual microbial species. 
However, when multiple microbes are modelled simultaneously it is not a reasonable 
assumption that all work together to maximize total biomass production. The examples 
discussed hereafter provide a rough overview of different approaches that have been taken to 
minimize or circumvent these issues.
The pioneering work in GEM-based multispecies modelling was directly combining two 
GEMs for the mutualistic bacterium Desulfovibrio vulgaris and archaeon Methanococcus 
maripaludis S2 into a single model with a shared extracellular environment (Stolyar, et al., 
2007).  In this ecologically relevant syntrophic relationship, D. vulgaris ferments lactate, and 
M. maripaludis consumes the fermentation products formate, dihydrogen and acetate. In this 
work, the aforementioned issue on optimizing for biomass production was evaluated by 
applying distinct weights to the different types of biomass. In other words, the mathematical 
optimization would prioritize one type of biomass over the other in order to explore how this 
would affect overall flux predictions. The predicted biomass production for D. vulgaris was 
practically independent of the relative weights, whereas the M. maripaludis biomass 
production increased if it received higher weights. This is due to the sequential nature of the 
interaction between these bacteria, where D. vulgaris effectively ‘feeds’ M. maripaludis. 
However, this approach is not suitable if the community members exhibit cross-feeding or 
substrate competition.
A similar approach was taken to identify media that stimulate commensal or mutualistic 
relationships between each possible pair of seven well-known microbes (Klitgord and Segre, 
2010). This number was rapidly expanded to 118 species coupled in 6.903 pairs driven by 
automated curation of over a hundred GEMs (Freilich, et al., 2011). The latter study not only 
focused on cooperation, but also specifically on identifying media that induce competition 
between pairs of microbes. It was found that competition was generally ‘won’ by species that 
grew fast on versatile media, such as E. coli, while cooperation was more evident in 
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Clostridia species that were able to degrade lignin and cellulose, which releases free sugars 
to other bacteria. This type of macromolecule degradation is highly important in degradation 
of host dietary compounds and thus directly relates to gut health. 
Instead of looking into the details of the interactions between a few species, GEMs have also 
been used to elucidate general properties of the co-occurrence of microbes. Specifically, there 
are two main mechanisms driving species co-occurrence: (i) habitat filtering: microbes 
occupy a similar nutritional niche and compete, and (ii) species assortment: microbes have 
complementary metabolisms and cooperate. A recent study aimed to identify which of these 
two mechanisms is the driving force behind the co-occurrence of microbes in the human gut 
(Levy and Borenstein, 2013). Therefore, they automatically generated 154 GEMs based on 
KEGG (Feng, et al., 2012, Kanehisa, et al., 2014) for gut microbes whose co-occurrences 
were determined based on a gut metagenome dataset containing measurements from 124 
individuals. These GEMs were used to determine metabolic competition and 
complementarity indices between each pair of species based on network topology, thereby 
circumventing the need for optimization based on an ambiguous multispecies metabolic goal. 
As the species co-occurrence was best explained via the metabolic competition index, the 
authors concluded that habitat filtering is the main driving force behind species co-occurrence 
in the human gut. In an other recent study, GEMs were used to study species co-occurrence 
based on 261 microbial species in 1297 communities from diverse habitats (Zelezniak, et al., 
2015). The GEMs were used to calculate both the resource competition and interaction 
potential within these communities based on network topology. Resource competition was 
significantly higher in the 1297 communities versus random assemblies, indicating that 
habitat filtering was again identified as the main driving force behind community 
composition. However, there were also 7221 sub-communities of up to 4 co-occurring 
species within the larger communities. Within these sub-communities, the interaction 
potential – defined as the difference in minimal number of metabolites required for growth 
between a non-interacting and a cooperating community - was significantly higher than in 
full communities and random assemblies. 
In order to understand how gut communities form and change, it is also important to consider 
spatial and temporal effects. The novel modelling framework COMETS (Harcombe, et al., 
2014) - Computation of Microbial Ecosystems in Time and Space – simulates multiple GEMs 
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on a lattice over time using dynamic FBA (Mahadevan, et al., 2002), which is based on 
simulating dynamics using successive steady-state optimizations. COMETS does not require 
any prior information on how the modelled microbes interact, but nonetheless captures 
interesting and non-intuitive spatiotemporal dynamics of multispecies interactions. For 
example, it correctly predicted that the slowest-growing microbe of a three-species ecosystem 
would also ultimately be the most-prevalent one, and that the growth rate of a colony with a 
mutualistic partner can be improved by placing a competing colony in between them. 
COMETS has also been used to study how robust competing and mutualistic interactions are 
to genetic perturbations. Specifically, it has been possible to predict the effects of gene 
knockouts on a synthetic community of Escherichia coli and Salmonella enterica
(Harcombe, 2010) on competition-inducing and mutualism-inducing growth media (Chubiz, 
et al., 2015).  Interestingly, the community was more robust to genetic perturbations in E. 
coli under cooperative conditions, but more robust to genetic perturbations in S. enterica 
under competing conditions (Chubiz, et al., 2015). These results highlight that GEMs can 
mechanistically explain the intriguing interactions of multispecies interactions.
A conceptually similar framework is BacArena (Bauer, et al., 2017). BacArena also uses a 
dynamic form of FBA simulations to model microbes over time, but simulates individual 
microbes across a 2D grid (Bauer, et al., 2017) rather than microbial communities on a lattice 
as in COMETS (Harcombe, et al., 2014). Of particular interest is the application of BacArena 
to the seven species SIHUMI community representative of a simplified human gut (Becker, 
et al., 2011). Initial simulations excluding glycan production in the lumen resulted in a 
community dominated by E. coli. However, as a mucus glycan gradient was imposed using 
diffusion on the 2D grid, the glycan-degrading Bacteroides thetaiotamicron became 
dominant in the mucosal layer, while the lumen represented a more varied community still 
dominated by E.coli.
A multispecies interaction of particular interest is the interaction between gut microbes and 
their host. The host is not only an important environmental factor for gut microbes, but is 
also metabolically active itself. Additionally, host behaviour such as diet intake has a great 
and reproducible influence on the microbiota composition (Flint, et al., 2017). GEMs have 
been created for hosts of particular interest, such as mouse (Sigurdsson, et al., 2010) and 
human (Thiele, et al., 2013), and have even been trimmed down to tissue-specific GEMs, 
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including a GEM for colon-derived tissue (Browne, et al., 2016). The human Recon 2.04 
GEM was adapted to be not only tissue specific but context specific as well. Transcriptome 
data obtained from inflamed mucosal tissue in IBD data was used to generate new GEMs 
(Hasler, et al., 2016). Subsequent combination of this data with bacterial expression data 
showed uncoupling of host-microbe metabolic interactions in IBD patients.  The mouse GEM 
(Sigurdsson, et al., 2010) was recently used to study how different diets and the presence of 
the gut microbe Bacteroides thetaiotaomicron affect its metabolism (Heinken, et al., 2014).
A B. thetaiotaomicron model was constructed using ModelSEED (Henry, et al., 2010) and, 
after manual curation, was linked to the mouse GEM via a shared lumen compartment. 
Although a single microbe is not directly representative of the gut community, the combined 
GEM mechanistically explained how both organisms benefit from the mutualism, correctly 
predicted how the interaction affects biofluid metabolome composition, and even described 
how gut microbes can rescue hosts with lethal gene deletions (Heinken, et al., 2014).
Host-microbe interactions have also been modelled using a single ‘supra-organism model’ 
(Borenstein, 2012) to represent all gut microbes simultaneously, thereby also avoiding 
optimization-related issues with multiple microbial biomass types. These GEMs don’t focus 
on individual microbes or their interactions, but rather on the interaction of the community 
with the environment or host. Such a GEM was used together with metagenomics data to 
study how host-microbe interactions differ in case of obesity or inflammatory bowel disease 
(IBD) (Greenblum, et al., 2012). This revealed a differential expression of enzyme groups 
expressed by the complete microbiota between diseased and healthy people, without 
investigating the roles of individual species or their interactions. The differences were found 
in the upregulation of membrane transport and downregulation of vitamin metabolism, 
nucleotide metabolism and transcription. This study suggests that the differences in enzyme 
expression originate from an altered interaction between the microbes and their environment. 
They are the result of a change in the environment of the bacteria and do not come from a 
change in core metabolic processes. By combining previous approaches of modelling 
interspecies interactions and considering the whole microbiota as one entity, a predictive tool 
for dietary interventions was created (Shoaie, et al., 2015). The tool, CASINO - Community 
And Systems-level Interactive and Optimization - predicts dietary interventions based on 
interactions between the host, the microbiota and the applied diet. CASINO was used to 
model the interactions of four microbes in two synthetic communities that differed by a single 
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microbe. It correctly predicted the produced metabolites, including essential amino acids, and 
the contribution of each species to the production of each metabolite. CASINO was then used 
to predict the impact of a dietary intervention in 44 individuals, based on relative abundances 
of the most prevalent microbes in each individual before and after the intervention. The 
predicted production of SCFAs and amino acids mostly matched the in vivo measurements. 
Finally, CASINO was used to design a beneficial diet for subjects with a poor microbiota 
composition (Shoaie, et al., 2015).
The use of GEMs to predict multispecies interactions and to study the influence of 
perturbations in environmental factors and communities is a valuable asset in microbiota 
function prediction. In this way it can be predicted how individual species contribute to 
healthy and diseased conditions. The increase in tools for the prediction of multispecies 
interactions highlights the importance of this application. Moreover, these predictions were 
instrumental in the prediction of diets to improve the metabolic function of gut microbiota 
(Shoaie, et al., 2015). Ultimately, this research will lead to increased understanding of the 
interactions of the gut microbiota and its host, and on its role in gut homeostasis and 
(dys)function, and it will ultimately pave to way to improve human health using specific gut 
microbes or dietary interventions. 
Conclusion and perspectives
After a few decades of characterizing gut microbiota composition many gut microbes have 
been sequenced (Peterson, et al., 2009, Qin, et al., 2010). Over 200 of these genome 
sequences have been used to generate GEMs, in most cases by automated tools (Henry, et 
al., 2010, Caspi, et al., 2014). These GEMs have been used to predict growth phenotypes of 
single microbes and communities in laboratory and in vivo settings.
Here, we reviewed three ways in which GEMs contribute in elucidating gut microbiome 
function. We described how GEMs are used to: (i) culture bacteria, (ii) predict bacterial 
phenotypes under changing conditions, and (iii)  study the interactions both among the 
bacterial species and with their host.
We have shown that recent advances in automated generation of GEMs (Henry, et al., 2010, 
Magnusdottir, et al., 2017), single-cell genomics (Blainey, 2013), metagenomics (Gill, et al., 
2006, Qin, et al., 2010) and metatranscriptomics (Bailly, et al., 2007, Maurice, et al., 2013, 
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GEM was adapted to be not only tissue specific but context specific as well. Transcriptome 
data obtained from inflamed mucosal tissue in IBD data was used to generate new GEMs 
(Hasler, et al., 2016). Subsequent combination of this data with bacterial expression data 
showed uncoupling of host-microbe metabolic interactions in IBD patients.  The mouse GEM 
(Sigurdsson, et al., 2010) was recently used to study how different diets and the presence of 
the gut microbe Bacteroides thetaiotaomicron affect its metabolism (Heinken, et al., 2014).
A B. thetaiotaomicron model was constructed using ModelSEED (Henry, et al., 2010) and, 
after manual curation, was linked to the mouse GEM via a shared lumen compartment. 
Although a single microbe is not directly representative of the gut community, the combined 
GEM mechanistically explained how both organisms benefit from the mutualism, correctly 
predicted how the interaction affects biofluid metabolome composition, and even described 
how gut microbes can rescue hosts with lethal gene deletions (Heinken, et al., 2014).
Host-microbe interactions have also been modelled using a single ‘supra-organism model’ 
(Borenstein, 2012) to represent all gut microbes simultaneously, thereby also avoiding 
optimization-related issues with multiple microbial biomass types. These GEMs don’t focus 
on individual microbes or their interactions, but rather on the interaction of the community 
with the environment or host. Such a GEM was used together with metagenomics data to 
study how host-microbe interactions differ in case of obesity or inflammatory bowel disease 
(IBD) (Greenblum, et al., 2012). This revealed a differential expression of enzyme groups 
expressed by the complete microbiota between diseased and healthy people, without 
investigating the roles of individual species or their interactions. The differences were found 
in the upregulation of membrane transport and downregulation of vitamin metabolism, 
nucleotide metabolism and transcription. This study suggests that the differences in enzyme 
expression originate from an altered interaction between the microbes and their environment. 
They are the result of a change in the environment of the bacteria and do not come from a 
change in core metabolic processes. By combining previous approaches of modelling 
interspecies interactions and considering the whole microbiota as one entity, a predictive tool 
for dietary interventions was created (Shoaie, et al., 2015). The tool, CASINO - Community 
And Systems-level Interactive and Optimization - predicts dietary interventions based on 
interactions between the host, the microbiota and the applied diet. CASINO was used to 
model the interactions of four microbes in two synthetic communities that differed by a single 
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microbe. It correctly predicted the produced metabolites, including essential amino acids, and 
the contribution of each species to the production of each metabolite. CASINO was then used 
to predict the impact of a dietary intervention in 44 individuals, based on relative abundances 
of the most prevalent microbes in each individual before and after the intervention. The 
predicted production of SCFAs and amino acids mostly matched the in vivo measurements. 
Finally, CASINO was used to design a beneficial diet for subjects with a poor microbiota 
composition (Shoaie, et al., 2015).
The use of GEMs to predict multispecies interactions and to study the influence of 
perturbations in environmental factors and communities is a valuable asset in microbiota 
function prediction. In this way it can be predicted how individual species contribute to 
healthy and diseased conditions. The increase in tools for the prediction of multispecies 
interactions highlights the importance of this application. Moreover, these predictions were 
instrumental in the prediction of diets to improve the metabolic function of gut microbiota 
(Shoaie, et al., 2015). Ultimately, this research will lead to increased understanding of the 
interactions of the gut microbiota and its host, and on its role in gut homeostasis and 
(dys)function, and it will ultimately pave to way to improve human health using specific gut 
microbes or dietary interventions. 
Conclusion and perspectives
After a few decades of characterizing gut microbiota composition many gut microbes have 
been sequenced (Peterson, et al., 2009, Qin, et al., 2010). Over 200 of these genome 
sequences have been used to generate GEMs, in most cases by automated tools (Henry, et 
al., 2010, Caspi, et al., 2014). These GEMs have been used to predict growth phenotypes of 
single microbes and communities in laboratory and in vivo settings.
Here, we reviewed three ways in which GEMs contribute in elucidating gut microbiome 
function. We described how GEMs are used to: (i) culture bacteria, (ii) predict bacterial 
phenotypes under changing conditions, and (iii)  study the interactions both among the 
bacterial species and with their host.
We have shown that recent advances in automated generation of GEMs (Henry, et al., 2010, 
Magnusdottir, et al., 2017), single-cell genomics (Blainey, 2013), metagenomics (Gill, et al., 
2006, Qin, et al., 2010) and metatranscriptomics (Bailly, et al., 2007, Maurice, et al., 2013, 
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Baldrian and Lopez-Mondejar, 2014) can increase the availability and accuracy of GEMs. 
Metagenomics as well as single-cell genomics will yield more genome sequences of microbes 
that can be used for generating GEMs. Moreover, developments in single molecule 
sequencing will allow for closed genomes that are in the end the golden standard to be used 
for generating GEMs. These GEMs will contribute in understanding how both uncultured 
and cultured bacteria live and behave in complex ecosystems (Ji and Nielsen, 2015). In vivo
or in vitro validation of GEM predictions and subsequent GEM updates remain key in 
improving GEM quality and ultimately understanding the complex gut ecosystem.
GEMs allow understanding why species are present and what they do, instead of who they 
are, as was the focus in the last decades. We expect that GEMs will contribute to elucidate 
the mechanisms behind known probiotics, as well as in identifying new probiotics, and 
understanding the role of different bacteria in complex ecosystems. Ultimately, GEMs can 
contribute to the design of controlled interventions that steer gut composition and activity to 
improve human health.
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Abstract
The abundance of the human intestinal symbiont Akkermansia muciniphila has found to be 
inversely correlated with several diseases, including metabolic syndrome and obesity. A. 
muciniphila is known to use mucin as sole carbon and nitrogen source. To study the 
physiology and the potential for therapeutic applications of this bacterium, we designed a 
defined minimal medium. The composition of the medium was based on the genome-scale 
metabolic model of A. muciniphila and the composition of mucin. Our results indicate that 
A. muciniphila does not code for GlmS, the enzyme that mediates the conversion of fructose-
6-phosphate (Fru6P) to glucosamine-6-phosphate (GlcN6P), which is essential in 
peptidoglycan formation. The only annotated enzyme that could mediate this conversion is 
Amuc-NagB on locus Amuc_1822. We found that Amuc-NagB was unable to form GlcN6P 
from Fru6P at physiological conditions, while it efficiently catalyzed the reverse reaction. To 
overcome this inability, N-acetylglucosamine needs to be present in the medium for A. 
muciniphila growth. With these findings the genome scale-metabolic model was updated and 
used to accurately predict growth of A. muciniphila on synthetic media. The finding that A.
muciniphila has a necessity for GlcNAc, which is present in mucin further prompts the 
adaptation to its mucosal niche.
Model-driven design of a minimal medium for Akkermansia muciniphila
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Introduction
Akkermansia muciniphila is a mucin-degrading bacterium that is present in the 
intestinal tract of a majority of people (Derrien, et al., 2008). On average the relative 
abundance of A. muciniphila is 0.1-4% in human fecal samples (Derrien, et al., 2008, Png, et 
al., 2010, Lyra, et al., 2012). Inverse correlations have been reported between the relative 
abundance of A. muciniphila and diseases and disorders such as metabolic syndrome, autism 
and obesity (Derrien, et al., 2008, Wang, et al., 2011, Derrien, et al., 2016, Gomez-Gallego, 
et al., 2016). In humans it was shown that weight loss interventions and gastric bypass surgery 
in obese people, increase the abundance of A. muciniphila (Liou, et al., 2013, Anhe, et al., 
2015, Dao, et al., 2015). Moreover, in a series of preclinical interventions in mice it was 
shown that A. muciniphila reversed diet induced metabolic fat-mass gain and insulin 
resistance (Everard, et al., 2013, Plovier, et al., 2017) possibly due to outer membrane 
produced pili (Ottman, et al., 2017a, Plovier, et al., 2017).
A. muciniphila was first isolated by using purified hog gastric mucus as sole carbon 
and nitrogen source (Derrien, et al., 2004). In addition to the degradation of intestinal mucins, 
A. muciniphila was shown to be closely associated to colonic epithelial cells producing these 
mucins (Derrien, et al., 2011). The adaptation to this niche is exemplified by the capabilities 
of A. muciniphila to utilize low concentrations of oxygen present in the mucus layer 
(Ouwerkerk, et al., 2016), even though it was previously characterized as a strictly anaerobic 
bacterium (Derrien, et al., 2004). The efficient use of mucin by A. muciniphila was shown in 
an in vitro intestinal model and upon addition of mucus, A. muciniphila abundance showed 
over 10.000 fold increase, the highest ever observed in this model (Van Herreweghen, et al., 
2017).
The mucin in the mucus layer lining the intestinal track is composed of a peptide backbone 
abundantly decorated with O-linked glycans (Johansson, et al., 2011, Thomsson, et al., 2012).
The peptide backbone is rich in threonine, serine, cysteine and proline, while the glycans are 
composed of a plethora of sugar groups that contain mannose, galactose, fucose and N-
acetylhexosamines such as N-acetylglucosamine (GlcNAc), and N-acetylgalactosamine 
(GalNAc). Some fecal microbiota species are known to have mucolytic activities (Variyam 
and Hoskins, 1981). Glycosidases needed to degrade polysaccharides have been isolated 
from the supernatant of cultures of Bifidobacterium and Ruminococcus spp (Hoskins, et al., 
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1985). These bacteria were supposed to be a distinct subpopulation of the normal fecal 
microbiota based on their glycosidase activity. The involvement of glycosidases in mucolytic 
activity has since been described for multiple species, including Bacteroides species and A. 
muciniphila (Tailford, et al., 2015). The subsequent degradation of polysaccharides and 
monosaccharides is a common feature in bacteria, as they are similar to diet derived sugars 
and used in fermentation (Chen, et al., 2002, Pereira and Berry, 2017). A. muciniphila is 
capable of fermenting some of the monosaccharides including galactose, fucose, glucose, 
GlcNAc and GalNAc, which have been reported to be used for both energy generation and 
as carbon source (Desai, et al., 2016, Ottman et al., 2017b). However, the degradation of 
these sugars is only possible in the presence of mucin or large amounts of a tryptic digest of 
casein (Desai, et al., 2016, Ottman et al., 2017b).
The genome-encoded metabolic potential of A. muciniphila has been previously 
exploited to design a genome scale model of its metabolism (van Passel, et al., 2011, Ottman
et al., 2017b). Extensive model curation and evaluation led to the prediction of an auxotrophy 
for L-threonine as well as predictions regarding the production of the short chain fatty acids 
(SCFA) acetate and propionate. The production of these SCFAs was confirmed by growth 
experiments, however in deviating ratios compared to the predictions. The addition of L-
threonine to the growth media did increase growth, but its essentiality for growth was not 
confirmed due to the presence of the partially undefined casein hydrolysate in the medium 
(Ottman et al., 2017b).
To better understand the physiological properties of A. muciniphila it is essential to 
have a defined minimal medium for growth. Such a medium can also be the basis for the 
application of A. muciniphila as a therapeutic microbe since the medium components should 
be defined and preferably of non-animal origin before clinical tests can be conducted. Here, 
we present a completely defined and minimal medium that supports growth of this beneficial 
microbe. We confirmed that the amino acid L-threonine is essential for growth and observed 
that the addition of either GlcNAc or GalNAc was essential for the growth of A. muciniphila.
Furthermore, we discovered A. muciniphila does not code for a functional GlmS and hence 
requires the exogenously added GlcNAc or GalNAc not only for fermentation, but also for 
peptidoglycan formation. 
Model-driven design of a minimal medium for Akkermansia muciniphila
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Materials and Methods 
Culturing A. muciniphila, optical density and HPLC
A. muciniphila was grown in anaerobic bottles containing 10 ml medium as 
described before (Derrien, et al., 2004), supplemented with 6 g/l of L-threonine and 25 mM 
sugar, as indicated in Table S1. Growth was determined by measuring the optical density at 
600 nm. High-pressure liquid chromatography (HPLC) was used to determine sugar 
consumption and SCFA production, as described before (Derrien, et al., 2004, Ouwerkerk, 
et al., 2016, Ottman et al., 2017b). Glucosamine (GlcN) concentration was determined by 
reagent free ion chromatography using a Dionex™ ICS-5000 (Thermo Scientific, Sunnyville, 
CA, USA), with a Dionex CarboPac PA20 Analytic column and 20mM NaOH as eluent. 
Further settings were according to manufacturer’s application note.  
Identification of GlmS and NagB homologues in A. muciniphila
Escherichia coli K12 NagB (NP_415204.1) and GlmS (NP_418185.1) amino acid 
sequences were used to identify enzymes that can mediate the formation of GlcN6P from 
Fru6P in Akkermansia (taxid:239934). This was done by selecting best bidirectional blastp 
(protein-protein BLAST) hits between both genomes (Altschul, et al., 1990). Analysis was 
performed on February 10, 2017. 
Enzyme expression and purification
The A. muciniphila gene NagB on locus Amuc_1822 (AMUC_RS09725) was 
amplified using the forward primer 5’-ATAGAGGTACCATGATCGGGGTGGAAAGT-3’ 
and the reverse primer 5’-
TATGCCCTAGGTTAATGGTGGTGGTGATGATGAAGGAGGGAAGCAGCCC-3’, 
adding a C-terminal His-tag (bold in primer sequence) and restriction sites (underlined in 
primer sequence). Genomic DNA from A. muciniphila ATCC BAA-835 was used as 
template. The purified amplicon and vector pCDF-1b (Novagen, Merck Milipore, Darmstadt, 
Germany) were digested using enzymes XmaIJ (Thermo Fisher Scientific) and KpnI HF 
(New England Biolabs) in Tango buffer (Thermo Fisher Scientific) for 1.5 hours at 37˚C. 
The DNA was purified again and ligated with 3:1 ratio (insert:vector) using T4 ligase 
(manufacturers protocol, Thermo Fisher Scientific). Competent Escherichia coli DH10B 
(manufacturers protocol, New England Biolabs) were transformed with 2 µL ligation mixture 
and plated on LB agar with 50 ug/mL spectinomycin. A selected colony was grown in 10 mL 
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liquid LB until an OD600 of 1 after which plasmids were purified. E. coli BL21 (DE3) 
(manufacturers protocol, New England Biolabs) was transformed with 1µL plasmid 
containing 60 ug/mL DNA, and 100 µL was plated on LB agar with 50 ug/mL spectinomycin. 
The transformed strain was grown in 250 mL liquid LB medium with 50 ug/mL 
spectinomycin until an OD600 of 0.5-1 after which is was induced with 1 mM IPTG for 4 
hours at 37˚C. The bacteria were collected by centrifugation at 5.000 g for 10 minutes and 
suspended in lysis buffer (50 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM MgCl2, 5 mM 
DTT, 1 mM PMSF). The cells were lysed by three passages in a French Press (15.000 psi, 
Pressure Cell Homogeniser, Stansted Fluid Power Ltd., Essex, UK). The lysate was cleared 
by centrifugation for 10 minutes at 16.000g. The proteins were purified using a nickel column 
(manufacturers protocol, Ni-NTA Agarose, Qiagen GmbH, Hilden, Germany). Purified 
fractions were dialyzed against 1 L of buffer A (25 mM KH2PO4/K2HPO4, pH 7.0, 0.5 mM 
PMSF, 1 mM DTT, 1 mM EDTA). Purity of the enzymes was checked using SDS-PAGE. 
Enzyme concentration was determined by BCA protein assay (manufacturers protocol, 
Thermo Fisher Scientific). 
Enzyme assays
Enzyme assays were performed as described before (Kwiatkowska-Semrau, et al., 2015).
Shortly, 1.5 mL tubes were filled with the buffer and substrates as indicated in Table S3. The 
enzymes were added last, after which the tubes were vortexed shortly and incubated at 37˚C 
for exactly 3 minutes. Subsequently, the tubes were placed at 99˚C for 1 minute and cooled 
on ice. To acetylate GlcN6P, 100 µL of 10% acetic acid in acetone and 200 µL of a saturated 
NaHCO3 solution were added, after which the samples were incubated for 3 minutes at 20˚C 
and 3 minutes at 99˚C. The samples were cooled on ice again, after which 200 µL of a 0.8 M 
potassium tetraborate hexahydrate solution was added. The samples were incubated for 3 
minutes at 99˚C and cooled on ice. Finally, 800 µL of these solution were added to 5 mL of 
reagent A (1 g of 4-dimethylaminobenzaldehyde in 100 mL of glacial acetic acid to which 
1.5 mL 37% HCl is added). The samples were incubated at 37˚C for 30 minutes, after which 
the absorbance was measured at 585 nm (manufacturer). The Km and Vmax values were 
determined by plotting the obtained data on a Lineweaver-Burk plot (Burk, et al., 1934).
Model-driven design of a minimal medium for Akkermansia muciniphila
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Genome-scale constraint based metabolic model
The genome scale constraint based model of A. muciniphila AkkMuc_588 reported 
previously (Ottman et al., 2017b) was used to assess growth potential on different media. The 
core of the model is S the stoichiometric matrix.  S is an m×n matrix, where n is the number 
of metabolites and m is the number of reactions in the model, 734 and 745 respectively. 
Entries of S represent the stoichiometric coefficients of each metabolite in each reaction.  In 
addition to reactions describing metabolic interconversions and transport, the model also 
contain reactions that describe the media composition and the uptake and secretion potential 
of the organism, these are the so-called exchange reactions. The usual convention, (followed 
in the A. municiniphila model) is to represent uptake and production as negative and positive 
fluxes through the exchange reactions respectively. The model was used to simulate steady 
state as, in such situation, production of intracellular metabolites equals consumption and the 
model was used to identify sets of reactions (or pathways) that carry flux in such a case. 
Moreover, flux balance analysis (FBA) can be used to identify optimal (maximal or minimal)  
theoretical values for selected objectives such as biomass synthesis or metabolite uptake or 
production (Orth, et al., 2010).
Model simulations were performed by simulating the experimentally tested media. 
Unlimited secretion was allowed for metabolites in the media by setting the upper bounds of 
the corresponding exchange reactions to 1000. Abundant metabolites in the media such as 
water, P, Mn, Mg, Fe, Cu, Co, Cl, H2O2, sulfate and dimethylbenzimidazole, were set to be 
non-limiting by setting the lower bounds of  the corresponding exchange reactions to -1000. 
Simulations involving threonine media supplementation were performed with a limited 
maximal possible uptake of 1. For all the tested sugars a range of uptake rates between 0 and 
10 were tested. Arbitrary units (a.u.) were used in all simulations. FBA and model simulations 
were performed using Python version 2.7.12 (Python, 2017) the COBRApy library (version 
0.4.1) (Ebrahim, et al., 2013) and  Gurobi solver (Gurobi Optimizer Version 6.5.1 linux64) 
(Gurobi, 2016).
Results and Discussion
GlcNAc is essential for A. muciniphila growth 
A. muciniphila was isolated using porcine gastric mucus and it was shown that this complex 
substrate could serve as the sole nitrogen and carbon source (Derrien, et al., 2004). Limited 
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growth was also observed when large amounts of tryptone, a tryptic digest of casein, were 
added as nitrogen source in combination with monosaccharides (Ottman et al., 2017b). This 
can be due to the presence of either amino acids or glycans in both complex substrates. Hence, 
the dependency of A. muciniphila on exogeneous nitrogen-containing compounds and sugars 
was tested in a series of growth experiments (Figure 1). The amino sugars tested (GlcNAc, 
GalNAc and GlcN) in these experiments were selected based on their presence in mucin 
glycans. We tested the essentiality of L-threonine by omitting it in the medium in the presence 
of ammonium and other amino acids, which resulted in no growth. This amino acid was 
selected based on the A. muciniphila genome scale constraint based model of metabolism, 
referred to as ‘the model’ hereafter (Ottman et al., 2017b). The final composition of the 
minimal medium is mineral CP medium (Derrien, et al., 2004) without ammonium chloride 
and added L-threonine and GlcNAc or GalNAc. 
Figure 1. Growth of A. muciniphila on CP medium supplemented with L-threonine and different sugars. All sugars 
were supplemented to a total of 25mM. The negative control was supplemented with GlcNAc/glucose and not 
inoculated. The data shown are averages of 3 biological replicates and two technical duplicates for each.
A growth rate of 0.056 h-1 was observed for medium containing 25mM GlcNAc, and a value 
of 0.084 h-1 was found for growth on 25mM GalNAc (Table 1). The growth rate was 
increased from 0.056 h-1 to 0.122 h-1 when half of the GlcNAc was replaced by an equimolar 
amount of glucose. The final density of the cells is similar for growth on GlcNAc, GalNAc 
and GlcNAc/glucose, (Figure 1). When GlcN was used as substrate, growth was only 
observed with the addition of glucose, at a very low growth rate of 0.005 h-1.
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Table 1 Growth rate per hour (µ) of A. muciniphila on different sugars, with 6 g/L L-Thr
Sugars µ (h-1) SD
GlcNAc/Glc 0.122 0.036
GlcNAc 0.056 0.023
GalNAc 0.084 0.014
GlcN/Glc 0.005 0.004
GlcN -0.001 0.002
Fru 0.000 0.000
Glc 0.000 0.000
Neg. control 0.000 0.000
The consumption and production of metabolites by A. muciniphila after growth were 
measured by HPLC and used to obtain insight in the pathways operating (Figure 2). This 
analysis showed that the consumption rates of glucose and GlcNAc were the same when both 
were present in the growth medium (Figure 2A). In case of GlcNAc and GalNAc degradation 
by A. muciniphila, the ratio of acetate and propionate production was the same, between 1.5:1 
and 2:1 (Figure 2B,C). Combination of GlcNAc and glucose in the medium leads to a 1:1 
ratio (Figure 2A). Degradation of glucose in the presence of GlcN produced acetate and 
propionate in a 1:2 ratio, GlcN as a sole carbon source was not able to sustain growth, 
nevertheless is degraded albeit in low amounts and did not contribute to SCFA production 
(Figure 2D,E). This level of SCFA production on glucose was in line with the predictions by 
the model (Ottman et al., 2017b), but not with previous findings in growth experiments where
an acetate to propionate ratio of 1:1 was found (Ottman et al., 2017b). The accurate 
determination of SCFA production on monosaccharides needed the minimal medium 
described here since on complex and undefined media with mucus or casein hydrolysate such 
measurements were inaccurate.  
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nevertheless is degraded albeit in low amounts and did not contribute to SCFA production 
(Figure 2D,E). This level of SCFA production on glucose was in line with the predictions by 
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Figure 2. SCFA production and degradation of sugars. The degradation of GlcNAc and glucose results in a 1:1 ratio 
of acetate and propionate (A). The degradation of GlcNAc and GalNAc results in similar acetate and propionate 
ratios of 1.5:1 to 2:1 (B, C). The production of acetate and propionate on glucose and GlcN is in a 1:2 ratio (D). 
GlcN is still degraded when not supplemented with glucose, but no SCFA production was observed (E).   
The production of SCFA after degradation of the acetylated aminosugars GlcNAc and 
GalNAc indicated that these compounds are degraded for the generation of energy in addition 
to their possible use for the formation of peptidoglycan. A ratio of 1.5:1 to 2:1 is in line with 
previous findings (Ottman et al., 2017b). The metabolic model predicts a 5:4 ratio, which 
slightly lower than the measured value (Ottman et al., 2017b). The early stagnation of growth 
on GlcN and glucose while there is some production of SCFA shows that the cells are active 
and alive, but limited in growth. This shows again that either GlcNAc or GalNAc is essential 
for growth in terms of biomass formation. 
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Although it has been suggested that A. muciniphila is able to degrade GalNAc (Ottman et al.,
2017b) the previous metabolic reconstruction of A. muciniphila contained no GalNAc
degradation pathways due to the current lack of reference degradation pathways in the 
MetaCyc  database (Caspi, et al., 2014). The growth of  A. muciniphila on GalNAc could 
possibly be explained by an isomerizing step from UDP-GalNAc to UDP-GlcNAc, mediated 
by the enzyme UDP-glucose 4-epimerase encoded on locus Amuc_1125 (AMUC_RS06020) 
(Thoden, et al., 2001, Bernatchez, et al., 2005, van Passel, et al., 2011). The growth of A. 
muciniphila on GlcN in combination with glucose could be due to acetylation of GlcN6P 
(Figure 3). This acetate group is known to be donated by acetyl-CoA, which can only be 
formed if a sugar is degraded first. Due to this constraint, the growth may be slower because 
it requires glucose to form acetyl-CoA. Additionally, from the metabolic model point of view, 
growth on GlcN is only impaired by the lack of a transport mechanism as we could not 
identify a gene in the A. muciniphila genome that would code for a transporter for GlcN. 
Therefore, it be could that the transport of GlcN to the cytoplasm is limited to transportation 
by other sugars transporters and thereby very inefficient.  
Figure 3. Schematic representation of sugar phosphorylation and conversion of phosphorylated sugars and formation 
of peptidoglycans. Co-metabolites are depicted when appropriate in italic, enzymes between square brackets [], 
arrows represent directionality, multiple arrows indicate multiple conversions. Blue arrows indicate the proposed 
Akkermansia GlcNAc shortcut for peptidoglycan formation.
The results indicated that amino sugars (GlcNAc, GalNAc and limited on GlcN) could 
support growth of A. muciniphila, but not glucose or fructose (Table S1). This suggested that 
A. muciniphila might lack the ability to aminate fructose-6-phospgate (Fru6P) to form 
glucosamine-6-phosphate (GlcN6P), which is an essential step in peptidoglycan synthesis 
(Barreteau, et al., 2008, Durand, et al., 2008), (Figure 3). This reaction is catalyzed by the 
enzyme GlmS (see below), which mediates the attachment of an amino group donated by 
glutamine to Fru6P to form GlcN6P (Durand, et al., 2008). This phosphorylated sugar is 
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support growth of A. muciniphila, but not glucose or fructose (Table S1). This suggested that 
A. muciniphila might lack the ability to aminate fructose-6-phospgate (Fru6P) to form 
glucosamine-6-phosphate (GlcN6P), which is an essential step in peptidoglycan synthesis 
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subsequently converted to N-acetylglucosamine-6-phosphate after the addition of an acetate 
group and isomerized to N-acetylglucosamine-1-phosphate (Barreteau, et al., 2008), (Figure 
3). The enzyme GlmS is essential in all peptidoglycan forming bacteria (Milewski, 2002) and 
Escherichia coli glms mutants are only viable if the growth medium is supplemented with 
GlcNAc (Wu and Wu, 1971). This indicates that the GlcNAc can be phosphorylated and used 
for peptidoglycan synthesis directly by A. muciniphila, an Akkermansia GlcNAc shortcut 
(Figure 3).
Genomic analysis of A. muciniphila for the identification of glucosamine-6-phosphate 
deaminase
We mined the A. muciniphila genome to identify genes encoding enzymes mediating 
conversions between Fru6P and GlcN6P. This lead to the finding that the genome of A. 
muciniphila does not code for a gene with high similarity to a characterized GlmS, see Table 
S5. The highest identity to E. coli GlmS was a von Willebrand factor type A domain protein 
(KXT50996.1) with an identity of 26% and an E-value of 0.68. There is also no gene 
homologues to GlmS from Verrucomicrobium spinosum, the type strain for 
Verrucromicrobiae, and thus a relative of A. muciniphila. Therefore, we consider A. 
muciniphila does not code for GlmS. The gene that encodes for glucosamine-6-phosphate 
deaminase (CDB55261.1) on locus amuc_1822 (AMUC_RS09725) is the only candidate 
gene that expresses an enzyme which could mediate the reaction between GlcN6P and Fru6P. 
No homologues were found in the A. muciniphila genome. The analogue in E. coli is named 
NagB. The directionality of this enzyme from different organisms is ambiguous (Vincent, et 
al., 2005). It has been found to predominantly mediate the reaction in the deaminating 
direction, but aminating activity has been found as well (Tanaka, et al., 2005, Kwiatkowska-
Semrau, et al., 2015). Hence, we focused our attention to the kinetic characterization of the 
A. muciniphila NagB homologue. 
Enzyme assays confirm the deamination properties of glucosamine-6-phosphate 
deaminase
We observed that A. muciniphila was not able to metabolise fructose and does not grow on 
glucose, while GlcN supports growth, although very limited, (Table 1). To assess the 
capabilities of A. muciniphila to convert fructose-6-phosphate (Fru6P) into glucosamine-6-
phosphate (GlcN6P) and vice versa, we overproduced the only possible candidate enzyme, 
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termed Amuc-NagB, encoded by gene amuc_1822 (AMUC_RS09725) in E. coli BL21 
(DE3) with a C-terminal His-tag and purified it to apparent homogeneity as a 33-kDa protein 
(Figure S2).  The purified Amuc-NagB was assayed for conversions in both the aminating 
and deaminating direction and with all possible substrates involved (Table S2). 
We found that the enzyme Amuc-NagB can mediate the reaction combining Fru6P and NH4 
to produce GlcN6P, with Km values for Fru6P and NH4 of 5.5 ± 0.9  mM and 41.3 ± 12.8 
mM respectively (Table 2), as calculated based on triplicate assays, one of which one is 
represented in a Lineweaver-Burk plot (Figure 4). However, the Km of GlcN6P value for the 
deaminating direction is much lower at 2.4 ± 0.2 mM, see Figure 4 and Table 2. The addition 
of GlcNAc6P as possible allosteric activator had no significant influence on the Km values 
(p > 0.05). On top of this, the activity of the purified Amuc-NagB on Fru6P with glutamine 
was measured to determine the possibility for this enzyme to mediate the conversion of Fru6P 
+ glutamine  GlcN6P + glutamate [EC 2.6.1.16]. No activity was found using these 
substrates. Additional controls using enzyme without substrates and substrate without 
enzyme also showed no activity (Table S8). 
Table 2 Enzyme kinetics of A. muciniphila NagB with and without GlcNAc6P. The addition of 0.25 mM GlcNAc6P 
as activator has no influence on the kinetics of the enzyme. 
Km (mM)
Activator: GlcNAc6P (mM) 0 (n=3) 25 (n=2) p-value
NH4 41.3 ± 12.8 50.6 ± 10.5 0.54
Fru6P 5.5 ± 0.9 8.4 ± 2.7 0.48
GlcN6P 2.4 ± 0.2 2.1 ± 0.8 0.75
The Km value of 41.3 mM for NH4 is high, but ammonium is not toxic at this concentration 
(Figure S3), and these concentrations are described to be present in the gut (Macfarlane, et 
al., 1986, Macfarlane, et al., 1992). The ammonium present in the gut diffuses through the 
cell to almost equilibrium (Muller, et al., 2006), so the required ammonium concentration for 
the aminating direction could take place as such in the A. muciniphila cells. However, the 
Km value of Fru6P at 5.5 mM is rather high, this compound is described to be toxic in these 
amounts in many bacteria (Kadner, et al., 1992). Additionally, the Km value of GlcN6P is 
lower at 2.4 mM. GlcN6P is the only compound involved in the deaminating direction (Table 
2, Table S8).
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represented in a Lineweaver-Burk plot (Figure 4). However, the Km of GlcN6P value for the 
deaminating direction is much lower at 2.4 ± 0.2 mM, see Figure 4 and Table 2. The addition 
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The kinetic values found for Amuc-NagB are in line with previously characterized NagB-
like enzymes (Calcagno, et al., 1984), except for the absence of the need for an allosteric 
activator. In all cases GlcNAc6P is described as an allosteric activator (Alvarez-Anorve, et 
al., 2005, Alvarez-Anorve, et al., 2016). Our results clearly show that the overexpressed 
Amuc-NagB is not allosterically activated by GlcNAc6P (Table 2). Considering the kinetic 
values of Amuc-NagB, it is unlikely for the aminating reaction to occur at physiological 
conditions, as also postulated before (Calcagno, et al., 1984). We assume an alternative route 
to synthesize phosphorylated amino glucoses (GlcN6P, GlcN1P, GlcNAc6P and GlcNAc1P) 
is taking place, which is provided by the addition of non-phosphorylated GlcNAc or GalNAc
to the growth medium. We propose that GlcNAc can be used by A. muciniphila to form 
peptidoglycan intermediates and ultimately peptidoglycan via the Akkermansia GlcNAc
shortcut (Figure 3). 
Figure 4. Lineweaver-Burk plot to determine the Km values of NH4 (triangles), Fru6P (squares) and GlcN6P 
(diamonds). The Km value is determined based on the trend line according to Lineweaver and Burk (Lineweaver, et 
al., 1934). The figure shows one of the three replicates. Formulas, trend line and R2 were obtained by Microsoft 
Excel 2010.
Optimization of the A. muciniphila genome-scale constraint-based model of metabolism
The growth on different sugars was compared with predictions from the A. muciniphila model 
as presented before (Ottman et al., 2017b). The initial version of the model (AkkMuc_588  
v1) predicted growth on all sugars testes, except GlcN, as discussed above. This is in 
discrepancy with growth in minimal medium and can be explained by the absence of GlmS, 
that was assumed to be present in the model due to the use of gap filling algorithms (Table 
3). Based on these findings, the model was adjusted by deleting the reaction Fru6P + 
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Glutamine  GlcN6P + Glutamate [EC 2.6.1.16]. This yielded correct growth predictions 
for glucose and GlcNAc. The adjusted model (AkkMuc_588 v2) still did not predict growth 
on GalNAc. This was solved by the additional annotation of UDP-glucose 4-epimerase on 
locus Amuc_1125 (AMUC_RS06020) as UDP-GlcNAc 4-epimerase and which supports the 
formation of UDP-GalNAc from GalNAc as discussed above. The epimerase has previously 
shown to bidirectional mediate the conversion of UDP-glucose to UDP-galactose and UDP-
GlcNAc to UDP-GalNAc in both bacteria and human (Thoden, et al., 2001, Bernatchez, et 
al., 2005). The improved version of the model contains 748 reactions describing conversions 
among 737 metabolites and can be found in SBML and table (xls) formats in the 
supplementary information. 
Qualitative predictions by the adjusted model (AkkMuc_588 v2) showed higher similarity to 
our laboratory experiments than the original model (Table 3). The only small difference 
between the model and laboratory experiments is the growth on a medium containing GlcN 
and glucose. While the model predicts no growth a growth rate of 0.005 h-1 was observed in 
the laboratory experiment. This could be caused by a limited uptake of GlcN, even though 
there is no GlcN transporter annotated. Simulations with an in silico generated mutant with 
a hypothetical GlcN transporter show that absence of this  transporter is the sole reason for 
the lack of growth predicted for this sugar. This small uptake could explain the low growth 
rate in the presence of both GlcN and glucose, thereby providing full agreement between the 
model qualitative predictions and the experimental results. Nevertheless  the role of glucose 
remains unclear, as from the experiments we see that it would be essential to enable this 
possible low uptake rate.
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Figure 4. Lineweaver-Burk plot to determine the Km values of NH4 (triangles), Fru6P (squares) and GlcN6P 
(diamonds). The Km value is determined based on the trend line according to Lineweaver and Burk (Lineweaver, et 
al., 1934). The figure shows one of the three replicates. Formulas, trend line and R2 were obtained by Microsoft 
Excel 2010.
Optimization of the A. muciniphila genome-scale constraint-based model of metabolism
The growth on different sugars was compared with predictions from the A. muciniphila model 
as presented before (Ottman et al., 2017b). The initial version of the model (AkkMuc_588  
v1) predicted growth on all sugars testes, except GlcN, as discussed above. This is in 
discrepancy with growth in minimal medium and can be explained by the absence of GlmS, 
that was assumed to be present in the model due to the use of gap filling algorithms (Table 
3). Based on these findings, the model was adjusted by deleting the reaction Fru6P + 
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Glutamine  GlcN6P + Glutamate [EC 2.6.1.16]. This yielded correct growth predictions 
for glucose and GlcNAc. The adjusted model (AkkMuc_588 v2) still did not predict growth 
on GalNAc. This was solved by the additional annotation of UDP-glucose 4-epimerase on 
locus Amuc_1125 (AMUC_RS06020) as UDP-GlcNAc 4-epimerase and which supports the 
formation of UDP-GalNAc from GalNAc as discussed above. The epimerase has previously 
shown to bidirectional mediate the conversion of UDP-glucose to UDP-galactose and UDP-
GlcNAc to UDP-GalNAc in both bacteria and human (Thoden, et al., 2001, Bernatchez, et 
al., 2005). The improved version of the model contains 748 reactions describing conversions 
among 737 metabolites and can be found in SBML and table (xls) formats in the 
supplementary information. 
Qualitative predictions by the adjusted model (AkkMuc_588 v2) showed higher similarity to 
our laboratory experiments than the original model (Table 3). The only small difference 
between the model and laboratory experiments is the growth on a medium containing GlcN 
and glucose. While the model predicts no growth a growth rate of 0.005 h-1 was observed in 
the laboratory experiment. This could be caused by a limited uptake of GlcN, even though 
there is no GlcN transporter annotated. Simulations with an in silico generated mutant with 
a hypothetical GlcN transporter show that absence of this  transporter is the sole reason for 
the lack of growth predicted for this sugar. This small uptake could explain the low growth 
rate in the presence of both GlcN and glucose, thereby providing full agreement between the 
model qualitative predictions and the experimental results. Nevertheless  the role of glucose 
remains unclear, as from the experiments we see that it would be essential to enable this 
possible low uptake rate.
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Table 3. Growth comparison between in vitro and in silico analyses. 
Sugar 1 Sugar 2 AkkMuc_588 v1  (y/n)
AkkMuc_588  
v2 (y/n)
AkkMuc_588 
v2 (au)
Lab (µ)
(h-1)
Glucose GlcN y n 0 0.005
GlcN n n 0 0
GlcNAc y y 0.09 0.056
GlcNAc Glucose y y 0.13 0.122
GalNAc y y 0.09 0.084
Glucose y n 0 0
Concluding, we have shown that GlcNAc or GalNAc with the addition of L-threonine are 
essential for growth of A. muciniphila. The dependency on GlcNAc or GalNAc is caused by 
the absence of a gene coding for GlmS, which mediates the aminating reaction from Fru6P 
to GlcN6P with glutamine as amino donor (Figure 3), while Amuc-NagB was shown to be 
NagB indeed. The absence of GlmS enzyme and the presence of GlcNAc in the ecological 
niche of A. muciniphila resulted in an alternative pathway for peptidoglycan formation. 
This finding supported the development of a growth medium that allows the use of A. 
muciniphila in pre-clinical and phase I clinical trials. Additionally, a minimal medium can 
be used for detailed physiological studies, and manipulation. With this information we 
adjusted an existing genome-scale metabolic model by deleting the reaction mediated by 
GlmS. This yielded a more accurate prediction of growth possibilities and growth rate by the 
metabolic model compared to the previous version of the model. The development of the 
defined minimal medium for A. muciniphila was based on gathered knowledge about this 
species and contributed to a better understanding of this organism and it evolutionary 
adaptation to mucin components.
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Availability of data and material
The genome-scale metabolic model of Akkermansia muciniphila AkkMuc_588_v2 is 
available as supplementary material together with a list of the changes respect to the previous 
version. Supplementary file contains the AkkMuc_588_v2 model in SBML level 2 and in 
table (xls) format. The file also contains documentation indicating the changes respect to the 
previous version. Finally, to ease model reutilization we have included a Python script to 
perform growth simulations on different media. The script requires the COBRApy library 
(and has been tested with version 0.4.1) (Ebrahim, et al., 2013) and an LP solver such as 
Gurobi  (Gurobi, 2016).
Supplementary Figures and Tables
Figure S1. Growth of A. muciniphila on CP medium supplemented with 25 mM of each glucose and GlcNAc. As 
nitrogen source was added 4 g/L of L-proline and either L-serine or L-threonine. In all bottles 0.3 g/L NH4Cl was 
added. Growth was only observed with the addition of L-threonine. 
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Figure S2. SDS-PAGE gel of overexpressed protein purification using a Ni-column. In lane 1: marker, lane 2: E. 
coli BL21-Amuc_1822 CFE, lane 3: wash flow through, lane 4: purified protein amuc_1822.  
Figure S3. Growth of A. muciniphila on CP medium supplemented with 25mM GlcNAc, 6g/L Thr and 0mM or 
50mM NH4Cl. 
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Table S1. Composition of tested media. The indicated compounds are added to CP medium without ammonium 
(Derrien, et al., 2004).
Carbon source
Glucose (mM) GlcNAc (mM)
Other sugars 
(mM)
12.5 12.5
0 0
0 25
12.5 12.5
0 0
0 25
12.5 0 12.5 GlcN
0 0 25 GalNAc
0 0 25 GlcN
12.5 0 12.5 GlcN
0 0 25 Fru
Table S2. Determination of protein concentrations by BCA assay used for enzyme assays. The BSA was used for a 
standard curve. The enzyme was diluted 5 times and 40 times to determine the protein concentration. 
BSA (ug/mL) 590nm 450nm OD590/450
0 0.45 0.74 0.61
1 0.46 0.75 0.61
5 0.50 0.73 0.69
10 0.57 0.70 0.81
50 0.97 0.54 1.78
100 1.31 0.42 3.14
5 × diluted Amuc-
NagB 1.82 0.29 6.28
40× diluted Amuc-
NagB 0.78 0.62 1.25
Concentration Amuc-NagB (mg/mL) SD
1.10 0.04
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Table S3. Overview of substrates used in enzyme assay. 
Substrates (mM) Activatorᶧ (mM)
Enzyme 
(µL)
#
tube
Fru6
P
NH
4
GlcN6
P (GlcNAC-6P)
AMINATING 1 15 50 0.25 5
2 10 50 0.25 5
3 7.5 50 0.25 5
4 5 50 0.25 5
5 2 50 0.25 5
6 1 50 0.25 5
7 20 50 0.25 5
8 20 25 0.25 5
9 20 10 0.25 5
10 20 5 0.25 5
11 20 2.5 0.25 5
DEAMINATIN
G 12* 15 0.25 1
13* 10 0.25 1
14* 7.5 0.25 1
15 5 0.25 1
16 2 0.25 1
17 1 0.25 1
Standard curve 18 0
19 0.5
20 1
21 2
Control 
GlcNAC6P
22 0.25
ᶧ Added in 2 out of 5 replicates. * Not used in determination of Km. 
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Table S4. BlastP of Escherichia coli K12 NagB (NP_415204.1) against Akkermansia (taxid:239934). All hits are 
shown.
Description
Max 
scor
e
Tota
l
scor
e
Quer
y
cover
E
value
Iden
t Accession
glucosamine-6-
phosphate deaminase 
[Akkermansia 
muciniphila 
CAG:154]
177 177 92% 5.00E-55 40% CDB55261.1
MULTISPECIES: 
glucosamine-6-
phosphate deaminase 
[Akkermansia]
176 176 92% 8.00E-55 40%
WP_067570388.
1
glucosamine-6-
phosphate deaminase 
[Akkermansia 
glycaniphila]
175 175 87% 2.00E-54 42%
WP_067775984.
1
glucosamine-6-
phosphate deaminase 
[Akkermansia 
muciniphila]
175 175 90% 1.00E-53 41%
WP_065529150.
1
glucosamine-6-
phosphate deaminase 
[Akkermansia 
muciniphila]
175 175 90% 1.00E-53 41%
WP_012420854.
1
glucosamine-6-
phosphate deaminase 
[Akkermansia sp.
CAG:344]
172 172 92% 3.00E-53 39% CDD98135.1
glucosamine-6-
phosphate deaminase 
[Akkermansia 
muciniphila]
173 173 90% 5.00E-53 40%
WP_031931289.
1
hypothetical protein 
HMPREF3038_0321
7 [Akkermansia sp. 
KLE1797]
24.6 24.6 4% 7.8 73% KXT46402.1
Table S5. BlastP of A muciniphila NagB (CDB55261.1) against all sequence except Akkermansia 
(taxid:239934). Top 5 hits are shown.
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Description Max score
Total 
score
Query 
cover
E
value Ident Accession
glucosamine-6-
phosphate 
deaminase 
[Rubritalea 
squalenifaciens
DSM 18772]
354 354 82% 3.00E-120 67% SHJ43774.1
glucosamine-6-
phosphate 
deaminase 
[Rubritalea 
marina]
319 319 81% 2.00E-106 61% WP_018969388.1
glucosamine-6-
phosphate 
deaminase 
[Capnocytophaga 
canis]
317 317 79% 2.00E-100 60% WP_042008125.1
Glucosamine-6-
phosphate 
deaminase 
[Flavobacterium 
aquidurense]
305 305 80% 2.00E-99 56% KQB39432.1
glucosamine-6-
phosphate 
deaminase 
[Capnocytophaga 
canis]
314 314 79% 2.00E-99 59% WP_042347886.1
Table S6. BlastP of Escherichia coli K12 GlmS (NP_418185.1) against Akkermansia (taxid:239934). All hits are 
shown. 
Description Max score
Total 
score
Query 
cover
E
value Ident Accession
von Willebrand 
factor type A domain 
protein 
[Akkermansia sp. 
KLE1797]
32 32 17% 0.68 26% KXT50996.1
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MULTISPECIES: 
hypothetical protein 
[Akkermansia]
32 32 17% 0.71 26% WP_067570323.1
queuine tRNA-
ribosyltransferase 
[Akkermansia 
muciniphila
CAG:154]
29.3 29.3 4% 3.9 40% CDB55386.1
tRNA guanosine(34) 
transglycosylase Tgt 
[Akkermansia sp. 
54_46]
29.3 29.3 4% 4.2 40% OLA88015.1
tRNA-guanine(34) 
transglycosylase 
[Akkermansia 
muciniphila]
29.3 29.3 4% 4.2 40% WP_031930139.1
tRNA guanosine(34) 
transglycosylase Tgt 
[Akkermansia 
muciniphila]
29.3 29.3 4% 4.4 40% WP_012419333.1
Table S7. BlastP of Verrucromicrobium spinosum GlmS (WP_009962724.1) against Akkermansia muciniphila. All 
hits are shown.
Description
Max 
score
Total 
score
Query 
cover
E
value
Ident Accession
tRNA-
guanine(34) 
transglycosylase 
[Akkermansia 
muciniphila]
30 30 5% 0.83 42% WP_031930139.1
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tRNA 
guanosine(34) 
transglycosylase 
Tgt [Akkermansia 
muciniphila]
30 30 5% 0.84 42% WP_012419333.1
hypothetical 
protein 
[Akkermansia 
muciniphila]
27.3 27.3 11% 6 25% WP_065529387.1
Table S8. Control reactions for enzyme assay of A. muciniphila NagB.  The amount of GlcN6P formed is not above 
0.01 mM in 10 minutes. 
Content assay OD585 GlcN6P (mM)
10 mM Fru6P + 10mM  glutamine
5 uL Enzyme
0.006 0.01
50 mM NH4Cl + 7,5mM Fru6P 0.000 0.00
5 uL Enzyme 0.000 0.00
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The influence of an animal componenT free medium on cell morphology and 
TherapeuTic efficacy of AkkermAnsiA muciniphilA
Kees C. H. van der Ark, Steven Aalvink, Laura Huuskonen, Hubert Plovier, Patrice Cani, Clara Belzer and 
Willem M. de Vos
The in vivo experiment described in this chapter was previously published in:
A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves 
metabolism in obese and diabetic mice, Nature medicine, 2017, 23: 107-113.Plovier, H., Everard, A., Druart, 
C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., Myridakis, A., 
Delzenne, N. M., Klievink, J., Bhattacharjee, A., van der Ark, C. H., Aalvink, S., Martinez, L. O., Dumas, M., 
Maiter, D., Loumaye, A., Hermans, M. P., Thissen, J.-P., Belzer, C., de Vos, W. M. and Cani, P. D.
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Abstract 
Presence of the symbiont Akkermansia muciniphila in the intestinal microbiota is associated 
with a healthy metabolic status. Previous studies have shown that administration of a daily 
dose of cells of A. muciniphila cultured on a mucus-based medium is able to protect mice 
from diet-induced obesity. Based on a recently developed genome-scale metabolic model, 
we designed an improved growth medium for A. muciniphila that was free from animal-
derived components. The medium composition was based on the discovery that N-
acetylglucosamine is essential for the growth of A. muciniphila. Moreover, to increase growth 
rate, we supplemented the synthetic growth medium with a plant protein hydrolysate, 
resulting in significant growth rate increase. We showed that A. muciniphila cells grown on 
this synthetic medium had a similar effect on mice compared to mucus-grown cells. To 
investigate the impact of the newly designed synthetic medium on the functionality of A. 
muciniphila, we compared the global gene expression of mucus and synthetic medium-grown 
cells by transcriptome analysis. The results revealed no major effects on the expression of 
household functions or genes involved in the production of the type IV pili, including that 
coding for the biologically active protein Amuc_1100 that was found to be not significantly 
increased during growth on the synthetic medium. However, we observed various genes 
involved in cell morphology to be significantly upregulated in the synthetic medium, 
including that coding for the cell-shape determining protein MreB.  Detailed cell analysis by 
quantitative phase-contrast and electron microscopy analysis revealed morphological 
changes of cells grown in the synthetic medium, mainly by elongation. In conclusion, we 
designed, tested and validated a medium free from animal components that showed improved 
growth and cell size but did not affect the efficacy of A. muciniphila in therapeutic 
applications. 
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Introduction
Cultivating bacteria has been the core focus for microbiologists since the discovery of the 
first pure culture in 1878 to show cause-effect relations (Santer, 2010). This provided the 
foundation for present day studies that showed that the ability to grow bacteria in pure culture 
allows for detailed studies of their metabolism, morphology, genetics and interactions with 
other bacteria, bacteriophages, and other organisms. Even in times of rapidly expanding 
methods of genomic and other molecular techniques to detect and characterize bacteria, there 
is the need to culture bacteria for physiological characterization and intervention studies. The 
recently developed high-throughput culture techniques have been helpful in cultivating more 
bacterial species from the intestinal tract (Nichols, et al., 2010, Lagier, et al., 2016). Culturing 
these intestinal bacteria is of specific interest since these may directly affect human health or 
are influenced by the health status of humans. One of these bacteria is the mucus-degrading 
intestinal symbiont Akkermansia muciniphila. This bacterium was isolated using pig gastric 
mucus as sole carbon and nitrogen source, supplemented with vitamins and minerals 
(Derrien, et al., 2004). Next to inverse correlations with several diseases based on relative 
abundances (Swidsinski, et al., 2011, Wang, et al., 2011, Derrien, et al., 2016), A. muciniphila
was also shown to be effective in preventing metabolic disorders during intervention studies 
(Derrien, et al., 2016). When administered by intestinal gavage in mice, A. muciniphila was 
able to reduce weight gain in diet-induced obesity (Everard, et al., 2013). The estimated 
amount of bacterial species in the gut is around 2500 based on 16S rRNA sequencing data 
(Ritari, et al., 2015). These intestinal bacteria could potentially be used as biomarkers or serve 
as therapeutic agents. The diseases that are associated with the abundance, presence or 
absence of bacterial species in the gut vary from inflammatory gut, metabolic and immune 
disorders to even psychological aberrations (Dinan, et al., 2013, Guinane and Cotter, 2013, 
Hur and Lee, 2015). Especially bacterial species that show an inversed correlation with the 
occurrence or severity of diseases are of interest for further development as therapeutic 
microbes. At present, several gut microbiota members have been identified that show such 
inverse correlations or, alternatively, show an increase in relative abundance upon treatment 
of the disease, including butyrate-producing bacteria such as Faecalibacterium prausnitzii, 
Clostridium butyricum, Eubacterium hallii and Intestimonas butyriciproducens (Bui, et al., 
2015, Kanai, et al., 2015, Quevrain, et al., 2016, Udayappan, et al., 2016), but also the 
previously mentioned Akkermansia muciniphila (Everard, et al., 2013, Derrien, et al., 2016).
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rate, we supplemented the synthetic growth medium with a plant protein hydrolysate, 
resulting in significant growth rate increase. We showed that A. muciniphila cells grown on 
this synthetic medium had a similar effect on mice compared to mucus-grown cells. To 
investigate the impact of the newly designed synthetic medium on the functionality of A. 
muciniphila, we compared the global gene expression of mucus and synthetic medium-grown 
cells by transcriptome analysis. The results revealed no major effects on the expression of 
household functions or genes involved in the production of the type IV pili, including that 
coding for the biologically active protein Amuc_1100 that was found to be not significantly 
increased during growth on the synthetic medium. However, we observed various genes 
involved in cell morphology to be significantly upregulated in the synthetic medium, 
including that coding for the cell-shape determining protein MreB.  Detailed cell analysis by 
quantitative phase-contrast and electron microscopy analysis revealed morphological 
changes of cells grown in the synthetic medium, mainly by elongation. In conclusion, we 
designed, tested and validated a medium free from animal components that showed improved 
growth and cell size but did not affect the efficacy of A. muciniphila in therapeutic 
applications. 
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Introduction
Cultivating bacteria has been the core focus for microbiologists since the discovery of the 
first pure culture in 1878 to show cause-effect relations (Santer, 2010). This provided the 
foundation for present day studies that showed that the ability to grow bacteria in pure culture 
allows for detailed studies of their metabolism, morphology, genetics and interactions with 
other bacteria, bacteriophages, and other organisms. Even in times of rapidly expanding 
methods of genomic and other molecular techniques to detect and characterize bacteria, there 
is the need to culture bacteria for physiological characterization and intervention studies. The 
recently developed high-throughput culture techniques have been helpful in cultivating more 
bacterial species from the intestinal tract (Nichols, et al., 2010, Lagier, et al., 2016). Culturing 
these intestinal bacteria is of specific interest since these may directly affect human health or 
are influenced by the health status of humans. One of these bacteria is the mucus-degrading 
intestinal symbiont Akkermansia muciniphila. This bacterium was isolated using pig gastric 
mucus as sole carbon and nitrogen source, supplemented with vitamins and minerals 
(Derrien, et al., 2004). Next to inverse correlations with several diseases based on relative 
abundances (Swidsinski, et al., 2011, Wang, et al., 2011, Derrien, et al., 2016), A. muciniphila
was also shown to be effective in preventing metabolic disorders during intervention studies 
(Derrien, et al., 2016). When administered by intestinal gavage in mice, A. muciniphila was 
able to reduce weight gain in diet-induced obesity (Everard, et al., 2013). The estimated 
amount of bacterial species in the gut is around 2500 based on 16S rRNA sequencing data 
(Ritari, et al., 2015). These intestinal bacteria could potentially be used as biomarkers or serve 
as therapeutic agents. The diseases that are associated with the abundance, presence or 
absence of bacterial species in the gut vary from inflammatory gut, metabolic and immune 
disorders to even psychological aberrations (Dinan, et al., 2013, Guinane and Cotter, 2013, 
Hur and Lee, 2015). Especially bacterial species that show an inversed correlation with the 
occurrence or severity of diseases are of interest for further development as therapeutic 
microbes. At present, several gut microbiota members have been identified that show such 
inverse correlations or, alternatively, show an increase in relative abundance upon treatment 
of the disease, including butyrate-producing bacteria such as Faecalibacterium prausnitzii, 
Clostridium butyricum, Eubacterium hallii and Intestimonas butyriciproducens (Bui, et al., 
2015, Kanai, et al., 2015, Quevrain, et al., 2016, Udayappan, et al., 2016), but also the 
previously mentioned Akkermansia muciniphila (Everard, et al., 2013, Derrien, et al., 2016).
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To allow application as food supplements in humans, therapeutic microbes should meet the 
safety regulations of novel foods and when health claims are made should live up to similar 
requirements as nowadays probiotics have in EU countries (Hill, et al., 2014, Kumar, et al., 
2015, Gomez-Gallego, et al., 2016). Regulations concerning pharmaceuticals are stricter and 
require large dossiers of preclinical testing and successful human trials. When A. muciniphila
would be marketed as a new therapeutic microbe, the development of an animal component-
free medium and further safety studies are required according to the novel food regulation of 
the EU (Gomez-Gallego, et al., 2016).
Probiotic bacteria are usually lactic acid bacteria, and can therefore tolerate a low pH and 
potentially oxygen (Higuchi, et al., 2000, Andriantsoanirina, et al., 2013). The growth media 
of these bacteria are based on complex media containing yeast extract, beef extract and 
tryptone (Chang and Liew, 2013), but successful growth on minimal and animal component 
free media have also been reported (Heenan, et al., 2002, Mattila-Sandholm, et al., 2002, 
Teusink, et al., 2006, Heinken, et al., 2014). Most of the potential therapeutic microbes (F.
prausnitzii, E. hallii,  I. butyriciproducens  and A. muciniphila) are strictly anaerobic or able 
to tolerate small amounts of oxygen. A. muciniphila can use only small amounts of oxygen 
for respiration (Flint, et al., 2007, Khan, et al., 2012, Bui, et al., 2015, Ouwerkerk, et al., 
2016b). This could pose technical challenges in large-scale production. We have previously 
shown that that A. muciniphila requires the addition of N-acetylglucosamine (GlcNAc) or N-
acetylgalactosamine (GalNAc) for growth since this bacterium is unable to synthesize the 
peptidoglycan building block uridine diphosphate (UDP)-GlcNAc via the amination of 
fructose-6-phosphate to glucosamine-6-phosphate (van der Ark, et al., 2017). This finding 
was the basis for further development of a synthetic medium for cultivation of A. muciniphila
suited for therapeutic applications with significant growth rate and yield. The impact of the 
optimized synthetic medium was analysed by characterizing the global gene expression and 
morphology.
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Materials and methods
A. muciniphila culturing
A. muciniphila was grown in carbonate buffered mineral medium as described previously 
(Derrien, et al., 2004, Ouwerkerk, et al., 2017), but without the addition of mucus. The mucus 
was replaced with either soy peptone or a combination of L-proline and L-threonine as 
nitrogen source and GlcNAc and glucose as carbon source.
In the text, the media are referred to as ‘soy medium’ and ‘PT medium’ when equimolar 
amounts of glucose and GlcNAc are used, to a total of 25 mM in case of the PT medium and 
25 mM for soy medium. When deviating sugar concentrations were used, it is mentioned in 
the text. Mucus medium always refers to medium in which 0.5% hog gastric mucus (Sigma) 
was used as described before (Derrien, et al., 2004).
Preparation of A. muciniphila for preclinical trials
A. muciniphila was grown in soy medium or mucus medium, after which the bacteria were 
collected essentially as described before (Everard, et al., 2013, Ouwerkerk, et al., 2017), with 
the adjustments described following. Bacteria were collected at the end of the growth phase 
(OD600 of 1.5-2 for soy medium or OD of 1 for mucus medium). All subsequent steps were 
executed in a sterile environment, at ambient air and at 4˚C or on ice. The bacteria were 
centrifuged at 10,000 g for 10 minutes. The supernatant was discarded, after which the 
pelleted cells were suspended in sterile PBS (manufacturer salt). Centrifugation was repeated, 
and cells were suspended again in sterile PBS. After a third centrifugation, cells were 
suspended in 1/10 of the original culture volume of sterile anaerobic PBS containing 25% 
glycerol and 0.05% L-cysteine-HcCl. Aliquots of 1 mL were made in 10 mL anaerobic bottles 
containing N2/CO2 80/20 (v/v) at 1.8 atm and stored immediately at -80˚C. Determination of 
Cfu’s in the aliquots and preparation for gavage was done exactly as described before 
(Ouwerkerk, et al., 2017).
Mice trials and analyses 
Mice were given daily gavages of 1.5 × 108 CFU A. muciniphila grown on either mucus 
medium or soy medium, or received a daily placebo, for 4 weeks. The gavages and 
measurements were performed in a non-blinded fashion. The mice were male C57BL/6J of 
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10 weeks old (Charles River, L'Arbresle, France). Food was freely available throughout the 
experiment, which was a chow diet (AIN93Mi, Research diet, New Brunswick, NJ, USA) 
during acclimatisation of all mice and for the control diet (ND) group, and a high-fat diet 
(HFD) (60% fat and 20% carbohydrates (kcal/100g) D12492i, Research diet, New 
Brunswick, NJ, USA) for the experimental groups. Body weight gain, food and water 
consumption were determined once a week. Body composition for fat mass detection was 
determined using 7.5 MHz time domain-nuclear magnetic resonance (TD-NMR) (LF50 
Minispec, Bruker, Rheinstetten, Germany). 
Mice were excluded when abnormal behaviour was shown, or tissue abnormalities where 
found during necropsy and sampling. All mouse experiments were approved by and 
performed in accordance with the guidelines of the local ethics committee. Housing 
conditions were specified by the Belgian Law of May 29, 2013, regarding the protection of 
laboratory animals (agreement number LA1230314). Further details of the mice experiments 
were described before, including description of statistical analyses (Plovier, et al., 2017).
Light microscopy, electron microscopy and cell size analysis
To determine the size of the bacteria, three soy medium cultures and two mucus medium 
cultures were visualised using phase-contract microscopy (microscope model). Cells on the 
image were analysed using ImageJ (version 1.51f). Scale was set using the scale bar on the 
microscopy image, selecting analyse, scale in Image J. The cell length was measured by 
selecting the longest diameter within the cell. Cells  were individually measured, after which 
the data was analysed using Excel 2016. Scanning electron microscopy was performed on 
soy medium grown A. muciniphila at an OD600 of 1.3 as described before (Ouwerkerk, et 
al., 2016a).
RNA sequencing
Samples for RNA sequencing were obtained at late exponential phase of cultures grown in 
soy medium and mucus medium. RNA isolation and sequencing was performed as described 
before (Ouwerkerk, et al., 2016b), with in this case duplicates of both soy and mucus medium. 
Sequencing was performed at Baseclear BV, the Netherlands. Gene annotations were as 
described and used before (Ottman, et al., 2017). Analysis of the expression profiles was 
performed with an in-house analysis pipeline (Koehorst, et al., 2016), including Bowtie2 
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(Galaxy Tool Version 0.6) for the mapping of reads against the reference genome (Langmead 
and Salzberg, 2012), htseq-count (Galaxy Tool Version 0.6.1galaxy1) to extract count tables 
per gene (Anders, et al., 2015) and DESeq2 (Galaxy Tool Version 2.1.8.0) for the analysis 
of differential expression (Love, et al., 2014).
Results 
Medium composition for optimal growth and therapeutic applications of A. muciniphila
From our improved metabolic model we concluded that A. muciniphila has a necessity for L-
threonine and GlcNAc to support growth (van der Ark, et al., 2017). Moreover, this model 
also predicted growth on glucose in the presence of these additions. Hence, we aimed to omit 
mucin from the bicarbonate-buffered mineral medium currently used to grow A. muciniphila
media (Derrien, et al., 2004) and added glucose and GlcNAc in different ratios as well as L-
threonine and L-proline. The latter was added as mucin is known to contain large amounts of 
proline. However, the specific growth rate on this PT medium was rather low and amounted 
to 0.06 h-1 (Table 1). Hence, to call for rapid growth we added protein hydrolysate plant 
origin (Table 1). The addition of soy protein hydrolysate resulted in a high growth rate of 
0.53 h-1 exceeding that of A. muciniphila on mucin, which is approximately 0.41 h-1 (Derrien, 
et al., 2004, Ottman, et al., 2017). Since the soy protein hydrolysate is derived from a plant 
source, it is an acceptable food-grade nitrogen source and applicable on a large scale. 
Moreover, as the growth rate on soy medium was higher than that on mucin and high cell 
densities were obtained, we decided to focus on this food-grade medium for further studies.
Table 1. Growth rate of A. muciniphila on soy and PT media, with GlcNAc and glucose as carbon sources. The ratio 
between acetate and propionate produced on each medium is in the last column
Medium Growth rate (h-1) st.dev Acetate/propionate ratio
Soy peptone 16g/L (soy medium)
Glu GlcNAc 0.53 0.05 0.92
Thr 6g/L, Pro 6g/L (PT medium)
GlcNAc 0.04 0.02 1.46
Glu GlcNAc 0.06 0.04 1.07
The different media tested showed no differences in fermentation profiles, when the same 
sugars were added to the growth medium. The ratio between acetate and propionate was 
found to be 1:1 when grown on equimolar quantities of glucose and GlcNAc, and 3:2 to 2:1 
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when only GlcNAc was added (Table 1) The addition of glucose to the growth medium 
increased the amount of propionate by a factor ~1.5, while the amount of acetate is reduced 
only ~0.9 fold. This is mainly due to the use of GlcNAc for fermentation, which results in 
the release of one acetate per GlcNAc molecule. 
Cell morphology changes in different media 
The cell shape of A. muciniphila has been described as an oval shaped bacterium of 
approximately 1 um in length (Derrien, et al., 2004). We observed aberrant cell shapes when 
growing A. muciniphila in PT medium or soy medium. When grown on mucus medium, the 
cells were nearly exclusive around 1 µm and oval shaped. When A. muciniphila is cultured 
on soy medium, the cell morphology became less uniform. Cells were elongated and even a 
‘tripod’ cell was observed (Figure 1A). The latter was the case when cells were cultured in 
soy medium with glucose and only 1 mM of GlcNAc was added. Besides, the cells also 
showed possible compartmentalisation inside the elongated cells (Figure 1A). When A. 
muciniphila was grown on PT medium, cell elongations of up to 50 µm were observed 
(Figure 1B). 
C
Figure 1. Aberrant cell morphologies of A. 
muciniphila. (A) A tripod cell and cells 
showing erroneous division or 
compartmentalisation were observed in soy 
medium containing 1 mM GlcNAc and 25 
mM glucose. (B) Elongated cells were found 
in PT medium measuring up to 50 µm. (C) 
A. muciniphila grown on mucus medium 
show small oval shaped bacteria. 
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To visualise the compartmentalisation of cells inside the elongated structures, we employed 
SEM (Figure 2). The images show that the elongated bacteria can be divided in two 
subgroups. One group with cell internally subdivided in compartments, the other group with 
cells elongated without visual subdivisions. These observations suggest that the regulation of 
cell division or cell shape is disturbed in the studied media. 
Figure 2. Scanning electron micrographs of A. muciniphila cultured on soy medium (A, B and C). The cells are 
elongated or do not divide properly. Normal shaped cells were observed in mucus medium (D). 
The cell length of bacteria grown in soy medium and mucus medium was measured to 
quantify the visual differences in length. We found that A. muciniphila cells grown on soy 
medium (n cells = 251) were larger compared to cells grown on mucus medium (n cells = 
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160) (p-value < 0.01), with an average cell length of 1.3 (±0.80) µm and 0.8 (±0.25) µm 
respectively (Figure 3).  
Figure 3. Cell length of cells grown in soy medium (black, left) and mucus medium (white dotted, right). The average 
cell length in soy medium is significantly larger compared to mucus medium. 
Gene expression in defined and undefined media
Using RNAseq analysis we compared the expression profile of A. muciniphila cultured on 
the soy medium with that obtained on mucus medium to study the cause of changes in cell 
morphology and pinpoint possible anabolic adaptations. A total of 133 genes was found to 
be differentially expressed between soy and mucus medium, out of a total 2138 genes 
predicted by the A. muciniphila genome (Table S1, Figure 4). Of these differentially 
expressed genes, 40 have no annotated function. The analysed samples cluster together with 
growth on different samples, allowing comparison of gene expression profiles (Figure S1).
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Figure 4. Volcano plot of all A. muciniphila genes expressed in soy medium versus mucus medium. Green dots 
represent the genes that are significantly different in expression between soy and mucus grown cells. 
When A. muciniphila was cultured on soy medium, the cells were found to be elongated. The 
cell shape determining protein MreB (Amuc_0540) was upregulated 8.9 fold in soy medium. 
Other regulated genes coding for proteins involved in cell division code for CcmA 
(Amuc_1317) and MraZ (Amuc_0649), which are both also 4-6 fold upregulated (Table 2). 
Other genes homologues to genes described to be involved in cell shape and cell division 
were not significantly regulated (Table 2).
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When A. muciniphila was cultured on soy medium, the cells were found to be elongated. The 
cell shape determining protein MreB (Amuc_0540) was upregulated 8.9 fold in soy medium. 
Other regulated genes coding for proteins involved in cell division code for CcmA 
(Amuc_1317) and MraZ (Amuc_0649), which are both also 4-6 fold upregulated (Table 2). 
Other genes homologues to genes described to be involved in cell shape and cell division 
were not significantly regulated (Table 2).
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Table 2. Genes homologues to genes described to be involved in cell shape regulation and cell division, in order of 
ascending q-value. Genes that are differentially expressed (q-value < 0.05) in green.  
Locus tag Annotation (NCBI) 2log fold change
q-
value
Amuc_0540 rod shape-determining protein MreB 3.16 0.01
Amuc_1317 Integral membrane protein CcmA involved in cell shape determination 2.19 0.01
Amuc_0649 Cell division protein MraZ 2.73 0.02
Amuc_0348 Cell division protein FtsH (EC 3.4.24.-) 2.00 0.11
Amuc_0514 Cell division protein FtsI [Peptidoglycan synthetase] (EC 2.4.1.129) 1.37 0.15
Amuc_1052 Cell division trigger factor (EC 5.2.1.8) 1.05 0.33
Amuc_1176 Cell division inhibitor -1.17 0.41
Amuc_2076 Cell division protein FtsK 0.47 0.69
Amuc_0662 Cell division protein FtsQ -0.57 0.71
Amuc_1558
Intramembrane protease RasP/YluC, 
implicated in cell division based on FtsL 
cleavage
-0.28 0.84
Amuc_0658 Cell division protein FtsW 0.31 0.87
Amuc_0152 Cell division protein FtsZ (EC 3.4.24.-) 0.23 0.89
Amuc_0153 Cell division protein FtsA 0.15 0.94
Amuc_0652 Cell division protein FtsI [Peptidoglycan synthetase] (EC 2.4.1.129) 0.03 0.99
Because the sugars present in the medium could influence the expression profiles of genes 
involved in polysaccharide degradation, we mined for regulation of those genes from our 
data. An upregulation of a fucosidase (Amuc_0146) and a galactosidase (Amuc_1666) was 
observed in mucus medium, represented by a negative fold change as compared to growth in 
soy medium (Table 3). A higher expression of genes belonging to the glycoside hydrolase 
families 109, 20 and 98 was found in soy medium. These hydrolases are usually involved in 
GlcNAc or GalNAc degradation.
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Table 3. Genes involved in polysaccharide degradation that are significantly regulated, ordered by q-value, with 
Uniprot annotations.
Locus tag 2log fold change q-value Annotation (Uniprot)
Amuc_0017 3.62 0.00 Glycosyl hydrolase family 109 protein 1 (EC 3.2.1.-)
Amuc_1666 -3.62 0.00 Beta-galactosidase (EC 3.2.1.23) (Lactase)
Amuc_2136 2.83 0.00 Glycoside hydrolase, family 20, catalytic core
Amuc_0146 -2.77 0.00 Alpha-L-fucosidase (EC 3.2.1.51)
Amuc_1438 2.27 0.01
Glycosyl hydrolase family 98 
putative carbohydrate binding 
module
Amuc_0920 1.97 0.03 Glycosyl hydrolase family 109 protein 2 (EC 3.2.1.-)
Finally, we studied the gene expression profiles of genes possibly involved in host 
interactions, such as the Amuc_1100 and its predicted gene cluster involved in the production 
of the outer membrane located type IV pilus secretin Amuc_1098 (PilQ). The expression of 
this gene was 1.6 times higher in soy medium when compared to mucus medium. No 
significant differences (q-value >0.05) were found in the expression of the whole gene cluster 
Amuc_1098-Amuc_1102, which was previously identified as possibly involved in host 
signalling (Ottman, et al., 2017).
Table 4. Expression of genes possibly involved in host signalling. 
Locus 
tag Annotation (Ottman, et al., 2016); NCBI)
2Log fold 
change
q-
value
Amuc_1
098 outer membrane located pilus secretin (PilQ)  1.6 0.06
Amuc_1
099 hypothetical protein 2.4 0.10
Amuc_1
100 hypothetical protein 0.2 0.89
Amuc_1
101
cell division protein FtsA/ Type IV pilus 
biogenesis protein PilM 0.5 0.73
Amuc_1
102 hypothetical protein 0.0 0.99
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Influence of growth medium on A. muciniphila efficacy in preclinical trials
To study the influence of medium composition on A. muciniphila therapeutic efficiency, we 
supplemented A. muciniphila grown on mucus or soy medium to mice fed a high-fat diet 
(HFD). We measured the weight gain and fat mass gain of these groups compared to mice 
fat a control chow diet (ND) and mice fed a HFD, which received a placebo treatment. After 
daily gavages for 5 weeks, the diet-induced fat mass gain was reduced by about 50% in both 
groups treated with A. muciniphila (Figure 5A). Similarly, the body mass gain was also 
reduced by both A. muciniphila grown on mucus and soy medium (Figure 5B). 
Discussion
We have shown that A. muciniphila can be optimally cultured in the previously described 
minimal medium with the addition of soy protein hydrolysate. The growth rate of A.
muciniphila in the soy medium was found to be slightly higher when compared to that in the 
original mucus medium, with a growth rate of 0.53 h-1 and 0.41 h-1, respectively. Previously, 
it was shown that A. muciniphila could be cultured with a low growth rate on a basal medium 
with high amounts of casein tryptone, without the addition of GlcNAc (Ottman et al., 2017).
This may be possible by the presence of glycosylated casein molecules that may contribute 
to an alternative carbon and energy source. Mucins in the mucus media contain a plethora of 
glycan structures, including galactose, GlcNAC, mannose, fucose and others. During the 
Figure 1. Fat mass gain of mice with ND, HFD and supplemented with A. muciniphila grown on mucus and soy 
(A). Weight gain of mice with ND, HFD and supplemented with A. muciniphila grown on mucus and soy (B). The 
fat mass gain and weight gain are reduced with supplementation of  A. muciniphila. *P < 0.05; **P < 0.001. No 
significant differences between HFD Akk Mucus and HFD Akk Soy.
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development of the minimal medium (van der Ark, et al., 2017), we found that the co-addition 
of glucose and GlcNAc increased the growth rate. Therefore, it is likely that the addition of 
more and different  sugars could even further increase the growth rate. 
Remarkably, we observed an altered morphology of A. muciniphila cells grown on soy media 
as compared to that found on mucin medium. Cells were in general approximately 1.5 times 
longer than when grown on mucus medium. An even further altered cell morphology was 
found when cells were grown on the PT medium. This could be a consequence of various 
factors, including protein source, ratio between glucose and GlcNAc, or growth rate. Further 
studies are needed to differentiate between those possibilities and address the exact 
morphology of A. muciniphila when grown in the human intestinal tract. 
The upregulation of the gene coding for MreB could explain the differences in cell 
morphology, because an increase of this protein increases the cell length (Jones, et al., 2001, 
Figge, et al., 2004). The other two significantly upregulated genes are CcmA (Amuc_1317) 
and MraZ (Amuc_0649). CcmA is involved in the determination of cell shape, by influencing 
peptidoglycan cross-linking in Helicobater pylori, and likely requires an cytoskeleton protein 
such as MreB for positioning. For the determination of cell shape in H. pylori, the role of 
CcmA is linked to genes coding for Csd1-3, which have no known homologues in A. 
muciniphila (Sycuro, et al., 2010, Typas, et al., 2011). Therefore, the function of CcmA in A. 
muciniphila might be regulated differently in the bacterium. CcmA could act as cytoskeleton 
scaffold involved in peptidoglycan synthesis as secondary function (Hay, et al., 1999).
The cell division genes of A. muciniphila were identified before, and include FtsQAZ 
(Pilhofer, et al., 2008). It has been found that the localization of the cell division protein 
cluster is different in A. muciniphila, where the gene ftsQ is not followed by genes encoding 
other members of the FTS-protein family, but by a homologue of the recA gene (Pilhofer, et
al., 2008). The function of MraZ in the cell division process is likely to be a transcriptional 
regulator (Eraso, et al., 2014). The protein function has been characterised in E. coli, in which 
it regulates the division and cell wall (cdw) gene cluster and it was found to be associated 
with DNA in the nucleoid. In A. muciniphila, the mraZ gene is located upstream of the 
peptidoglycan synthesis gene cluster. None of the genes involved in this cluster 
(Amuc_0650-0661) was found to be up or down regulated in this study (Table S1). These 
findings are in line with previous findings that the overexpression of the mraZ gene leads to 
4Chapter 4. 
110
Influence of growth medium on A. muciniphila efficacy in preclinical trials
To study the influence of medium composition on A. muciniphila therapeutic efficiency, we 
supplemented A. muciniphila grown on mucus or soy medium to mice fed a high-fat diet 
(HFD). We measured the weight gain and fat mass gain of these groups compared to mice 
fat a control chow diet (ND) and mice fed a HFD, which received a placebo treatment. After 
daily gavages for 5 weeks, the diet-induced fat mass gain was reduced by about 50% in both 
groups treated with A. muciniphila (Figure 5A). Similarly, the body mass gain was also 
reduced by both A. muciniphila grown on mucus and soy medium (Figure 5B). 
Discussion
We have shown that A. muciniphila can be optimally cultured in the previously described 
minimal medium with the addition of soy protein hydrolysate. The growth rate of A.
muciniphila in the soy medium was found to be slightly higher when compared to that in the 
original mucus medium, with a growth rate of 0.53 h-1 and 0.41 h-1, respectively. Previously, 
it was shown that A. muciniphila could be cultured with a low growth rate on a basal medium 
with high amounts of casein tryptone, without the addition of GlcNAc (Ottman et al., 2017).
This may be possible by the presence of glycosylated casein molecules that may contribute 
to an alternative carbon and energy source. Mucins in the mucus media contain a plethora of 
glycan structures, including galactose, GlcNAC, mannose, fucose and others. During the 
Figure 1. Fat mass gain of mice with ND, HFD and supplemented with A. muciniphila grown on mucus and soy 
(A). Weight gain of mice with ND, HFD and supplemented with A. muciniphila grown on mucus and soy (B). The 
fat mass gain and weight gain are reduced with supplementation of  A. muciniphila. *P < 0.05; **P < 0.001. No 
significant differences between HFD Akk Mucus and HFD Akk Soy.
                             The influence of an animal component free medium
111
development of the minimal medium (van der Ark, et al., 2017), we found that the co-addition 
of glucose and GlcNAc increased the growth rate. Therefore, it is likely that the addition of 
more and different  sugars could even further increase the growth rate. 
Remarkably, we observed an altered morphology of A. muciniphila cells grown on soy media 
as compared to that found on mucin medium. Cells were in general approximately 1.5 times 
longer than when grown on mucus medium. An even further altered cell morphology was 
found when cells were grown on the PT medium. This could be a consequence of various 
factors, including protein source, ratio between glucose and GlcNAc, or growth rate. Further 
studies are needed to differentiate between those possibilities and address the exact 
morphology of A. muciniphila when grown in the human intestinal tract. 
The upregulation of the gene coding for MreB could explain the differences in cell 
morphology, because an increase of this protein increases the cell length (Jones, et al., 2001, 
Figge, et al., 2004). The other two significantly upregulated genes are CcmA (Amuc_1317) 
and MraZ (Amuc_0649). CcmA is involved in the determination of cell shape, by influencing 
peptidoglycan cross-linking in Helicobater pylori, and likely requires an cytoskeleton protein 
such as MreB for positioning. For the determination of cell shape in H. pylori, the role of 
CcmA is linked to genes coding for Csd1-3, which have no known homologues in A. 
muciniphila (Sycuro, et al., 2010, Typas, et al., 2011). Therefore, the function of CcmA in A. 
muciniphila might be regulated differently in the bacterium. CcmA could act as cytoskeleton 
scaffold involved in peptidoglycan synthesis as secondary function (Hay, et al., 1999).
The cell division genes of A. muciniphila were identified before, and include FtsQAZ 
(Pilhofer, et al., 2008). It has been found that the localization of the cell division protein 
cluster is different in A. muciniphila, where the gene ftsQ is not followed by genes encoding 
other members of the FTS-protein family, but by a homologue of the recA gene (Pilhofer, et
al., 2008). The function of MraZ in the cell division process is likely to be a transcriptional 
regulator (Eraso, et al., 2014). The protein function has been characterised in E. coli, in which 
it regulates the division and cell wall (cdw) gene cluster and it was found to be associated 
with DNA in the nucleoid. In A. muciniphila, the mraZ gene is located upstream of the 
peptidoglycan synthesis gene cluster. None of the genes involved in this cluster 
(Amuc_0650-0661) was found to be up or down regulated in this study (Table S1). These 
findings are in line with previous findings that the overexpression of the mraZ gene leads to 
Chapter 4. 
112
filamentation of the cells and even cell death (Eraso, et al., 2014). The combination of 
upregulated MreB, CcmA and MraZ is likely to result in cells with filamentous phenotypes 
and low division rates. The effect on morphology could be caused by adjusted signalling for 
cell division, which is partly dependent on peptidoglycan formation and hydrolysis (Keep, et 
al., 2006, Typas, et al., 2011). As shown in previous research (van der Ark, et al., 2017), the 
peptidoglycan formation of A. muciniphila is likely to follow an alternative route, with the 
UDP-GlcNAc precursors being formed directly from GlcNAc. A misbalance between 
GlcNAc and glucose in metabolism could change the formation kinetics of the cell membrane 
and thereby the cell division signalling.   
Additionally, the function of gene Amuc_1101 is annotated as FtsA. However, recent insight 
suggests it could rather have the function of the pili-associated protein PilM as it is located 
in close proximity to the gene for the type IV pilus secretin pilQ (Amuc_1098) (Ottman, et 
al., 2016). This alternative annotation is also reflected in Table 4 and a previous proteomics 
study, where the protein encoded by this gene was located on the outer membrane (Ottman, 
et al., 2017). The gene upstream of this putative ftsA/pilM gene, is the gene coding for a 
hypothetical protein on locus Amuc_1100, and its product was found to be involved in host 
signalling (Plovier, et al., 2017). We found no significant differences in the expression 
profiles of this gene. Therefore, we hypothesized that the cultivation of A. muciniphila on 
soy medium has no influence on the efficacy of bacteria in preclinical trials. Indeed, there 
was no observed difference between the efficacy of the two treatments in terms of body mass 
gain and fat mass gain. Thereby we confirmed the applicability of soy medium for 
intervention studies and clinical trials. Further clinical trials are needed to investigate the 
efficacy of soy medium grown A. muciniphila in humans and the first results indicate that 
there are no safety issues (Plovier et al., 2017). 
Conclusion
We have shown that A. muciniphila can be efficiently grown in a synthetic medium devoid 
of animal-derived compounds. Cells grown on the newly developed synthetic medium 
showed morphological changes that could be explained by upregulation of cell shape 
determining genes when the global A. muciniphila expression was compared to that when 
grown in the original mucus medium. The expression of genes that are potentially involved 
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in host signalling were not found to be influenced by cultivation in the synthetic medium. 
Finally, there were no observed differences between the therapeutic efficacy of cells grown 
in mucus or synthetic medium in preclinical mice trials. 
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Supplementary information
Figure S1 Sample-to-sample distance of RNA sequencing results by medium type. Both soy and mucus samples 
cluster together, with a higher similarity between soy samples.
Table S1 Genes up- or downregulated in soy versus mucus medium. A positive value means upregulated in soy 
medium. NCBI annotation. 
Locus 
tag Annotation
2log fold 
change
q-
valu
e
Amuc_
1602 hypothetical protein 3.7 0.00
Amuc_
0017 oxidoreductase domain-containing protein 3.6 0.00
Amuc_
1677 type III restriction protein res subunit -3.7 0.00
Amuc_
1068 Methionine adenosyltransferase 3.2 0.00
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Amuc_
1711 hypothetical protein -5.4 0.00
Amuc_
2046 hypothetical protein 3.3 0.00
Amuc_
1896 histone family protein DNA-binding protein 3.5 0.00
Amuc_
1495 3-dehydroquinate dehydratase 3.5 0.00
Amuc_
1115 integrase -4.1 0.00
Amuc_
1666 glycoside hydrolase family 2 -3.6 0.00
Amuc_
2136 Glycoside hydrolase, family 20, catalytic core 2.8 0.00
Amuc_
1304 phosphate ABC transporter permease -4.3 0.00
Amuc_
2053 hypothetical protein 3.0 0.00
Amuc_
0146 alpha-L-fucosidase -2.8 0.00
Amuc_
1002 Carboxymuconolactone decarboxylase -3.5 0.00
Amuc_
1335 Bacteriophage capsid protein-like protein -2.8 0.00
Amuc_
0627 hypothetical protein 2.4 0.00
Amuc_
1305
binding-protein-dependent transporters inner 
membrane component -4.3 0.00
Amuc_
1717 hypothetical protein 2.9 0.00
Amuc_
1958 hypothetical protein -4.0 0.00
Amuc_
2038
PUR-alpha/beta/gamma DNA/RNA-binding 
protein 3.1 0.00
Amuc_
0200 methylmalonyl-CoA epimerase 2.6 0.00
Amuc_
0643 hypothetical protein -2.6 0.00
Amuc_
1069 S-adenosyl-L-homocysteine hydrolase 2.7 0.00
Amuc_
0955 ribosome-binding factor A 3.4 0.00
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Amuc_
1088 ferrous iron transport protein B 2.2 0.00
Amuc_
1298 sulfate adenylyltransferase, large subunit -2.9 0.00
Amuc_
1405 group 1 glycosyl transferase -3.2 0.00
Amuc_
0963 ABC transporter -3.1 0.00
Amuc_
2045 hypothetical protein -3.4 0.01
Amuc_
1167 hypothetical protein -2.8 0.01
Amuc_
1340 hypothetical protein -2.8 0.01
Amuc_
1560 hypothetical protein 2.7 0.01
Amuc_
0107
hydrophobe/amphiphile efflux-1 (HAE1) 
family transporter -2.8 0.01
Amuc_
0233 L-threonine 3-dehydrogenase 2.7 0.01
Amuc_
1005 aldo/keto reductase -3.9 0.01
Amuc_
1074 sulfatase 2.2 0.01
Amuc_
1300 adenylylsulfate reductase -2.9 0.01
Amuc_
0025 hypothetical protein 2.2 0.01
Amuc_
0540 rod shape-determining protein MreB 3.2 0.01
Amuc_
0174 hypothetical protein 3.3 0.01
Amuc_
1303 phosphate ABC transporter ATPase -3.1 0.01
Amuc_
0794 hypothetical protein 2.5 0.01
Amuc_
2072 rubrerythrin 2.5 0.01
Amuc_
0085 thiamine biosynthesis protein ThiS -3.9 0.01
Amuc_
0841 argininosuccinate lyase 2.3 0.01
Amuc_
1438 glycosyl hydrolase family protein 2.3 0.01
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Amuc_
1766 family 2 glycosyl transferase 2.1 0.01
Amuc_
0037 amino acid permease -2.3 0.01
Amuc_
0383 30S ribosomal protein S15 3.1 0.01
Amuc_
1317 hypothetical protein 2.2 0.01
Amuc_
1148 hypothetical protein -3.8 0.01
Amuc_
1157 beta-lactamase -2.8 0.01
Amuc_
1379 ABC transporter 3.1 0.01
Amuc_
0956 translation initiation factor IF-2 2.2 0.02
Amuc_
1348 phage tape measure protein -2.5 0.02
Amuc_
0403 ABC transporter 2.0 0.02
Amuc_
0927 30S ribosomal protein S8 2.1 0.02
Amuc_
2075 hypothetical protein 2.9 0.02
Amuc_
0649 MraZ protein 2.7 0.02
Amuc_
0602 hypothetical protein -2.4 0.02
Amuc_
0149 metallophosphoesterase -2.3 0.02
Amuc_
0215 hypothetical protein 2.2 0.02
Amuc_
0414 phosphoheptose isomerase 2.5 0.02
Amuc_
0967 RNP-1 like RNA-binding protein 2.9 0.02
Amuc_
1336 peptidase S49 -3.0 0.02
Amuc_
1358 hypothetical protein -3.0 0.02
Amuc_
1533 indole-3-glycerol-phosphate synthase 2.5 0.02
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Amuc_
0026 hypothetical protein 2.4 0.02
Amuc_
0536 hypothetical protein 2.0 0.02
Amuc_
1332 hypothetical protein -3.6 0.02
Amuc_
1159 serine/threonine protein kinase -2.3 0.02
Amuc_
0774 major facilitator superfamily protein -2.4 0.02
Amuc_
1597 polyprenyl synthetase 1.8 0.02
Amuc_
1205 50S ribosomal protein L9 2.3 0.02
Amuc_
2123 hypothetical protein 2.0 0.03
Amuc_
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Amuc_
1786 hypothetical protein 2.0 0.03
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0414 phosphoheptose isomerase 2.5 0.02
Amuc_
0967 RNP-1 like RNA-binding protein 2.9 0.02
Amuc_
1336 peptidase S49 -3.0 0.02
Amuc_
1358 hypothetical protein -3.0 0.02
Amuc_
1533 indole-3-glycerol-phosphate synthase 2.5 0.02
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0490 hypothetical protein -2.2 0.03
Amuc_
1531 anthranilate synthase 2.8 0.03
Amuc_
1630
RpiB/LacA/LacB family sugar-phosphate 
isomerase 1.8 0.03
Amuc_
1926 cytochrome c assembly protein -2.8 0.03
Amuc_
2096 polysaccharide biosynthesis protein -2.6 0.03
Amuc_
1114
outer membrane autotransporter barrel domain-
containing protein -2.2 0.03
Amuc_
0323 phage transcriptional regulator, AlpA -2.7 0.03
Amuc_
1996 hypothetical protein -3.0 0.03
Amuc_
0925 KOW domain-containing protein 2.4 0.03
Amuc_
1256 ribonuclease P protein component 2.2 0.03
Amuc_
0172 hypothetical protein 1.9 0.03
Amuc_
1418 phosphoglycerate kinase 2.0 0.03
Amuc_
0362 hypothetical protein 1.8 0.04
Amuc_
0545 hypothetical protein -2.0 0.04
Amuc_
1112 hypothetical protein -3.3 0.04
Amuc_
1343 hypothetical protein -2.4 0.04
Amuc_
0830 potassium-transporting ATPase subunit A -2.6 0.04
Amuc_
2177 Preprotein translocase subunit SecA 2.0 0.04
Amuc_
0297 30S ribosomal protein S3 2.9 0.04
Amuc_
0335 ABC transporter 1.9 0.04
                             The influence of an animal component free medium
123
Amuc_
1293 hypothetical protein -2.3 0.04
Amuc_
1368 hypothetical protein 2.6 0.04
Amuc_
1417
glyceraldehyde-3-phosphate dehydrogenase, 
type I 2.1 0.04
Amuc_
1377
DnaB domain-containing protein helicase 
domain-containing protein -2.4 0.04
Amuc_
1930 transporter permease -2.5 0.04
Amuc_
0712 hypothetical protein -3.2 0.04
Amuc_
1365 hypothetical protein 2.4 0.04
Amuc_
1899 flavodoxin/nitric oxide synthase 2.5 0.04
Amuc_
2173 Redoxin domain-containing protein 2.3 0.04
Amuc_
1372 hypothetical protein -3.2 0.04
Amuc_
0628 hypothetical protein 2.4 0.04
Amuc_
0675 hypothetical protein -2.1 0.04
Amuc_
0913 ATP/cobalamin adenosyltransferase 2.4 0.04
Amuc_
1668 ATPase AAA -2.3 0.04
Amuc_
0985 succinate dehydrogenase flavoprotein subunit 2.1 0.04
Amuc_
0371
two component regulator propeller domain-
containing protein -1.9 0.05
Amuc_
1931 transporter permease -2.5 0.05
Amuc_
1349 hypothetical protein -2.4 0.05
Amuc_
1515 major facilitator superfamily protein -2.4 0.05
Amuc_
1613
NADH dehydrogenase (ubiquinone) 24 kDa 
subunit 2.3 0.05
Amuc_
0694 hypothetical protein 1.7 0.05
Amuc_
1169 hypothetical protein -2.1 0.05
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Abstract 
Akkermansia muciniphila colonizes the mucus layer of the gastrointestinal tract where the 
organism can be exposed to the oxygen that diffuses from epithelial cells. To understand how 
A. muciniphila is able to survive and grow at this oxic-anoxic interface, its oxygen tolerance, 
response and reduction capacities were studied. A. muciniphila was found to be oxygen-
tolerant. On top of this, under aerated conditions, A. muciniphila showed significant oxygen 
reduction capacities and its growth rate and yield were increased as compared to strict 
anaerobic conditions. Transcriptome analysis revealed an initial oxygen stress response upon 
exposure to oxygen. Hereafter, genes related to respiration were expressed, including those 
coding for the cytochrome bd complex, which can function as terminal oxidase. The 
functionality of A. muciniphila cytochrome bd genes was proven by successfully 
complementing the cytochrome-deficient Escherichia coli strain ECOM4. We conclude that 
A. muciniphila can use oxygen when present at nanomolar concentrations.
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Introduction
The gastrointestinal (GI) tract harbors a rich and diverse microbial community, which has 
proven to play a role in host health and physiology (Flint, et al., 2012). This microbial 
community is not in direct contact with epithelial cells, in between is a thin layer of host-
derived mucus. The outer layer of mucus is colonized with microbes that differ in 
composition from the luminal microbiota (Swidsinski, et al., 2002, Zoetendal, et al., 2002).
The mucin glycans are used by some bacteria as growth substrates resulting in the production 
of short chain fatty acids (SCFAs) (Manach, et al., 2004). To the host the SCFAs are 
important modulators of gut health (Manach, et al., 2004). To the microbial community 
SCFAs are a necessary waste product, the production process of SCFAs is required to 
maintain the redox balance in the cell, as it can restore the NAD+/NADH ratio (van Hoek and 
Merks, 2012).
One member of the mucosa-associated microbiota is Akkermansia muciniphila, a mucin-
degrading specialist that can use mucin as sole carbon and nitrogen source (Derrien, et al., 
2004). A. muciniphila is associated with a healthy GI tract as its abundance is inversely 
correlated with several GI tract related disorders (Belzer and de Vos, 2012). Moreover, it has 
been shown that A. muciniphila has immune-stimulatory capacities, stimulates host mucin 
production, increases the mucus layer thickness (Derrien, et al., 2004, Derrien, et al., 2011, 
Everard, et al., 2013, Reunanen, et al., 2015), and possibly strengthens the intestinal barrier 
function (Derrien, et al., 2011, Shin, et al., 2014). On top of this a causal role between A. 
muciniphila in the protection against high-fat-diet-induced obesity in mice was reported 
(Everard, et al., 2013) and its abundance has been identified as potential prognostic marker 
for predicting the success of dietary interventions for diabetes (Dao, et al., 2015).
A. muciniphila was initially described as a strict anaerobe (Derrien, et al., 2004). However 
more recently, it was reported that A. muciniphila can tolerate low amounts of oxygen 
(Reunanen, et al., 2015). The oxygen that diffuses from the gastrointestinal epithelial cells is 
thought to be one of the factors that keep strictly anaerobic commensal microbiota at a 
distance (Van den Abbeele, et al., 2011, Khan, et al., 2012). However, several mucosa-
associated bacteria have developed strategies to cope with low levels of oxygen (Espey, 
2013).
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Many microorganisms have to build up mechanisms to protect themselves against oxidative 
stress, with enzymes such as catalase and superoxide dismutase, small proteins like 
thioredoxin and glutaredoxin, and molecules such as glutathione (Cabiscol, et al., 2000).
Some molecules are constitutively present and help to maintain an intracellular reducing 
environment or to scavenge chemically reactive oxygen species (ROS). Among these 
molecules are non-enzymatic antioxidants such as NADPH and NADH. However, enzymes 
such as superoxide dismutases (SOD), catalases and hydroperoxidases are under 
transcriptional regulation and can decrease the steady-state levels of ROS.
Since the adaptation of A. muciniphila to the oxygen levels in the mucus layer has not been 
studied, we used an integrated physiological, genetic and biochemical approach to 
characterize the oxygen response of this mucosal symbiont. Herein we show that A.
muciniphila is able to survive and grow at nanomolar levels of oxygen, exposes a complex 
transcriptional response to oxygen, and contains a functional cytochrome bd complex that 
could be used as terminal oxidase. 
Materials and methods
Growth conditions A. muciniphila
A. muciniphila MucT (CIP 107961T) was grown in a bicarbonate-buffered basal medium 
(Derrien, et al., 2004) with a pH of 6.5-7.0, supplemented with 0.5% (w/v) hog gastric mucin 
(Type III; Sigma-Aldrich, St. Louis, MO, USA), as described previously (Miller and 
Hoskins, 1981). On plates, A. muciniphila was grown on the same mucin-based medium 
supplemented with 0.8% agar (Oxoid, Baringstoke, UK) further referred to as mucin-based 
plates (Derrien, et al., 2004). The correlation of optical density at 600 nm (OD600) to counted 
colony-forming units (CFU) on plates was determined to be 4.0x108 CFU per ml for an 
OD600 of 1.0. 
Oxygen survival and tube experiment
A fully-grown culture was exposed to ambient air and incubated at 37˚C while shaking. 
Survival rate was determined in fourfold over a period of 48 hours. Series of 10-fold dilutions 
were made and 2 μl of each dilution was spotted on mucin-based plates. 
To test for growth at different oxygen concentrations, gas tube experiments were performed, 
essentially as described previously (Khan, et al., 2012). For this purpose a 1% inoculum of a 
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mucin-grown culture was mixed with 20 ml of either molten mucin- based medium 
supplemented with 0.8% agar (~40 °C). Medium was poured into glass tubes under strict 
anaerobic conditions and sealed with a metal cap trough which ambient air could diffuse. 
Hereafter, the tubes were placed in ambient air. The oxygen penetration was measured by the 
pink-to-colorless turning point of the resazurin color indicator (Sigma-Aldrich) while growth 
was observed by the turbidity in the tube. The experiments were repeated at leas 3 times. 
Fermentor growth of A. muciniphila
Bacterial cultures were grown in two parallel 1.2 l fermentors (Bio Console ADI1025 and 
Bio Controller ADI 1010, Applikon Biotechnology B.V., Delft, The Netherlands) using 0.67 
l medium. The pH was controlled at 7.2, stirring at 50 rpm, initial gas flow N2/CO2 (80/20%) 
of 2 l/h, and the temperature was set at 37˚C. The mucin-medium used was slightly altered 
replacing the phosphate buffer with a 40mM MOPS buffer (Carl Roth Gmbh, Karlsruhe, 
Germany), and supplemented with 0.25% hog gastric mucin (Type III; Sigma-Aldrich, St. 
Louis, MO, USA) as sole carbon and nitrogen source (Plugge, 2005). Hereafter, the medium 
was sparged with N2/CO2 to remove all oxygen from the medium. A 0.2 l/h gas flow of 
ambient air was applied to the medium to measure the oxygen uptake rate of the medium 
without A. muciniphila, after which the medium was made anaerobic again using N2/CO2 at 
2 l/h. A 1% A. muciniphila inoculum was used to inoculate the fermentors after which growth 
was monitored by measuring the OD600 over a period of 27 h. At an optical density of 0.1, 
one of the fermentors was switched to 0.2 l/h of ambient airflow while the other remained 
under 2 l/h N2/CO2 flow. Samples for transcriptome and metabolic analyses were taken as 
described below.
To determine heme dependent oxygen reduction, A. muciniphila was grown in a heme 
deprived synthetic medium using five parallel fermentors (Dasgip-Eppendorf). 
Hemin (Sigma Aldrich) was added in three fermentors at a concentration of 2ug/ml. Oxygen 
was introduced at 0.2 l/h at an OD600 of 1 to one fermentor with hemin containing medium 
and to one fermentor with hemin deprived medium. The remaining fermentors were used as 
controls.
Metabolic analysis
To determine the production of metabolites, 1.5 ml of bacterial cultures were centrifuged and 
the supernatant was stored at −20°C. Short Chain Fatty Acids (SCFAs) were determined by 
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High-Performance Liquid Chromatography (HPLC) as previously described (van Gelder, et 
al., 2012). Total protein concentrations were determined by Pierce BCA protein assay kit 
(Thermo Scientific, Rockford, USA) and Qubit® (Life Technologies, Eugene, USA) 
according to manufacturer’s protocols. The concentration of proteins determined to be 32 
mg/l at an OD600 of 0.1. Metabolic data were analyzed with the student t-test and the Mann-
Whitney test. Two-tailed P values of <0.05 were considered statistically significant.
RNA sequencing and transcriptome analysis
Cells were collected under N2 flow, and immediately centrifuged (4,800 Xg, 5 min, 4°C). 
Cell pellets were directly suspended into Trizol® Reagent (Ambion, Life Technologies, 
Carlsbad, CA, USA) and stored at −80°C until RNA was purified. 
Total RNA was isolated by a method combining the Trizol® Reagent and the RNeasy Mini 
kit (QIAGEN GmbH, Hilden, Germany), essentially as described previously (Chomczynski, 
1993, Zoetendal, et al., 2006). Genomic DNA was removed by on-column DNase digestion 
step during RNA purification (DNase I recombinant, RNase-free, Roche Diagnostics GmbH, 
Mannheim, Germany). Yield and RNA quality were assessed using the Experion™ RNA 
StdSens Analysis Kit in combination with the Experion™ System (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA). Depletion of rRNA was performed using the Ribo-Zero™ Kit for 
bacteria (Epicentre, Madison, WI, USA) according to manufacturer’s instructions. The 
success of the rRNA depletion step was checked using the Experion™ RNA StdSens 
Analysis Kit in combination with the Experion™ System. Library construction for whole-
transcriptome sequencing (RNA-Seq) was done by ScriptSeq™ v2 RNA-Seq Library 
Preparation Kit in combination with ScriptSeq™ Index PCR primers (Epicentre, Madison, 
WI, USA) according to the manufacturer’s instructions. 
The barcoded cDNA libraries were sent to BaseClear (Leiden, The Netherlands), where they 
were pooled and 50 bp sequencing (single end reads) was performed on two lanes using the 
Illumina HiSeq2500 platform in combination with the TruSeq Rapid SBS and TruSeq Rapid 
SR Cluster Kits (Illumina, San Diego, USA).
Reads were mapped to the genome of A. muciniphila with Bowtie2 v2.2.1 (Langmead and 
Salzberg, 2012) using default settings and BAM files were converted with SAMtools v0.1.19 
(Li, et al., 2009). BEDTools v2.17.0 was used to determine the read count for each protein-
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coding region (Quinlan and Hall, 2010). Only reads with a minimum 30% length overlap and 
mapped on the correct strand were counted. Differential gene expression was assessed using 
edgeR (Robinson, et al., 2010) with default trimmed mean of M-values (TMM) settings. 
Sequences have been deposited under ArrayExpress accession E-MTAB-5111.
Cloning of A. muciniphila cytochrome bd
The cytochrome bd genes (Amuc_1694 and Amuc_1695) were amplified from genomic 
DNA using the following primers: Rev_1694 
AGATCACTCGAGAAAGGATCCTCAGTAACTGTGTTCGTTGAGCTGGA and 
FW_1695 
TGAACTAGATCTTTTAAGAAGGAGATATACATATGGACGATCCGGTCTTATTAT
CCC. The PCR reaction was done with Phusion polymerase (Thermo Scientific, Waltham, 
MA, USA). The PCR reaction conditions were as follows: denaturation at 96°C for 5 min 
followed by 35 cycles of a denaturation step at 96°C for 10s, an annealing step at 59°C for 
30 s and an extension step at 72°C for 1 min, and one final extension step at 72°C for 8 min. 
The PCR product was cloned into plasmid pBbA5c (Addgene plasmid #35281) containing 
an IPTG-inducible PlacUV5 promoter, a terminator, p15a origin of replication and a 
chloramphenicol resistance marker (Lee, et al., 2011). For this purpose, the PCR product and 
the destination vector were digested with BglII and XhoI (FastDigest, Thermo Scientific, 
Waltham, MA, USA) after which they were ligated with T4 ligase (Thermo Scientific, 
Waltham, MA, USA) overnight at 15˚C. 2 μl of the ligation mixture was used directly to 
transform Escherichia coli NEB5α (New England Biolabs, Ipswich, MA, USA) chemical 
competent cells according to manufacturer’s instructions. Transformants were selected on
plates with LB agar with 25 µg/ml chloramphenicol (Oxoid, Baringstoke, UK) and incubated 
overnight at 37˚C. The resulting vector pBbA5c-AmuCytbd was confirmed by Sanger 
sequencing.
Transformation of E. coli ECOM4
Electrocompetent cells of the cytochrome deficient, kanamycin resistant E. coli ECOM4 
(Portnoy, et al., 2010), kindly provided by Prof. Bernhard Ø. Palsson, were prepared by 
inoculating with 1% of an overnight E. coli ECOM4 pre-culture (OD600 of 0.6-0.7) in 1 l 
M9 medium (Sigma-Aldrich Chemie, Steinheim, Germany) with 25 μg/l kanamycin (Carl 
Roth Gmbh, Karlsruhe, Germany) and grown at 37˚C shaking at 180 rpm until exponential 
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High-Performance Liquid Chromatography (HPLC) as previously described (van Gelder, et 
al., 2012). Total protein concentrations were determined by Pierce BCA protein assay kit 
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Whitney test. Two-tailed P values of <0.05 were considered statistically significant.
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Salzberg, 2012) using default settings and BAM files were converted with SAMtools v0.1.19 
(Li, et al., 2009). BEDTools v2.17.0 was used to determine the read count for each protein-
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an IPTG-inducible PlacUV5 promoter, a terminator, p15a origin of replication and a 
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Waltham, MA, USA) after which they were ligated with T4 ligase (Thermo Scientific, 
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transform Escherichia coli NEB5α (New England Biolabs, Ipswich, MA, USA) chemical 
competent cells according to manufacturer’s instructions. Transformants were selected on
plates with LB agar with 25 µg/ml chloramphenicol (Oxoid, Baringstoke, UK) and incubated 
overnight at 37˚C. The resulting vector pBbA5c-AmuCytbd was confirmed by Sanger 
sequencing.
Transformation of E. coli ECOM4
Electrocompetent cells of the cytochrome deficient, kanamycin resistant E. coli ECOM4 
(Portnoy, et al., 2010), kindly provided by Prof. Bernhard Ø. Palsson, were prepared by 
inoculating with 1% of an overnight E. coli ECOM4 pre-culture (OD600 of 0.6-0.7) in 1 l 
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Roth Gmbh, Karlsruhe, Germany) and grown at 37˚C shaking at 180 rpm until exponential 
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phase (OD600 of 0.3-0.4). The bacterial culture was cooled down on ice for 15 min and 
centrifuged (5,000 Xg, 15 min, 4˚C); cells were washed twice with 400 ml of cold demi-
water, once with 10 ml of icecold 10% (v/v) glycerol and resuspended in 2 ml of 10% 
glycerol. Finally, 80 μl aliquots were prepared and stored at -80˚C for later transformation. 
Competent E. coli ECOM4 cells were transformed with pBbA5c-AmuCytbd using 
electroporation in a 2mm electroporation cuvette at the following settings: 2500 V, 200 Ω 
and 25 μF (ECM630 Precision Pulse, Harvard Apparatus, Inc., Holliston, USA). Immediately 
after, 1 ml of SOC medium (0.5 g/l NaCl, 20g/l tryptone, 5 g/l yeast extract, 2.5 ml/l KCl, 
2.03 g/l MgCl2∙6H2O), 3.60 g/l glucose) was added and cells were recovered for 1 hour at 
37˚C. The transformed cells were then plated on LB agar plates with appropriate antibiotics 
(20 µg/ml kanamycin and 25 µg/ml chloramphenicol). to select for ECOM4-AmuCytbd cells
Growth of E. coli ECOM4-AmuCytbd and metabolic profiling
E. coli ECOM4 and ECOM4-AmuCytbd strains were grown on M9 medium (Sigma-Aldrich 
Chemie, Steinheim, Germany) with 20 µg/ml kanamycin and 25 µg/ml chloramphenicol, at 
37˚C while shaking at 180 rpm. For metabolic analysis, cells were grown in pre-cultured, 
after which equal cell amounts were inoculated in M9 medium containing 18 mM glucose, 
either induced with the tested optimal concentration (data not shown) of 25 µM IPTG 
(Fischer Scientific, Fair Lawn, USA), or without inducer. Samples were taken over a period 
of 50 h, growth was determined measuring optical density (OD600) and HPLC analysis was 
done as described for A. muciniphila samples. 
Spectra of cytochrome bd 
Erlenmeyer flasks containing 500 ml M9 medium were inoculated with E. coli ECOM4 and 
E. coli ECOM4-Amucytbd with and without IPTG. Cells were collected at the end of the 
exponential phase by centrifugation (4,800 Xg, 10 min). A. muciniphila cells were grown in 
200mL cultures in anaerobic bottles. Pellets of E. coli ECOM4 (Amucytbd) and A. 
muciniphila were dissolved in 1 ml lysis buffer (50 mM Tris-HCl pH 8, 1 mM EDTA, 150 
mM NaCl, 1mM DDT, 0.5 mM PMSF, 1% dodecylmaltoside) and lysed by 2 passages 
through a French press (SPHC, Stansted Fluid Power Ltd, Essex, UK) at 16.000 psi or 4 times 
30 seconds sonication at output 3.5. Cell debris was removed by centrifugation (10,500 Xg, 
10 min). Spectra were measured by UV-2501PC (Shimadzu corporation, Kyoto, Japan) at 
380-700 nm and solutions were reduced using 50 mM sodium dithionite. 
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Results
Oxygen tolerance and oxygen reduction of A. muciniphila
To test oxygen tolerance, survival of A. muciniphila cells was measured after exposure to 
ambient air. Based on CFU counts, A. muciniphila cells were able to survive up to 48 hours 
in ambient air. The viability had dropped to 25% after 24 hours and was only 1% after 48 
hours (Figure 1A). To test the oxygen reduction capacity of A. muciniphila, the penetration 
depth of oxygen was measured in a gas tube assay based on the turning point of a redox 
indicator (resazurin). The oxygenated zone was deeper in non-inoculated tubes (10.0 ± 1.0 
mm) compared to the tubes where A. muciniphila was growing (5.0 ± 1.0 mm) (Figure 1B).
Figure 1. (A) Survival of A. muciniphila after exposure to oxygen over time. 1% of survival was measured during 
48 hours exposure to ambient air (---) while in anaerobic cultures were still >90% were viable (  ). Points depict the 
average of 4 replicates. B) Growth of A. muciniphila in the tube assay. Left a control tube. Right an A. muciniphila
inoculated tube. The lowest line indicates the resazurin oxidized zone in the control tube, the upper line indicates 
the reduced oxidized zone in the tube where A. muciniphila was growing A representative picture of 4 repeats is 
shown.
A. muciniphila shows enhanced growth under aerated conditions 
The growth of A. muciniphila at aerated conditions was investigated in a fermentor system 
controlled for temperature and pH. Both dissolved oxygen concentration (dO2%) and redox 
(mV) were measured throughout the experiment. Before growing A. muciniphila in the 
fermentor system, a control fermentor (negative control) was run to measure the increase in 
redox potential and oxygen diffusion by switching the gas flow from an N2 flow of 2.0 l/h to 
an ambient airflow of 0.2 l/h (Figure 2C). Hereafter, experiments were run in two parallel 
fermenters, at T1 (the beginning of the exponential phase at OD600 ≈ 0.1, grey-shaded area 
in Figure 2) one of the two fermentors was switched to an ambient airflow of 0.2 l/h (aerated 
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A. muciniphila shows enhanced growth under aerated conditions 
The growth of A. muciniphila at aerated conditions was investigated in a fermentor system 
controlled for temperature and pH. Both dissolved oxygen concentration (dO2%) and redox 
(mV) were measured throughout the experiment. Before growing A. muciniphila in the 
fermentor system, a control fermentor (negative control) was run to measure the increase in 
redox potential and oxygen diffusion by switching the gas flow from an N2 flow of 2.0 l/h to 
an ambient airflow of 0.2 l/h (Figure 2C). Hereafter, experiments were run in two parallel 
fermenters, at T1 (the beginning of the exponential phase at OD600 ≈ 0.1, grey-shaded area 
in Figure 2) one of the two fermentors was switched to an ambient airflow of 0.2 l/h (aerated 
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fermentor) and the other fermentor was kept under strict anaerobic conditions (anaerobic 
fermentor). At T1, the redox potential showed an increase after the introduction of ambient 
air (Figure 2B); this increase, however, declined and the redox potential was lowered again 
until A. muciniphila reached stationary phase pointing towards the potential use of oxygen as 
final electron acceptor. The oxygen concentration remained under our detection level of 0.1% 
dO2 during the complete growth curve of A. muciniphila and only increased in stationary 
phase (Figure 2B). 
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Figure 2. Growth, oxygen concentration and redox potential of A. muciniphila in aerated fermentor system. (A) 
Growth of A. muciniphila measured by OD600 in the aerated and anaerobic fermentor, and the dissolved oxygen 
concentration (dO2) in the aerated fermentor. Grey-shaded area indicates switch to ambient airflow of 0.2 l/h. (B) 
Redox potential (mV) (---) and the oxygen concentration (dO2%) (   ) during the growth of A. muciniphila in the 
aerated fermentor. Grey-shaded area indicates switch to ambient airflow of 0.2 l/h. (C) Redox potential (mV) (---)
and the oxygen concentration (dO2%) ( ) of the negative control (without A. muciniphila). Figures show solely one 
experiment but are representative for all four experiments performed.
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Under aerated conditions a significantly higher growth rate (P=0.02) and significantly higher 
OD600 (P=0.05) at the end-exponential phase were measured (Figure 3B, C). The 
fermentation profile of A. muciniphila consisted of acetate, propionate, and small amounts of 
1,2-propanediol, typical for growth in mucin-based medium (Figure 3A)(38). Under aerated 
conditions however, the ratio of acetate to propionate was altered from 1.2 to 1.5 (P=0.03) 
(Figure 3D), suggesting an altered fermentation pathway. 
Figure 3. Growth and physiology of A. muciniphila in the aerated fermentor system. (A) SCFA production profile 
of A. muciniphila at stationary phase including acetate, propionate, and 1,2-propanediol. (B) Maximal OD600 
reached during growth in the aerated fermentor and the anaerobic fermentor. (C) Growth rate (μ) based on the OD600 
during the exponential growth phase in the aerated fermentor and the anaerobic fermentor. (D) Ratio of the 
production of acetate to the production of propionate per fermentor run in the aerated fermentor and the anaerobic 
fermentor. Bars represent the mean of n=4, error bars represent the standard deviation (SD). (*) Indicates significant 
difference using the two-tailed student T-test. B p=0.05; C p=0.02; D p=0.03. (+) Indicates significant using the one-
tailed Mann-Whitney Test (p=0.03).
The minimal oxygen-reducing capacity of A. muciniphila under the given fermentor 
conditions was calculated based on the oxygen uptake rate in the negative control and the 
protein concentration of A. muciniphila cultures. The increase in oxygen concentration of the 
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negative control was calculated to be 69.4±31.9 mU/l (mU is defined as nanomole substrate 
per minute). This calculation is based on the difference between the increase in oxygen 
concentration of the negative control (dO2% in Figure 2C) and the increase in oxygen 
concentration of the A. muciniphila grown fermentor (dO2% in Figure 2B) for all four 
experiments. The oxygen reduction capacity of A. muciniphila was determined to be 
2.26±0.99 mU/mg total protein (n=4).
Initial transcriptional response of A. muciniphila to aerated conditions is dominated by 
oxygen stress response
The transcriptome of A. muciniphila was determined by RNAseq analysis for both aerated 
and anaerobic fermentor conditions at the beginning of exponential phase (before aeration) 
(T1), during mid-exponential phase (T2), and at end-exponential phase of growth (T3) (black 
arrows in Figure 2A). All genes that differed significantly between the conditions can be 
found in Table S1. At T1 (before aeration) both parallel fermentors had identical gene 
expression profiles (Figure 4A). Comparing the aerated to the non-aerated fermentor at T2
(mid-exponential) resulted in 38 genes that were expressed significantly different (Figure 
4B). During this initial transcriptional response a total of 26 genes were significantly 
upregulated due to the presence of oxygen. Only 18 of the genes are annotated of which 6 
were annotated as potential oxygen stress related genes: superoxide dismutase; 
hydroperoxidase; entericidin EcnAB, homologous to the EcnAB of E. coli that is involved in 
the stress response (Bishop, et al., 1998); rubrerythrin, previously implied in the protection 
from oxidative damage in sulfate-reducing bacteria (Zhou, et al., 2011); excinuclease, 
controlling for potential ROS-mediated DNA damage; and a family 2 glycosyl transferase, 
part of the capsular polysaccharide biosynthesis pathway upregulated to potentially protect 
the cells against the presence of oxygen (Table 1). Also one potential oxidoreductase, and six 
genes that are broadly categorized as potential growth phase dependent were significantly 
upregulated (Table 1). Twelve genes were significantly downregulated under aerated 
conditions. Five of these genes encode for the assimilatory sulfate reduction pathway (Figure 
4B, Table 1). The expression of the oxygen stress-related genes, after the initial oxygen 
response, was assessed by comparing the aerated fermentor at T2 and T3. The expression of 
these genes did not further increase significantly, except for hydroperoxidase (Table S1).
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conditions was calculated based on the oxygen uptake rate in the negative control and the 
protein concentration of A. muciniphila cultures. The increase in oxygen concentration of the 
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negative control was calculated to be 69.4±31.9 mU/l (mU is defined as nanomole substrate 
per minute). This calculation is based on the difference between the increase in oxygen 
concentration of the negative control (dO2% in Figure 2C) and the increase in oxygen 
concentration of the A. muciniphila grown fermentor (dO2% in Figure 2B) for all four 
experiments. The oxygen reduction capacity of A. muciniphila was determined to be 
2.26±0.99 mU/mg total protein (n=4).
Initial transcriptional response of A. muciniphila to aerated conditions is dominated by 
oxygen stress response
The transcriptome of A. muciniphila was determined by RNAseq analysis for both aerated 
and anaerobic fermentor conditions at the beginning of exponential phase (before aeration) 
(T1), during mid-exponential phase (T2), and at end-exponential phase of growth (T3) (black 
arrows in Figure 2A). All genes that differed significantly between the conditions can be 
found in Table S1. At T1 (before aeration) both parallel fermentors had identical gene 
expression profiles (Figure 4A). Comparing the aerated to the non-aerated fermentor at T2
(mid-exponential) resulted in 38 genes that were expressed significantly different (Figure 
4B). During this initial transcriptional response a total of 26 genes were significantly 
upregulated due to the presence of oxygen. Only 18 of the genes are annotated of which 6 
were annotated as potential oxygen stress related genes: superoxide dismutase; 
hydroperoxidase; entericidin EcnAB, homologous to the EcnAB of E. coli that is involved in 
the stress response (Bishop, et al., 1998); rubrerythrin, previously implied in the protection 
from oxidative damage in sulfate-reducing bacteria (Zhou, et al., 2011); excinuclease, 
controlling for potential ROS-mediated DNA damage; and a family 2 glycosyl transferase, 
part of the capsular polysaccharide biosynthesis pathway upregulated to potentially protect 
the cells against the presence of oxygen (Table 1). Also one potential oxidoreductase, and six 
genes that are broadly categorized as potential growth phase dependent were significantly 
upregulated (Table 1). Twelve genes were significantly downregulated under aerated 
conditions. Five of these genes encode for the assimilatory sulfate reduction pathway (Figure 
4B, Table 1). The expression of the oxygen stress-related genes, after the initial oxygen 
response, was assessed by comparing the aerated fermentor at T2 and T3. The expression of 
these genes did not further increase significantly, except for hydroperoxidase (Table S1).
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Figure 4. Differentially expressed genes of A. muciniphila under aerated conditions. (A) Schematic representation 
of the significant differentially expressed genes between aerated and non-aerated conditions at the different time 
points. A red arrow indicate downregulated genes, a green indicates upregulated genes. (B) Volcano plot of the 
aerated fermentor versus the non-aerated fermentor at T2. (C) Volcano plot of the aerated fermentor versus the non-
aerated fermentor at T3. The p-values were determined using edgeR (Robinson, et al., 2010) with default trimmed 
mean of M-values (TMM) settings (significant differences of gene expression between all conditions can be found 
in Table S1).
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Table 3.  Oxygen responsive genes that are significant differentially expressed between aerated and non-aerated 
fermentor at T2 and T3. Only genes that are involved in oxygen metabolism are included in this table, all other 
differentially expressed genes can be found in Table S1.
Gene or pathway Gene number
Fold 
chang
e T2
Fold 
chang
e T3
Potential 
mechanism
T2 
aerated vs non aerated fermetner
amino acid permease Amuc_0037 2.19 2.13
Enhanced 
growth
ion transport 2 domain-containing protein Amuc_0236 1.84 0.79
Enhanced 
growth
Entericidin EcnAB Amuc_0580 3.82 0.94
Response to 
starvation 
conditions
short-chain dehydrogenase/reductase SDR Amuc_0777 2.66 2.30
Oxidoreductas
e
cupin barrel domain containing protein Amuc_0883 1.08 1.96
Enhanced 
growth
sigma 54 modulation protein/ribosomal protein S30EA Amuc_0999 2.11 1.33
Enhanced 
growth
superoxide dismutase Amuc_1592 1.90 1.22
2 O- + 2 H+ -->
H2O2
sulfatase Amuc_1655 1.66 0.54
Sulfate 
cleavage from 
mucin protein 
for enhanced 
growth
heavy metal translocating P-type ATPase Amuc_1839 11.39 1.68
Enhanced 
growth
hydroperoxidase Amuc_2070 2.23 1.90
2 H2O2 → 2 
H2O + O2
rubrerythrin Amuc_2072 1.97 2.48
Stress 
response
family 2 glycosyl transferase Amuc_2081 1.81 1.18
Capsular 
polysaccharide 
biosynthesis 
pathway 
upregulated 
potentially to 
protect against 
the oxygen 
presence
excinuclease Amuc_2176 2.21 2.29
To control for 
potential ROS 
mediated DNA 
damage
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Figure 4. Differentially expressed genes of A. muciniphila under aerated conditions. (A) Schematic representation 
of the significant differentially expressed genes between aerated and non-aerated conditions at the different time 
points. A red arrow indicate downregulated genes, a green indicates upregulated genes. (B) Volcano plot of the 
aerated fermentor versus the non-aerated fermentor at T2. (C) Volcano plot of the aerated fermentor versus the non-
aerated fermentor at T3. The p-values were determined using edgeR (Robinson, et al., 2010) with default trimmed 
mean of M-values (TMM) settings (significant differences of gene expression between all conditions can be found 
in Table S1).
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Assimilatory sulfate reduction (Amuc_1294 - Amuc_1301)
Amuc_129
3 -2.40 -1.35
Not functional 
due to high 
redox potential
Amuc_129
5 -3.30 -2.25
Amuc_129
6 -3.17 -1.87
Amuc_129
7 -2.96 -2.27
Amuc_129
8 -2.35 -2.67
T3 
aerated vs non-aerated fermentor
Suf pathway (Amuc_0486 - Amuc_0489)
Amuc_048
8 1.20 1.82
Iron uptake 
[Fe-S]
Amuc_048
9 1.17 2.18
oxoglutarate dehydrogenase (Amuc_1692 - Amuc_1693)
Amuc_169
2 1.61 2.28 Potential read-
trough of 
transcriptAmuc_169
3 1.65 2.96
cytochrome bd complex (Amuc_1694 - Amuc_1695) Amuc_1694 0.91 2.77
Aerobic 
respiration
Feo iron transporter (Amuc_1089 - Amuc_1090)
Amuc_108
9 0.88 2.22
Iron uptake
Amuc_109
0 0.75 2.33
nickel-dependent hydrogenase (Amuc_2128 - Amuc_2132)
Amuc_212
9 1.41 2.74
Oxygen 
tolerant 
hydrogenase 
that  might use 
the H2 present 
at its 
ecological 
niche
Amuc_213
0 1.32 2.98
Amuc_213
1 1.78 3.46
ATPase AAA Amuc_0059 1.26 2.05
UvrB/UvrC 
protein; 
ATPase 
binding 
domain; 
part of NER. 
To control for 
potential ROS 
mediated DNA 
damage
Phosphopyruvate hydratase Amuc_0844 2.65 4.37
Involved in 
glycolysis, 
enhanced 
growth
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heavy metal translocating P-type ATPase Amuc_0876 1.63 2.72
Enhanced 
growth
alkyl hydroperoxide reductase Amuc_1321 1.25 5.06
ROS 
scavenger
ferodoxin Amuc_1922 1.01 2.09 Iron uptake
rubrerythrin Amuc_2072 1.97 2.48
Stress 
response
excinuclease Amuc_2176 2.21 2.29
To control for 
potential ROS 
mediated DNA 
damage
Potential flavin biosynthesis (Amuc_0421 - Amuc_1426)
Amuc_042
2 -1.15 -2.00
Electron sink
Amuc_042
3 -1.51 -2.45
Amuc_042
4 -1.26 -1.92
Amuc_042
5 -1.08 -2.20
Amuc_042
6 -1.40 -1.91
Assimilatory sulfate reduction (Amuc_1294 - Amuc_1301)
Amuc_129
5 -3.30 -2.25
Redox to high 
to be 
functional
Amuc_129
7 -2.96 -2.27
Amuc_129
8 -2.35 -2.67
Amuc_129
9 -1.74 -2.83
Amuc_130
0 -1.51 -2.51
Amuc_130
1 -1.05 -2.28
NADH-quinone oxidoreductase complex (Amuc_1604 -
Amuc_1614)
Amuc_160
9 -1.28 -1.98
Not essential 
in the electron 
transport from 
NADH to 
oxygen in a 
mutant E. coli 
strain
Amuc_161
2 -1.14 -1.72
Menaquinone pathway Amuc_1017 -1.56 -2.43
Menaquinone 
pathway
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End-exponential transcriptional response of A. muciniphila to aerated conditions points 
towards respiration using cytochrome bd as terminal oxidase
Comparing the aerated to the non-aerated fermentor at T3 (end-exponential) resulted in 107 
significantly altered genes (Figure 4C, Table S1). During this end-exponential transcriptional 
response, a total of 57 genes were significantly upregulated under aerated conditions. As well 
as at T2 a series of oxygen stress related genes was upregulated (Figure 4C, Table 1). Three 
major gene clusters were significantly upregulated under aerated conditions: (i) a cluster 
involved in iron transport including the Feo iron transporters; (ii) a respiratory gene cluster 
including oxoglutarate dehydrogenase subunits and its adjacent gene cytochrome d ubiquinol 
oxidase subunit II, and (iii) a nickel-dependent hydrogenase cluster, from which 3 out of 5 
genes were significantly oxygen induced, pointing towards the use of cytochrome bd as 
terminal oxidase. The cytochrome bd ubiquinol oxidase subunit I, although abundantly 
present in the transcriptome, showed no transcriptional induction by oxygen. However, when 
comparing the expression of the cytochrome bd subunits in the aerated fermentor at T2 and 
T3, we see that both subunits have an increased expression over time in aerated conditions 
(Table S1). At T3, both the SUF pathway, and the ferredoxin gene were significantly 
upregulated and are potentially involved in electron transfer. In addition, two genes broadly 
categorized as potential growth phase dependent genes were significantly upregulated under 
aerated conditions (Figure 4C, Table 1). A total of 50 genes were significantly downregulated 
under aerated conditions (Table S1) and included the following 3 major gene clusters: (i) the 
assimilatory sulfate reduction, (ii) the potential flavin biosynthesis, and (iii) the NADH-
quinone oxidoreductase complex (Figure 4C, Table 1). 
Cytochrome bd genes of A. muciniphila restore respiration in the cytochrome-deficient 
mutant Escherichia coli ECOM4
Under aerated conditions A. muciniphila showed both slightly increased growth (Figure 3) 
and oxygen reduction capacities of 2.26±0.99 mU/mg total protein, pointing towards the 
potential use of oxygen as final electron acceptor. Moreover, the A. muciniphila genome 
contains the genes for cytochrome bd subunits I (Amuc_1695) and II (Amuc_1694) and the 
gene coding for subunit II was significantly upregulated under aerated conditions (Figure 4). 
To test if the A. muciniphila cytochrome bd genes encode a functional cytochrome bd 
complex that can be used for respiration, we complemented the cytochrome-deficient E. coli
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ECOM4 with the pBbA5c-AmuCytbd expressing the genes for cytochrome bd subunits I 
(Amuc_1695) and II (Amuc_1694) of A. muciniphila, resulting in strain ECOM4-AmuCytbd. 
As previously shown by Portnoy et al. (Portnoy, et al., 2010), there was no production of 
acetate by the cytochrome-deficient E. coli ECOM4 under oxic conditions, in contrast to the 
parental strain E. coli MG1655, which produces ample amounts of acetate (Portnoy, et al., 
2010). However, in the strain ECOM4-amuCytbd, expressing the A. muciniphila cytochrome 
bd genes, the acetate production is partly restored upon induction with IPTG (3.2 ± 0.8 mM) 
and slightly lower without induction (2.2 ± 0.4 mM) (Table 2). Moreover, the growth yield 
increased from an OD600 of 0.18 ± 0.04 to 0.43 ± 0.03 in this complemented strain (Table 
2). 
Table 4. Acetate production of ECOM4-AmuCytbd, ECOM4 and wild type E. coli MG1655. A negative control of 
M9 medium without bacteria was included (-). Values represent mean (SD), n=3. Data with different superscript 
letters are significantly different are significantly different using 2-tailed student t-test. 
Strain ECOM4-AmuCytbd ECOM4
IPTG concentration 25 μM 0 μM 25 μM
Acetate (mM) 3.3 (0.8)a 2.2 (0.4)a 0.0 (0.0)b
Yield (OD600) 0.4 (0.0)c 0.4 (0.0)c 0.2 (0.0)d
Cytochrome bd is present and functional in A. muciniphila
Finally, the presence of the cytochrome bd complex of A. muciniphila was confirmed by 
spectra showing a small peak at 560 nm, and a larger peak at 430nm, indicating the presence 
of cytochromes (Figure 5A). The presence of the cytochrome bd complex in the 
complemented strain ECOM4-AmuCytbd was confirmed using an spectrum measurement 
that showed a major peak at 430nm, which is in line with the Soret peak of cytochrome bd 
(Figure 5B), as previously described (Borisov, 2008, Bloch, et al., 2009). To determine if the 
oxygen reduction was heme and thus cytochrome bd dependent, three parallel fermentors 
containing medium with and without hemin were used. Without bacteria, there was no 
difference observed in dO% between a fermentor with heme and a fermentor without heme 
(10.5±0.2 %). In the presence of A. muciniphila without hemin, the oxygen concentration 
reached an average saturation of 1.1±0.2% in the first 400min of aeration. With hemin, the 
same amount of cells was able to directly and completely reduce the oxygen, preventing 
accumulation of oxygen in the system. The saturation remained constant at 0.1±0.0% (Figure 
S3). 
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Figure 5. Cytochrome bd complex of A. muciniphila. (A) Spectrum of A. muciniphila cell free extract. Spectrum 
shows the oxidized spectrum minus the dithionate-reduced spectrum. (B) Spectrum of E. coli ECOM4-AmuCytbd 
cell free extract minus the ECOM4 cell free extract spectrum. The baseline is set for absorbance at 700 nm. Both 
spectra show a similar pattern at 430nm.
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Discussion
A. muciniphila is known to colonize the oxic-anoxic interface of the mucus layer. Using an 
integrated physiological, genetic and transcriptomic approach the oxygen response of A. 
muciniphila was addressed and shown to be highly complex, effective, and to involve a 
functional respiratory complex. Analysis of the global transcriptional response identified 137 
genes involved in the reaction to oxygen and other formed ROS (Table S1). This could testify
for an adaptation of A. muciniphila to continuous exposure to these products in its natural 
habitat. Moreover, we also observed the effective use of oxygen in a rudimentary respiratory 
chain involving a cytrochrome bd complex, indicating that A. muciniphila is capable of 
competing with other strict anaerobes that may colonize the mucosal layer.
The oxygen survival of A. muciniphila is in line with anaerobic gut colonizers such as 
Bacteroides fragilis and Bifidobacterium adolescentis, which were still viable after 48 hours 
of ambient air exposure (Rolfe, et al., 1978). As previously described for gut colonizers 
Faecalibacterium prausnitzii (Khan, et al., 2012) and B. fragilis (Baughn and Malamy, 
2004), A. muciniphila had enhanced growth at the oxic-anoxic interphase as shown in the gas 
tube assay (Figure 1B). The presence of riboflavin or other vitamins did not affect the 
observed growth ring (data not shown). Therefore, a riboflavin dependent extracellular 
electron shuttle as was proposed for the enhanced growth F. prausnitzii at the oxic-anoxic 
interface, is probably not present in A. muciniphila. For B. fragilis cytochrome bd oxidase 
was shown to be essential for growth at nanomolar oxygen concentrations (Baughn and 
Malamy, 2004). The genes for cytochrome bd subunits I (Amuc_1695) and II (Amuc_1694) 
are present in A. muciniphila and we confirmed their presence by spectral measurements. We 
also showed the functional relevance of the cytochrome bd complex by the lower oxygen 
reduction capacity in heme-deprived medium. The bacteria were only able to fully reduce the 
oxygen when heme was supplemented. Evolutionary, the A. muciniphila cytochrome bd 
genes are closest related to that of some aerobic members of the Verrucomicrobia, including 
Verrucomicrobium spinosum, and Opitutus tarae. The presence of the cytochrome bd genes 
in A. muciniphila might therefore be conserved during adaptation to the intestinal 
environment. 
Apart from oxygen tolerance, the oxygen reduction capacity of A. muciniphila was 
demonstrated in the gas tube assay, and quantified in the fermentor system to be at least 2.26 
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mU/mg total protein. This lower limit of oxygen conversion capacity of A. muciniphila is 
less than previously characterized anaerobic bacteria that employ the cytochrome bd, 
including B. fragilis (9 nmole/min/mg total protein) and Moorella thermoacetica (29.8 
nmole/min/mg protein) (Baughn and Malamy, 2004, Das, et al., 2005). However, A. 
muciniphila is clearly able to reduce nanomolar concentrations of oxygen. Given the actual 
concentrations of oxygen in the mucus layer, which has been estimated to be 15 mmHg (~210 
nM) (Espey, 2013), we speculate that A. muciniphila can take advantage of these nanomolar 
concentrations in its ecological niche to compete with other strict anaerobes. The cytochrome 
bd complex was described to be essential in intestinal colonization of mice as was reported 
using respiratory mutants of E. coli (Jones, et al., 2007) and B. fragilis (Baughn and Malamy, 
2004). Hence, it is tempting to suggest that A. muciniphila might need the cytochrome bd in 
initial colonization of its host as well.
The mechanism behind the oxygen response was investigated by analyzing the transcriptional 
response of A. muciniphila under aerated condition in the fermentor system. Two different 
responses to oxygen could be distinguished: the detoxification of oxygen and the use of 
oxygen in aerobic respiration. A variety of mechanisms could explain the upregulated and 
downregulated genes after aeration at both T2 (mid-exponential) and T3 (end-exponential 
phase) (Table 1). The detoxification of oxygen is reflected in the initial transcriptional 
response of A. muciniphila. Both superoxide dismutase (Amuc_1592), and hydroperoxidase 
(Amuc_2070) are upregulated to scavenge the ROS. Oxygen also induced the transcription 
of both rubrytrin genes of A. muciniphila, previously shown to be upregulated as well in the 
acute murine colitis model where there is an increase of ROS in the GI tract (Berry, et al., 
2012). In conclusion, A. muciniphila harbors an arsenal of genes to detoxify oxygen that are 
significantly upregulated under aerated conditions. However this does not explain the 
observed enhanced growth and the shift towards higher acetate to propionate ratio.
The transcriptome of A. muciniphila at the end-exponential phase points towards the use of 
oxygen in aerobic respiration mediated by cytochrome bd. As the energy yield of aerobic 
respiration is higher than fermentation, this might be the reason for the enhanced growth we 
observed under aerated conditions (Figure 4) (Lechardeur, et al., 2011). The cytochrome d 
ubiquinol oxidase (subunit II) (Amuc_1694) was significantly upregulated, while subunit I 
(Amuc_1695), although abundantly present in the transcriptome, showed no transcriptional 
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induction by oxygen (both T2 and T3). To be functional, the cytochrome bd complex needs 
to be coupled to an NADH dehydrogenase to recycle its menaquinone and produce NAD+
(Figure 6). A. muciniphila harbors a NADH hydrogenase complex consisting of the following 
13 genes: Amuc_1604-Amuc_1614, Amuc_1551, and Amuc_2157-Amuc_2158. While the 
first gene cluster was downregulated under aerated conditions, the other genes were slightly 
(~1.5 fold) upregulated, though not significantly. Moreover, this NADH hydrogenase 
complex belongs to the NADH dehydrogenase type I (Baranova, et al., 2007), which has been 
shown not to be essential in the electron transport from NADH to oxygen in a mutant E. coli
strain (Tran, et al., 1997). Therefore, we screened the genome for another potential NADH 
dehydrogenase and found that Amuc_1809 might be a candidate. Although abundantly 
expressed at all tested conditions, Amuc_1809 was slightly upregulated under aerated 
conditions at T2 (1.1 fold upregulated) and T3 (1.3 fold upregulated), not significantly. 
Hence, this NADH dehydrogenase might operate in conjunction with the cytochrome bd 
complex to use oxygen as final electron acceptor. 
The enhanced growth under aerated conditions was observed together with a marginal but 
significant shift towards a higher acetate to propionate ratio. As cytochrome bd uses oxygen 
as final electron acceptor, resulting in the production of H2O and NAD+ (Figure 6); to 
maintain the NAD+:NADH ratios, the extra NAD+ production needs to be balanced by 
additional NADH regeneration. Therefore, the metabolism might shift from propionate, 
where net 2 NADH are oxidized to 2 NAD+, towards acetate production, where 1 NAD+ is 
reduced to 1 NADH (simplified schematic representation in Figure S2). More acetate 
production will lead towards more ATP production as well. As acetate is a more oxidized 
fermentation product, more electrons are released from pyruvate and donated to NAD+
leading to the production of more NADH. The NADH can be oxidized and the electrons can 
be transferred back to oxygen via an NADH dehydrogenase, menaquinones and cytochrome 
bd. Due to the change in acetate to propionate ratio, more ATP and NADH can be generated, 
leading to a slightly increased growth rate and yield, as observed in our fermentor 
experiments. This was confirmed by increased growth and acetate production of ECOM4-
AmuCytbd (Table 2), and its presence in A. muciniphila was confirmed by spectral 
measurements (Figure 5). 
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The cytochrome bd complex is likely to involve iron-containing hemes as cofactor. Both Feo 
iron transporters (Amuc_1089-Amuc_1090) predicted to be involved in Fe2+ transport were 
significantly upregulated under aerated conditions. This might point towards increased iron 
uptake to allow incorporation of the iron-containing heme cofactors in the cytochrome bd. 
All known members of the bd-family of oxygen reductases most commonly use ubiquinol or 
menaquinol as substrate (Borisov, et al., 2011). A. muciniphila is predicted to harbor the 
complete pathway to produce menaquinones (Figure S1). However, one gene (Amuc_1017) 
was significantly downregulated at T3 while the other 8 were not significantly altered under 
aeration condition. 
Taken together, we showed that a subunit of cytochrome bd complex is transcriptionally 
induced under aerated conditions and its presence in A. muciniphila was confirmed by 
spectrum measurements. The genes for both Feo iron transporters were significantly 
upregulated to potentially employ the iron-consisting-heme cofactors of the cytochrome bd. 
The oxygen conversion capacity of A. muciniphila is  lower compared previously 
characterized cytochrome bd of two other bacteria (Baughn and Malamy, 2004, Das, et al., 
2005), yet it clearly possesses the ability to reduce oxygen. Finally, the functionality of the 
cytochrome bd complex of A. muciniphila was confirmed by the increased growth and the 
acetate production of ECOM4-AmuCytbd. On top of this A. muciniphila had a lower oxygen 
reduction capacity in absence of heme. Therefore we propose the following mechanism 
(Figure 6): A. muciniphila uses the cytochrome bd complex coupled to an unidentified NADH 
dehydrogenase (possible candidate Amuc_1809) to use oxygen as final electron acceptor. 
The use of oxygen as final electron acceptor by cytochrome bd oxidase shifts the metabolic 
process towards higher acetate to propionate ratio, resulting in more ATP and NADH and 
eventually leading to an slightly increased growth rate and yield. In its ecological niche A. 
muciniphila might use this additional energy to outcompete strict anaerobes in the mucus 
layer. 
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Figure 6. Schematic representation of aerobic respiration by A. muciniphila under nanomolar oxygen concentrations.
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Supplementary Information
Figure S1. Menaquinol pathway. This figure illustrates the Menoquinol pathway as proposed by KEGG. Colored 
genes are present in A. muciniphila MucT.
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Figure S2. Simplified schematic representation of the metabolic pathways propionate and acetate (NAD+ pool) of 
A. muciniphila. Pyruvate to propionate results in netto 2 oxidized NADH to 2 NAD+, while pyruvate to acetate 
production results in netto 1 reduced NAD+.
Figure S3. Heme depended oxygen reduction. The oxygen was completely reduced when heme was present (aerobic 
fermentor + heme) and accumulated when no heme was present (aerobic fermentor – heme). The anaerobic 
fermentor was included to determine the influence of heme. The negative control fermentors without bacteria and 
with and without heme showed no difference in dissolved oxygen concentration. 
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Table S1. Significantly altered genes between all tested conditions
T1vsT2_no_O2
Gene code Annotation
2log
FC
2log
CPM PValue
Amuc_0037 amino acid permease 1.03 9.57 2.85E-02
Amuc_0038 glutaminase 1.18 8.97 1.68E-02
Amuc_0089 hypothetical protein 1.44 7.19 3.89E-03
Amuc_0101 hypothetical protein -1.29 14.74 4.25E-02
Amuc_0239 hypothetical protein -1.12 5.05 3.67E-02
Amuc_0242 pseudouridine synthase -0.78 10.15 2.28E-02
Amuc_0259 hypothetical protein -1.05 6.67 3.38E-02
Amuc_0266 50S ribosomal protein L32 -0.86 8.06 4.85E-02
Amuc_0330 hypothetical protein -1.13 9.17 9.20E-03
Amuc_0410 hypothetical protein 1.03 4.21 4.38E-02
Amuc_0468
DeoR family 
transcriptional regulator -0.84 8.62 2.29E-02
Amuc_0469 N-acetyltransferase GCN5 -1.04 9.10 1.92E-02
Amuc_0504 hypothetical protein 0.75 6.62 4.67E-02
Amuc_0566 hypothetical protein -1.66 2.63 1.57E-02
Amuc_0580 entericidin EcnAB -1.31 8.16 3.10E-02
Amuc_0606 hypothetical protein -1.43 7.69 1.30E-02
Amuc_0691 thioredoxin -0.84 10.35 4.79E-02
Amuc_0748
riboflavin biosynthesis 
protein RibF -0.74 7.49 4.26E-02
Amuc_0753
glycosyl transferase 
family protein 0.80 7.34 4.68E-02
Amuc_0819
multi antimicrobial 
extrusion protein MatE -1.22 7.51 3.30E-02
Amuc_0976 hypothetical protein -0.85 7.69 8.90E-03
Amuc_1022
G-D-S-L family lipolytic 
protein 0.74 7.77 3.02E-02
Amuc_1087 hypothetical protein -2.70 6.04 3.46E-02
Amuc_1137 hypothetical protein -0.93 7.06 4.75E-02
Amuc_1363 hypothetical protein -1.00 8.97 2.59E-02
Amuc_1364 hypothetical protein -1.10 9.28 1.33E-02
Amuc_1386 dihydropteroate synthase -1.00 6.83 1.24E-02
Amuc_1409 hypothetical protein -1.54 12.23 1.21E-02
Amuc_1430 50S ribosomal protein L31 -0.97 9.98 1.02E-02
Amuc_1508 hypothetical protein 1.98 0.56 1.09E-02
Amuc_1529 hypothetical protein -1.09 9.42 5.54E-03
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Table S1. Significantly altered genes between all tested conditions
T1vsT2_no_O2
Gene code Annotation
2log
FC
2log
CPM PValue
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Amuc_0101 hypothetical protein -1.29 14.74 4.25E-02
Amuc_0239 hypothetical protein -1.12 5.05 3.67E-02
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Amuc_0468
DeoR family 
transcriptional regulator -0.84 8.62 2.29E-02
Amuc_0469 N-acetyltransferase GCN5 -1.04 9.10 1.92E-02
Amuc_0504 hypothetical protein 0.75 6.62 4.67E-02
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Amuc_0580 entericidin EcnAB -1.31 8.16 3.10E-02
Amuc_0606 hypothetical protein -1.43 7.69 1.30E-02
Amuc_0691 thioredoxin -0.84 10.35 4.79E-02
Amuc_0748
riboflavin biosynthesis 
protein RibF -0.74 7.49 4.26E-02
Amuc_0753
glycosyl transferase 
family protein 0.80 7.34 4.68E-02
Amuc_0819
multi antimicrobial 
extrusion protein MatE -1.22 7.51 3.30E-02
Amuc_0976 hypothetical protein -0.85 7.69 8.90E-03
Amuc_1022
G-D-S-L family lipolytic 
protein 0.74 7.77 3.02E-02
Amuc_1087 hypothetical protein -2.70 6.04 3.46E-02
Amuc_1137 hypothetical protein -0.93 7.06 4.75E-02
Amuc_1363 hypothetical protein -1.00 8.97 2.59E-02
Amuc_1364 hypothetical protein -1.10 9.28 1.33E-02
Amuc_1386 dihydropteroate synthase -1.00 6.83 1.24E-02
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Amuc_1531 anthranilate synthase 0.97 9.01 7.01E-03
Amuc_1540 50S ribosomal protein L36 -1.09 10.25 1.07E-02
Amuc_1567
methylated-DNA--
protein-cysteine 
methyltransferase -0.84 6.78 1.10E-02
Amuc_1593 hypothetical protein 0.75 6.06 4.54E-02
Amuc_1679
Xylose isomerase domain-
containing protein TIM 
barrel 0.78 6.21 4.79E-02
Amuc_1717 hypothetical protein -0.94 11.51 2.78E-02
Amuc_1790
PDZ/DHR/GLGF 
domain-containing protein 0.75 6.54 3.16E-02
Amuc_1896
histone family protein 
DNA-binding protein -1.31 11.34 9.73E-03
Amuc_1899
flavodoxin/nitric oxide 
synthase -1.24 8.82 9.58E-03
Amuc_1936 hypothetical protein -1.30 9.84 2.44E-03
Amuc_2072 rubrerythrin -1.09 9.02 2.72E-03
T1vsT2_O2
Gene code Annotation 2logFC
2logC
PM PValue
Amuc_0016 hypothetical protein 1.02 12.90 4.84E-02
Amuc_0037 amino acid permease 2.16 9.57 6.76E-06
Amuc_0038 glutaminase -1.34 8.97 1.73E-04
Amuc_0089 hypothetical protein 2.65 7.19 9.65E-08
Amuc_0130 hypothetical protein 1.33 4.14 4.30E-02
Amuc_0131 hypothetical protein 1.70 3.97 2.71E-03
Amuc_0204
sodium ion-translocating 
decarboxylase subunit 
beta 0.66 9.01 4.58E-02
Amuc_0213
glutamyl-tRNA(Gln) 
amidotransferase subunit 
B -0.79 10.09 3.76E-02
Amuc_0220
hydrophobe/amphiphile 
efflux-1 (HAE1) family 
transporter -2.10 9.32 8.69E-04
Amuc_0236
Ion transport 2 domain-
containing protein 0.95 7.04 5.38E-03
Amuc_0237
arsenate reductase-like 
protein 0.65 8.11 3.47E-02
Amuc_0267 hypothetical protein -0.73 10.97 4.23E-02
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Amuc_0270 shikimate kinase -1.00 8.85 1.11E-02
Amuc_0271 30S ribosomal protein S16 -1.14 9.45 1.68E-02
Amuc_0275
preprotein translocase 
subunit YajC -0.86 10.48 2.10E-02
Amuc_0327 hypothetical protein -1.57 9.96 2.79E-02
Amuc_0328 hypothetical protein -1.19 11.38 4.94E-02
Amuc_0330 hypothetical protein -1.72 9.17 7.01E-04
Amuc_0372 glutamate decarboxylase 1.22 11.79 7.61E-03
Amuc_0384
Maltose O-
acetyltransferase 0.62 7.40 4.86E-02
Amuc_0469 N-acetyltransferase GCN5 -1.04 9.10 1.92E-02
Amuc_0485 50S ribosomal protein L27 -0.94 9.05 3.41E-02
Amuc_0583 hypothetical protein -1.29 6.30 2.56E-02
Amuc_0606 hypothetical protein -1.46 7.69 1.11E-02
Amuc_0632
family 2 glycosyl 
transferase -0.68 7.73 3.73E-02
Amuc_0677 hypothetical protein 0.66 7.05 3.80E-02
Amuc_0687
outer membrane 
autotransporter barrel 
domain-containing protein -1.15 11.64 1.16E-04
Amuc_0717 amino acid permease 0.86 8.64 1.70E-02
Amuc_0748
riboflavin biosynthesis 
protein RibF -0.76 7.49 3.77E-02
Amuc_0767 hypothetical protein 1.09 7.65 2.60E-03
Amuc_0772 phosphoglycerate mutase 1.15 8.95 1.74E-03
Amuc_0773 acyltransferase 3 0.69 7.14 3.59E-02
Amuc_0777
short-chain 
dehydrogenase/reductase 
SDR 2.51 6.92 3.49E-05
Amuc_0778 hypothetical protein 0.83 6.04 4.84E-02
Amuc_0803
coagulation factor 5/8 type 
domain-containing protein 0.87 9.38 1.62E-02
Amuc_0818 adenosylhomocysteinase -0.83 7.14 3.20E-02
Amuc_0819
multi antimicrobial 
extrusion protein MatE -1.28 7.51 2.48E-02
Amuc_0868
beta-N-
acetylhexosaminidase 0.74 7.29 3.14E-02
Amuc_0882 hypothetical protein 1.34 12.90 4.17E-03
Amuc_0883 hypothetical protein 1.38 9.10 1.47E-03
Amuc_0907 hypothetical protein -1.26 9.19 3.09E-02
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Amuc_1531 anthranilate synthase 0.97 9.01 7.01E-03
Amuc_1540 50S ribosomal protein L36 -1.09 10.25 1.07E-02
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2logC
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Amuc_0089 hypothetical protein 2.65 7.19 9.65E-08
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sodium ion-translocating 
decarboxylase subunit 
beta 0.66 9.01 4.58E-02
Amuc_0213
glutamyl-tRNA(Gln) 
amidotransferase subunit 
B -0.79 10.09 3.76E-02
Amuc_0220
hydrophobe/amphiphile 
efflux-1 (HAE1) family 
transporter -2.10 9.32 8.69E-04
Amuc_0236
Ion transport 2 domain-
containing protein 0.95 7.04 5.38E-03
Amuc_0237
arsenate reductase-like 
protein 0.65 8.11 3.47E-02
Amuc_0267 hypothetical protein -0.73 10.97 4.23E-02
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Amuc_0270 shikimate kinase -1.00 8.85 1.11E-02
Amuc_0271 30S ribosomal protein S16 -1.14 9.45 1.68E-02
Amuc_0275
preprotein translocase 
subunit YajC -0.86 10.48 2.10E-02
Amuc_0327 hypothetical protein -1.57 9.96 2.79E-02
Amuc_0328 hypothetical protein -1.19 11.38 4.94E-02
Amuc_0330 hypothetical protein -1.72 9.17 7.01E-04
Amuc_0372 glutamate decarboxylase 1.22 11.79 7.61E-03
Amuc_0384
Maltose O-
acetyltransferase 0.62 7.40 4.86E-02
Amuc_0469 N-acetyltransferase GCN5 -1.04 9.10 1.92E-02
Amuc_0485 50S ribosomal protein L27 -0.94 9.05 3.41E-02
Amuc_0583 hypothetical protein -1.29 6.30 2.56E-02
Amuc_0606 hypothetical protein -1.46 7.69 1.11E-02
Amuc_0632
family 2 glycosyl 
transferase -0.68 7.73 3.73E-02
Amuc_0677 hypothetical protein 0.66 7.05 3.80E-02
Amuc_0687
outer membrane 
autotransporter barrel 
domain-containing protein -1.15 11.64 1.16E-04
Amuc_0717 amino acid permease 0.86 8.64 1.70E-02
Amuc_0748
riboflavin biosynthesis 
protein RibF -0.76 7.49 3.77E-02
Amuc_0767 hypothetical protein 1.09 7.65 2.60E-03
Amuc_0772 phosphoglycerate mutase 1.15 8.95 1.74E-03
Amuc_0773 acyltransferase 3 0.69 7.14 3.59E-02
Amuc_0777
short-chain 
dehydrogenase/reductase 
SDR 2.51 6.92 3.49E-05
Amuc_0778 hypothetical protein 0.83 6.04 4.84E-02
Amuc_0803
coagulation factor 5/8 type 
domain-containing protein 0.87 9.38 1.62E-02
Amuc_0818 adenosylhomocysteinase -0.83 7.14 3.20E-02
Amuc_0819
multi antimicrobial 
extrusion protein MatE -1.28 7.51 2.48E-02
Amuc_0868
beta-N-
acetylhexosaminidase 0.74 7.29 3.14E-02
Amuc_0882 hypothetical protein 1.34 12.90 4.17E-03
Amuc_0883 hypothetical protein 1.38 9.10 1.47E-03
Amuc_0907 hypothetical protein -1.26 9.19 3.09E-02
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Amuc_0925
KOW domain-containing 
protein -0.93 10.99 4.35E-02
Amuc_0947
biotin/lipoyl attachment 
domain-containing protein 0.70 7.78 3.24E-02
Amuc_0998 hypothetical protein 1.28 7.62 9.53E-03
Amuc_1090 FeoA family protein -0.88 9.43 4.82E-02
Amuc_1107
ATP 
phosphoribosyltransferase -0.98 11.20 3.17E-02
Amuc_1141
glycosyl transferase 
family protein 1.76 6.93 1.46E-02
Amuc_1176 hypothetical protein -0.76 8.59 8.01E-05
Amuc_1177 lipocalin family protein 1.39 6.25 9.40E-04
Amuc_1196 hypothetical protein -0.90 7.77 1.67E-02
Amuc_1213 hypothetical protein -1.53 10.91 5.35E-04
Amuc_1229 hypothetical protein -0.80 11.64 4.14E-02
Amuc_1293 hypothetical protein -1.79 6.81 6.33E-05
Amuc_1294 sulfite reductase -1.45 11.21 3.11E-03
Amuc_1295
binding-protein-
dependent transporters 
inner membrane 
component -2.08 10.99 4.19E-06
Amuc_1296 ABC transporter -1.88 9.96 5.47E-05
Amuc_1297
substrate-binding protein 
of aliphatic sulfonate ABC 
transporter -2.01 10.18 2.19E-06
Amuc_1298
sulfate 
adenylyltransferase, large 
subunit -1.72 10.77 4.30E-05
Amuc_1299
sulfate 
adenylyltransferase 
subunit 2 -1.25 10.39 6.08E-03
Amuc_1300 adenylylsulfate reductase -0.85 10.96 3.33E-02
Amuc_1342 hypothetical protein 1.08 10.14 4.64E-02
Amuc_1363 hypothetical protein -0.99 8.97 2.83E-02
Amuc_1364 hypothetical protein -1.16 9.28 9.50E-03
Amuc_1365 hypothetical protein -1.52 9.52 6.28E-03
Amuc_1368 hypothetical protein -1.22 8.45 9.89E-03
Amuc_1381 ABC transporter 0.86 6.46 1.83E-02
Amuc_1394 hypothetical protein 1.20 7.82 4.38E-03
Amuc_1409 hypothetical protein -1.20 12.23 4.84E-02
Amuc_1451 hypothetical protein -0.97 8.25 6.97E-03
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Amuc_1497 hypothetical protein 1.04 8.19 3.51E-02
Amuc_1529 hypothetical protein -1.10 9.42 5.08E-03
Amuc_1540 50S ribosomal protein L36 -0.86 10.25 4.27E-02
Amuc_1594
NCAIR mutase-like 
protein 0.77 6.24 4.66E-02
Amuc_1602 hypothetical protein 0.93 8.25 2.62E-02
Amuc_1613
NADH dehydrogenase 
(ubiquinone) 24 kDa 
subunit -0.81 9.83 3.93E-02
Amuc_1674 hypothetical protein 1.16 4.70 4.30E-02
Amuc_1676
Eco57I restriction 
endonuclease -1.11 7.50 2.81E-02
Amuc_1684 TonB-dependent receptor 0.72 7.88 4.36E-02
Amuc_1692
2-oxoglutarate 
dehydrogenase, E2 
subunit, dihydrolipoamide 
succinyltransferase 1.02 7.77 1.53E-02
Amuc_1693
2-oxoglutarate 
dehydrogenase, E1 
subunit 0.99 9.86 1.70E-02
Amuc_1717 hypothetical protein -1.30 11.51 2.65E-03
Amuc_1743 hypothetical protein 0.98 7.43 8.84E-03
Amuc_1770
AsnC family 
transcriptional regulator -0.83 9.13 2.02E-02
Amuc_1812 alpha-amylase 1.89 10.22 5.33E-05
Amuc_1838 hypothetical protein -1.04 7.93 4.40E-03
Amuc_1839
heavy metal translocating 
P-type ATPase 3.19 7.44 1.31E-05
Amuc_1870 Alpha-glucosidase -0.77 9.54 2.61E-02
Amuc_1896
histone family protein 
DNA-binding protein -1.39 11.34 6.39E-03
Amuc_1904 hypothetical protein 1.42 5.93 4.38E-03
Amuc_1914
restriction modification 
system DNA specificity 
domain -0.87 9.25 4.02E-02
Amuc_1990
pyrroline-5-carboxylate 
reductase 0.76 5.90 4.00E-02
Amuc_2015
thiamine-phosphate 
pyrophosphorylase -1.91 9.49 8.48E-04
Amuc_2016
Hydroxyethylthiazole 
kinase -0.94 9.55 2.54E-02
Amuc_2035 hypothetical protein 1.31 5.04 3.25E-02
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subunit 2 -1.25 10.39 6.08E-03
Amuc_1300 adenylylsulfate reductase -0.85 10.96 3.33E-02
Amuc_1342 hypothetical protein 1.08 10.14 4.64E-02
Amuc_1363 hypothetical protein -0.99 8.97 2.83E-02
Amuc_1364 hypothetical protein -1.16 9.28 9.50E-03
Amuc_1365 hypothetical protein -1.52 9.52 6.28E-03
Amuc_1368 hypothetical protein -1.22 8.45 9.89E-03
Amuc_1381 ABC transporter 0.86 6.46 1.83E-02
Amuc_1394 hypothetical protein 1.20 7.82 4.38E-03
Amuc_1409 hypothetical protein -1.20 12.23 4.84E-02
Amuc_1451 hypothetical protein -0.97 8.25 6.97E-03
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Amuc_1497 hypothetical protein 1.04 8.19 3.51E-02
Amuc_1529 hypothetical protein -1.10 9.42 5.08E-03
Amuc_1540 50S ribosomal protein L36 -0.86 10.25 4.27E-02
Amuc_1594
NCAIR mutase-like 
protein 0.77 6.24 4.66E-02
Amuc_1602 hypothetical protein 0.93 8.25 2.62E-02
Amuc_1613
NADH dehydrogenase 
(ubiquinone) 24 kDa 
subunit -0.81 9.83 3.93E-02
Amuc_1674 hypothetical protein 1.16 4.70 4.30E-02
Amuc_1676
Eco57I restriction 
endonuclease -1.11 7.50 2.81E-02
Amuc_1684 TonB-dependent receptor 0.72 7.88 4.36E-02
Amuc_1692
2-oxoglutarate 
dehydrogenase, E2 
subunit, dihydrolipoamide 
succinyltransferase 1.02 7.77 1.53E-02
Amuc_1693
2-oxoglutarate 
dehydrogenase, E1 
subunit 0.99 9.86 1.70E-02
Amuc_1717 hypothetical protein -1.30 11.51 2.65E-03
Amuc_1743 hypothetical protein 0.98 7.43 8.84E-03
Amuc_1770
AsnC family 
transcriptional regulator -0.83 9.13 2.02E-02
Amuc_1812 alpha-amylase 1.89 10.22 5.33E-05
Amuc_1838 hypothetical protein -1.04 7.93 4.40E-03
Amuc_1839
heavy metal translocating 
P-type ATPase 3.19 7.44 1.31E-05
Amuc_1870 Alpha-glucosidase -0.77 9.54 2.61E-02
Amuc_1896
histone family protein 
DNA-binding protein -1.39 11.34 6.39E-03
Amuc_1904 hypothetical protein 1.42 5.93 4.38E-03
Amuc_1914
restriction modification 
system DNA specificity 
domain -0.87 9.25 4.02E-02
Amuc_1990
pyrroline-5-carboxylate 
reductase 0.76 5.90 4.00E-02
Amuc_2015
thiamine-phosphate 
pyrophosphorylase -1.91 9.49 8.48E-04
Amuc_2016
Hydroxyethylthiazole 
kinase -0.94 9.55 2.54E-02
Amuc_2035 hypothetical protein 1.31 5.04 3.25E-02
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Amuc_2038
PUR-alpha/beta/gamma 
DNA/RNA-binding 
protein -0.90 10.64 2.56E-02
Amuc_2051 glutamate dehydrogenase -0.98 10.01 2.27E-02
Amuc_2053 hypothetical protein -1.04 8.02 1.03E-02
Amuc_2055 hypothetical protein 1.18 9.20 6.54E-03
Amuc_2058 hypothetical protein 1.13 6.15 1.59E-02
Amuc_2060 hypothetical protein 0.95 6.42 2.67E-02
Amuc_2061 hypothetical protein 1.28 4.07 2.91E-02
Amuc_2070 hydroperoxidase II -0.95 10.78 8.61E-05
Amuc_2078
capsular polysaccharide 
biosynthesis protein 0.87 9.28 2.26E-02
Amuc_2079
PHP domain-containing 
protein 1.15 6.07 3.06E-02
Amuc_2080 sugar transferase 1.37 7.19 1.63E-03
Amuc_2081
family 2 glycosyl 
transferase 1.05 6.65 7.28E-03
Amuc_2082
group 1 glycosyl 
transferase 0.94 7.07 1.31E-02
Amuc_2084
group 1 glycosyl 
transferase 1.16 6.54 1.15E-02
Amuc_2085 hypothetical protein 1.55 5.56 2.67E-03
Amuc_2088
group 1 glycosyl 
transferase 1.21 4.75 4.48E-02
Amuc_2093
family 2 glycosyl 
transferase 1.15 4.42 2.35E-02
Amuc_2094
family 2 glycosyl 
transferase 0.88 4.65 4.71E-02
Amuc_2129
nickel-dependent 
hydrogenase large subunit 0.97 9.03 1.10E-02
Amuc_2130 cytochrome B561 0.96 8.73 1.00E-02
Amuc_2131
hydrogenase maturation 
protease 1.31 6.72 5.55E-03
Amuc_2132
hydrogenase nickel 
incorporation protein 
HypA 1.02 5.39 1.77E-02
Amuc_2141 hypothetical protein -0.92 9.89 2.68E-02
Amuc_2176
excinuclease ABC subunit 
A 0.90 8.75 5.75E-03
T2_O2vsT2_no_O2
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Gene code Annotation 2logFC
2logC
PM PValue
Amuc_0037 amino acid permease 1.13 9.57 2.88E-02
Amuc_0089 hypothetical protein 1.21 7.19 1.58E-02
Amuc_0236
Ion transport 2 domain-
containing protein 0.88 7.04 1.73E-02
Amuc_0342 OsmC family protein 0.81 6.76 3.25E-02
Amuc_0580 entericidin EcnAB 1.93 8.16 2.65E-03
Amuc_0687
outer membrane 
autotransporter barrel 
domain-containing protein 1.31 11.64 3.28E-02
Amuc_0719 hypothetical protein -1.14 9.81 1.08E-02
Amuc_0777
short-chain 
dehydrogenase/reductase 
SDR 1.41 6.92 2.53E-02
Amuc_0844
Phosphopyruvate 
hydratase 1.40 8.27 3.18E-02
Amuc_0882 hypothetical protein 1.00 12.90 4.94E-02
Amuc_0883 hypothetical protein 1.56 9.10 1.10E-03
Amuc_0998 hypothetical protein 1.37 7.62 1.17E-02
Amuc_0999
sigma 54 modulation 
protein/ribosomal protein 
S30EA 1.08 10.76 1.02E-02
Amuc_1016 hypothetical protein -0.82 6.43 4.36E-02
Amuc_1176 hypothetical protein 0.88 8.59 3.43E-02
Amuc_1177 lipocalin family protein 0.96 6.25 2.85E-02
Amuc_1255 hypothetical protein -0.72 7.52 3.83E-02
Amuc_1293 hypothetical protein -1.26 6.81 5.75E-03
Amuc_1295
binding-protein-
dependent transporters 
inner membrane 
component -1.72 10.99 1.90E-04
Amuc_1296 ABC transporter -1.66 9.96 5.41E-04
Amuc_1297
substrate-binding protein 
of aliphatic sulfonate ABC 
transporter -1.56 10.18 3.19E-04
Amuc_1298
sulfate 
adenylyltransferase, large 
subunit -1.23 10.77 4.39E-03
Amuc_1394 hypothetical protein 1.41 7.82 2.28E-03
Amuc_1570 hypothetical protein -0.76 7.92 2.11E-02
Amuc_1592 Superoxide dismutase 0.92 9.77 4.91E-02
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Amuc_2038
PUR-alpha/beta/gamma 
DNA/RNA-binding 
protein -0.90 10.64 2.56E-02
Amuc_2051 glutamate dehydrogenase -0.98 10.01 2.27E-02
Amuc_2053 hypothetical protein -1.04 8.02 1.03E-02
Amuc_2055 hypothetical protein 1.18 9.20 6.54E-03
Amuc_2058 hypothetical protein 1.13 6.15 1.59E-02
Amuc_2060 hypothetical protein 0.95 6.42 2.67E-02
Amuc_2061 hypothetical protein 1.28 4.07 2.91E-02
Amuc_2070 hydroperoxidase II -0.95 10.78 8.61E-05
Amuc_2078
capsular polysaccharide 
biosynthesis protein 0.87 9.28 2.26E-02
Amuc_2079
PHP domain-containing 
protein 1.15 6.07 3.06E-02
Amuc_2080 sugar transferase 1.37 7.19 1.63E-03
Amuc_2081
family 2 glycosyl 
transferase 1.05 6.65 7.28E-03
Amuc_2082
group 1 glycosyl 
transferase 0.94 7.07 1.31E-02
Amuc_2084
group 1 glycosyl 
transferase 1.16 6.54 1.15E-02
Amuc_2085 hypothetical protein 1.55 5.56 2.67E-03
Amuc_2088
group 1 glycosyl 
transferase 1.21 4.75 4.48E-02
Amuc_2093
family 2 glycosyl 
transferase 1.15 4.42 2.35E-02
Amuc_2094
family 2 glycosyl 
transferase 0.88 4.65 4.71E-02
Amuc_2129
nickel-dependent 
hydrogenase large subunit 0.97 9.03 1.10E-02
Amuc_2130 cytochrome B561 0.96 8.73 1.00E-02
Amuc_2131
hydrogenase maturation 
protease 1.31 6.72 5.55E-03
Amuc_2132
hydrogenase nickel 
incorporation protein 
HypA 1.02 5.39 1.77E-02
Amuc_2141 hypothetical protein -0.92 9.89 2.68E-02
Amuc_2176
excinuclease ABC subunit 
A 0.90 8.75 5.75E-03
T2_O2vsT2_no_O2
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Gene code Annotation 2logFC
2logC
PM PValue
Amuc_0037 amino acid permease 1.13 9.57 2.88E-02
Amuc_0089 hypothetical protein 1.21 7.19 1.58E-02
Amuc_0236
Ion transport 2 domain-
containing protein 0.88 7.04 1.73E-02
Amuc_0342 OsmC family protein 0.81 6.76 3.25E-02
Amuc_0580 entericidin EcnAB 1.93 8.16 2.65E-03
Amuc_0687
outer membrane 
autotransporter barrel 
domain-containing protein 1.31 11.64 3.28E-02
Amuc_0719 hypothetical protein -1.14 9.81 1.08E-02
Amuc_0777
short-chain 
dehydrogenase/reductase 
SDR 1.41 6.92 2.53E-02
Amuc_0844
Phosphopyruvate 
hydratase 1.40 8.27 3.18E-02
Amuc_0882 hypothetical protein 1.00 12.90 4.94E-02
Amuc_0883 hypothetical protein 1.56 9.10 1.10E-03
Amuc_0998 hypothetical protein 1.37 7.62 1.17E-02
Amuc_0999
sigma 54 modulation 
protein/ribosomal protein 
S30EA 1.08 10.76 1.02E-02
Amuc_1016 hypothetical protein -0.82 6.43 4.36E-02
Amuc_1176 hypothetical protein 0.88 8.59 3.43E-02
Amuc_1177 lipocalin family protein 0.96 6.25 2.85E-02
Amuc_1255 hypothetical protein -0.72 7.52 3.83E-02
Amuc_1293 hypothetical protein -1.26 6.81 5.75E-03
Amuc_1295
binding-protein-
dependent transporters 
inner membrane 
component -1.72 10.99 1.90E-04
Amuc_1296 ABC transporter -1.66 9.96 5.41E-04
Amuc_1297
substrate-binding protein 
of aliphatic sulfonate ABC 
transporter -1.56 10.18 3.19E-04
Amuc_1298
sulfate 
adenylyltransferase, large 
subunit -1.23 10.77 4.39E-03
Amuc_1394 hypothetical protein 1.41 7.82 2.28E-03
Amuc_1570 hypothetical protein -0.76 7.92 2.11E-02
Amuc_1592 Superoxide dismutase 0.92 9.77 4.91E-02
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Amuc_1655 sulfatase 0.73 8.98 2.62E-02
Amuc_1812 alpha-amylase 1.02 10.22 4.37E-02
Amuc_1839
heavy metal translocating 
P-type ATPase 3.51 7.44 2.46E-05
Amuc_1904 hypothetical protein 1.12 5.93 3.56E-02
Amuc_1936 hypothetical protein 1.24 9.84 5.74E-03
Amuc_2015
thiamine-phosphate 
pyrophosphorylase -0.75 9.49 4.47E-02
Amuc_2055 hypothetical protein 1.22 9.20 1.04E-02
Amuc_2069 hypothetical protein -2.11 3.59 3.80E-02
Amuc_2070 hydroperoxidase II 1.16 10.78 3.71E-02
Amuc_2072 rubrerythrin 0.98 9.02 9.80E-03
Amuc_2081
family 2 glycosyl 
transferase 0.86 6.65 4.01E-02
Amuc_2111
ErfK/YbiS/YcfS/YnhG 
family protein -0.80 8.57 3.29E-02
Amuc_2176
excinuclease ABC subunit 
A 1.14 8.75 1.29E-03
T3_O2vsT3_no_O2
Gene code Annotation 2logFC
2logC
PM PValue
Amuc_0038 glutaminase 1.32 8.97 3.47E-02
Amuc_0059 ATPase AAA 1.04 11.25 1.68E-02
Amuc_0175
PDZ/DHR/GLGF 
domain-containing protein 1.30 8.86 3.57E-03
Amuc_0213
glutamyl-tRNA(Gln) 
amidotransferase subunit 
B -1.18 10.09 6.68E-03
Amuc_0250 hypothetical protein -1.71 8.08 2.23E-02
Amuc_0252 hypothetical protein -1.02 7.89 1.67E-02
Amuc_0270 shikimate kinase -0.95 8.85 3.27E-02
Amuc_0291 valyl-tRNA synthetase -0.89 9.57 2.10E-02
Amuc_0337 prephenate dehydrogenase 0.82 6.99 3.14E-02
Amuc_0360 hypothetical protein 1.12 8.92 2.42E-02
Amuc_0422
3,4-dihydroxy-2-butanone 
4-phosphate synthase -1.00 9.48 2.25E-02
Amuc_0423
6,7-dimethyl-8-
ribityllumazine synthase -1.29 6.90 6.87E-03
Amuc_0424
NusB antitermination 
factor -0.94 7.59 4.26E-02
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Amuc_0425
signal recognition 
particle-docking protein 
FtsY -1.14 7.15 1.21E-02
Amuc_0426
radical SAM enzyme, Cfr 
family -0.93 9.11 1.46E-02
Amuc_0436
HAD-superfamily 
hydrolase -0.90 8.49 3.38E-02
Amuc_0439 30S ribosomal protein S13 -1.03 9.91 1.58E-02
Amuc_0445
GTP-binding protein 
YchF -0.97 8.61 2.08E-02
Amuc_0463
Phosphopantothenoylcyst
eine decarboxylase -0.81 7.30 3.09E-02
Amuc_0469 N-acetyltransferase GCN5 1.35 9.10 1.28E-02
Amuc_0475 methyltransferase 0.81 6.76 4.60E-02
Amuc_0485 50S ribosomal protein L27 -1.00 9.05 4.80E-02
Amuc_0488
FeS assembly protein 
SufB 0.87 9.43 3.33E-02
Amuc_0489 SufBD protein 1.13 9.26 1.26E-02
Amuc_0533 hypothetical protein -0.89 7.79 3.24E-02
Amuc_0534
phosphoribosylformylgly
cinamidine synthase II -0.79 9.89 4.91E-02
Amuc_0556
FmdB family regulatory 
protein 1.11 5.23 3.44E-02
Amuc_0573 3'-5' exonuclease -0.88 9.20 3.85E-02
Amuc_0616
protein serine/threonine 
phosphatase 1.09 7.42 4.60E-02
Amuc_0642
tRNA delta(2)-
isopentenylpyrophosphate 
transferase -1.13 5.44 3.68E-02
Amuc_0650
S-adenosyl-
methyltransferase MraW 0.75 9.03 4.51E-02
Amuc_0760 hypothetical protein -0.95 7.28 4.94E-02
Amuc_0775 thioesterase 1.28 7.60 4.20E-02
Amuc_0787 rhomboid family protein -1.25 9.21 1.69E-02
Amuc_0844
Phosphopyruvate 
hydratase 2.13 8.27 7.11E-03
Amuc_0850
RNA methyltransferase, 
TrmA family -0.78 7.96 4.04E-02
Amuc_0865 rubrerythrin 2.03 9.33 1.97E-03
Amuc_0868
beta-N-
acetylhexosaminidase 0.92 7.29 3.25E-02
Amuc_0876
heavy metal translocating 
P-type ATPase 1.45 8.47 5.57E-03
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Amuc_1655 sulfatase 0.73 8.98 2.62E-02
Amuc_1812 alpha-amylase 1.02 10.22 4.37E-02
Amuc_1839
heavy metal translocating 
P-type ATPase 3.51 7.44 2.46E-05
Amuc_1904 hypothetical protein 1.12 5.93 3.56E-02
Amuc_1936 hypothetical protein 1.24 9.84 5.74E-03
Amuc_2015
thiamine-phosphate 
pyrophosphorylase -0.75 9.49 4.47E-02
Amuc_2055 hypothetical protein 1.22 9.20 1.04E-02
Amuc_2069 hypothetical protein -2.11 3.59 3.80E-02
Amuc_2070 hydroperoxidase II 1.16 10.78 3.71E-02
Amuc_2072 rubrerythrin 0.98 9.02 9.80E-03
Amuc_2081
family 2 glycosyl 
transferase 0.86 6.65 4.01E-02
Amuc_2111
ErfK/YbiS/YcfS/YnhG 
family protein -0.80 8.57 3.29E-02
Amuc_2176
excinuclease ABC subunit 
A 1.14 8.75 1.29E-03
T3_O2vsT3_no_O2
Gene code Annotation 2logFC
2logC
PM PValue
Amuc_0038 glutaminase 1.32 8.97 3.47E-02
Amuc_0059 ATPase AAA 1.04 11.25 1.68E-02
Amuc_0175
PDZ/DHR/GLGF 
domain-containing protein 1.30 8.86 3.57E-03
Amuc_0213
glutamyl-tRNA(Gln) 
amidotransferase subunit 
B -1.18 10.09 6.68E-03
Amuc_0250 hypothetical protein -1.71 8.08 2.23E-02
Amuc_0252 hypothetical protein -1.02 7.89 1.67E-02
Amuc_0270 shikimate kinase -0.95 8.85 3.27E-02
Amuc_0291 valyl-tRNA synthetase -0.89 9.57 2.10E-02
Amuc_0337 prephenate dehydrogenase 0.82 6.99 3.14E-02
Amuc_0360 hypothetical protein 1.12 8.92 2.42E-02
Amuc_0422
3,4-dihydroxy-2-butanone 
4-phosphate synthase -1.00 9.48 2.25E-02
Amuc_0423
6,7-dimethyl-8-
ribityllumazine synthase -1.29 6.90 6.87E-03
Amuc_0424
NusB antitermination 
factor -0.94 7.59 4.26E-02
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Amuc_0425
signal recognition 
particle-docking protein 
FtsY -1.14 7.15 1.21E-02
Amuc_0426
radical SAM enzyme, Cfr 
family -0.93 9.11 1.46E-02
Amuc_0436
HAD-superfamily 
hydrolase -0.90 8.49 3.38E-02
Amuc_0439 30S ribosomal protein S13 -1.03 9.91 1.58E-02
Amuc_0445
GTP-binding protein 
YchF -0.97 8.61 2.08E-02
Amuc_0463
Phosphopantothenoylcyst
eine decarboxylase -0.81 7.30 3.09E-02
Amuc_0469 N-acetyltransferase GCN5 1.35 9.10 1.28E-02
Amuc_0475 methyltransferase 0.81 6.76 4.60E-02
Amuc_0485 50S ribosomal protein L27 -1.00 9.05 4.80E-02
Amuc_0488
FeS assembly protein 
SufB 0.87 9.43 3.33E-02
Amuc_0489 SufBD protein 1.13 9.26 1.26E-02
Amuc_0533 hypothetical protein -0.89 7.79 3.24E-02
Amuc_0534
phosphoribosylformylgly
cinamidine synthase II -0.79 9.89 4.91E-02
Amuc_0556
FmdB family regulatory 
protein 1.11 5.23 3.44E-02
Amuc_0573 3'-5' exonuclease -0.88 9.20 3.85E-02
Amuc_0616
protein serine/threonine 
phosphatase 1.09 7.42 4.60E-02
Amuc_0642
tRNA delta(2)-
isopentenylpyrophosphate 
transferase -1.13 5.44 3.68E-02
Amuc_0650
S-adenosyl-
methyltransferase MraW 0.75 9.03 4.51E-02
Amuc_0760 hypothetical protein -0.95 7.28 4.94E-02
Amuc_0775 thioesterase 1.28 7.60 4.20E-02
Amuc_0787 rhomboid family protein -1.25 9.21 1.69E-02
Amuc_0844
Phosphopyruvate 
hydratase 2.13 8.27 7.11E-03
Amuc_0850
RNA methyltransferase, 
TrmA family -0.78 7.96 4.04E-02
Amuc_0865 rubrerythrin 2.03 9.33 1.97E-03
Amuc_0868
beta-N-
acetylhexosaminidase 0.92 7.29 3.25E-02
Amuc_0876
heavy metal translocating 
P-type ATPase 1.45 8.47 5.57E-03
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Amuc_0888
MerR family 
transcriptional regulator 0.99 6.48 4.90E-02
Amuc_0955 ribosome-binding factor A -1.21 9.71 3.21E-02
Amuc_0961 hypothetical protein 1.61 8.11 2.03E-04
Amuc_0962 4Fe-4S ferredoxin 1.10 7.63 4.60E-03
Amuc_0983 YD repeat protein 1.18 10.61 2.85E-02
Amuc_0988
TatD-related 
deoxyribonuclease 0.98 7.03 1.61E-02
Amuc_1017 hypothetical protein -1.28 7.25 3.61E-02
Amuc_1030 cupin -1.08 5.44 3.27E-02
Amuc_1084 hypothetical protein 4.33 7.04 6.64E-04
Amuc_1089 FeoA family protein 1.15 10.63 3.98E-02
Amuc_1090 FeoA family protein 1.22 9.43 2.58E-02
Amuc_1145 hypothetical protein -0.98 10.22 2.49E-02
Amuc_1177 lipocalin family protein 1.15 6.25 2.27E-02
Amuc_1187 Alpha-galactosidase 1.04 9.85 4.58E-02
Amuc_1211
N-acetylmuramoyl-L-
alanine amidase family 2 
protein 0.91 7.15 3.60E-02
Amuc_1219 hypothetical protein -1.35 9.65 4.26E-02
Amuc_1222 oligopeptide transporter -0.75 8.69 3.53E-02
Amuc_1250
carbamoyl-phosphate 
synthase small subunit -0.88 8.15 2.08E-02
Amuc_1290 hypothetical protein 1.02 9.17 2.42E-02
Amuc_1291 surface layer protein 1.32 7.32 7.79E-03
Amuc_1295
binding-protein-
dependent transporters 
inner membrane 
component -1.17 10.99 1.75E-02
Amuc_1297
substrate-binding protein 
of aliphatic sulfonate ABC 
transporter -1.18 10.18 1.11E-02
Amuc_1298
sulfate 
adenylyltransferase, large 
subunit -1.42 10.77 2.47E-03
Amuc_1299
sulfate 
adenylyltransferase 
subunit 2 -1.50 10.39 3.57E-03
Amuc_1300 adenylylsulfate reductase -1.33 10.96 3.49E-03
Amuc_1301 cysteine synthase A -1.19 11.38 1.13E-02
Amuc_1309 aldose 1-epimerase 1.30 8.74 3.02E-03
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Amuc_1310 17 kDa surface antigen 0.91 9.36 2.70E-02
Amuc_1321
alkyl hydroperoxide 
reductase 2.34 10.72 6.90E-04
Amuc_1343 hypothetical protein -1.30 7.46 3.23E-02
Amuc_1408 chaperonin GroEL 0.91 12.13 4.18E-02
Amuc_1412 hypothetical protein 0.85 10.64 4.93E-02
Amuc_1517
ECF subfamily RNA 
polymerase sigma-24
subunit 0.86 7.61 3.19E-02
Amuc_1537
outer membrane 
autotransporter barrel 
domain-containing protein 1.12 11.00 1.77E-02
Amuc_1609 4Fe-4S ferredoxin -0.99 8.25 1.36E-02
Amuc_1612
NADH dehydrogenase 
(quinone) -0.79 9.51 2.83E-02
Amuc_1653
Ribulose-phosphate 3-
epimerase -0.84 7.02 3.81E-02
Amuc_1654 leucyl-tRNA synthetase -0.89 10.73 3.05E-02
Amuc_1692
2-oxoglutarate 
dehydrogenase, E2 
subunit, dihydrolipoamide 
succinyltransferase 1.19 7.77 2.35E-02
Amuc_1693
2-oxoglutarate 
dehydrogenase, E1 
subunit 1.57 9.86 3.34E-03
Amuc_1694
cytochrome d ubiquinol 
oxidase, subunit II 1.47 7.92 6.53E-03
Amuc_1757
phosphotransferase 
system, phosphocarrier 
protein HPr 1.45 9.97 4.13E-03
Amuc_1764 hypothetical protein -1.28 7.66 1.20E-02
Amuc_1776 hypothetical protein 1.09 9.66 1.74E-02
Amuc_1777
von Willebrand factor 
type A 1.19 12.17 2.25E-02
Amuc_1780 hypothetical protein 0.93 7.67 3.35E-02
Amuc_1814 hypothetical protein -1.34 5.86 3.92E-02
Amuc_1843 hypothetical protein 1.17 6.11 3.16E-02
Amuc_1901 metallophosphoesterase -1.23 8.28 2.28E-02
Amuc_1902 hypothetical protein -1.44 10.54 2.39E-03
Amuc_1903 hypothetical protein -1.06 9.13 2.02E-02
Amuc_1922 ferredoxin 1.07 11.13 3.88E-02
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Amuc_0888
MerR family 
transcriptional regulator 0.99 6.48 4.90E-02
Amuc_0955 ribosome-binding factor A -1.21 9.71 3.21E-02
Amuc_0961 hypothetical protein 1.61 8.11 2.03E-04
Amuc_0962 4Fe-4S ferredoxin 1.10 7.63 4.60E-03
Amuc_0983 YD repeat protein 1.18 10.61 2.85E-02
Amuc_0988
TatD-related 
deoxyribonuclease 0.98 7.03 1.61E-02
Amuc_1017 hypothetical protein -1.28 7.25 3.61E-02
Amuc_1030 cupin -1.08 5.44 3.27E-02
Amuc_1084 hypothetical protein 4.33 7.04 6.64E-04
Amuc_1089 FeoA family protein 1.15 10.63 3.98E-02
Amuc_1090 FeoA family protein 1.22 9.43 2.58E-02
Amuc_1145 hypothetical protein -0.98 10.22 2.49E-02
Amuc_1177 lipocalin family protein 1.15 6.25 2.27E-02
Amuc_1187 Alpha-galactosidase 1.04 9.85 4.58E-02
Amuc_1211
N-acetylmuramoyl-L-
alanine amidase family 2 
protein 0.91 7.15 3.60E-02
Amuc_1219 hypothetical protein -1.35 9.65 4.26E-02
Amuc_1222 oligopeptide transporter -0.75 8.69 3.53E-02
Amuc_1250
carbamoyl-phosphate 
synthase small subunit -0.88 8.15 2.08E-02
Amuc_1290 hypothetical protein 1.02 9.17 2.42E-02
Amuc_1291 surface layer protein 1.32 7.32 7.79E-03
Amuc_1295
binding-protein-
dependent transporters 
inner membrane 
component -1.17 10.99 1.75E-02
Amuc_1297
substrate-binding protein 
of aliphatic sulfonate ABC 
transporter -1.18 10.18 1.11E-02
Amuc_1298
sulfate 
adenylyltransferase, large 
subunit -1.42 10.77 2.47E-03
Amuc_1299
sulfate 
adenylyltransferase 
subunit 2 -1.50 10.39 3.57E-03
Amuc_1300 adenylylsulfate reductase -1.33 10.96 3.49E-03
Amuc_1301 cysteine synthase A -1.19 11.38 1.13E-02
Amuc_1309 aldose 1-epimerase 1.30 8.74 3.02E-03
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Amuc_1310 17 kDa surface antigen 0.91 9.36 2.70E-02
Amuc_1321
alkyl hydroperoxide 
reductase 2.34 10.72 6.90E-04
Amuc_1343 hypothetical protein -1.30 7.46 3.23E-02
Amuc_1408 chaperonin GroEL 0.91 12.13 4.18E-02
Amuc_1412 hypothetical protein 0.85 10.64 4.93E-02
Amuc_1517
ECF subfamily RNA 
polymerase sigma-24
subunit 0.86 7.61 3.19E-02
Amuc_1537
outer membrane 
autotransporter barrel 
domain-containing protein 1.12 11.00 1.77E-02
Amuc_1609 4Fe-4S ferredoxin -0.99 8.25 1.36E-02
Amuc_1612
NADH dehydrogenase 
(quinone) -0.79 9.51 2.83E-02
Amuc_1653
Ribulose-phosphate 3-
epimerase -0.84 7.02 3.81E-02
Amuc_1654 leucyl-tRNA synthetase -0.89 10.73 3.05E-02
Amuc_1692
2-oxoglutarate 
dehydrogenase, E2 
subunit, dihydrolipoamide 
succinyltransferase 1.19 7.77 2.35E-02
Amuc_1693
2-oxoglutarate 
dehydrogenase, E1 
subunit 1.57 9.86 3.34E-03
Amuc_1694
cytochrome d ubiquinol 
oxidase, subunit II 1.47 7.92 6.53E-03
Amuc_1757
phosphotransferase 
system, phosphocarrier 
protein HPr 1.45 9.97 4.13E-03
Amuc_1764 hypothetical protein -1.28 7.66 1.20E-02
Amuc_1776 hypothetical protein 1.09 9.66 1.74E-02
Amuc_1777
von Willebrand factor 
type A 1.19 12.17 2.25E-02
Amuc_1780 hypothetical protein 0.93 7.67 3.35E-02
Amuc_1814 hypothetical protein -1.34 5.86 3.92E-02
Amuc_1843 hypothetical protein 1.17 6.11 3.16E-02
Amuc_1901 metallophosphoesterase -1.23 8.28 2.28E-02
Amuc_1902 hypothetical protein -1.44 10.54 2.39E-03
Amuc_1903 hypothetical protein -1.06 9.13 2.02E-02
Amuc_1922 ferredoxin 1.07 11.13 3.88E-02
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Amuc_1960
PA14 domain-containing 
protein 1.07 6.59 4.92E-02
Amuc_1965 aspartate kinase -0.82 8.72 3.67E-02
Amuc_1972 HhH-GPD family protein -0.86 7.24 4.69E-02
Amuc_1985 hypothetical protein 0.88 9.05 1.89E-02
Amuc_2051 glutamate dehydrogenase -1.01 10.01 3.73E-02
Amuc_2054 hypothetical protein -1.08 6.15 3.90E-02
Amuc_2072 rubrerythrin 1.31 9.02 3.07E-03
Amuc_2111
ErfK/YbiS/YcfS/YnhG 
family protein -0.95 8.57 1.96E-02
Amuc_2120 hypothetical protein 1.12 7.78 9.56E-03
Amuc_2129
nickel-dependent 
hydrogenase large subunit 1.46 9.03 2.85E-03
Amuc_2130 cytochrome B561 1.58 8.73 1.04E-03
Amuc_2131
hydrogenase maturation 
protease 1.79 6.72 3.28E-03
Amuc_2136
Glycoside hydrolase, 
family 20, catalytic core 0.98 10.15 1.47E-02
Amuc_2148
beta-N-
acetylhexosaminidase 1.03 7.62 2.30E-02
Amuc_2154 hypothetical protein 1.64 8.54 8.00E-03
Amuc_2176
excinuclease ABC subunit 
A 1.19 8.75 3.74E-03
T2_O2vsT3_O2 logFC
logCP
M Pvalue
Amuc_1901 metallophosphoesterase 3.08 8.26 4.06E-10
Amuc_1301 cysteine synthase A -2.83 11.36 2.56E-09
Amuc_0439 30S ribosomal protein S13 -2.35 9.90 4.13E-09
Amuc_2051 glutamate dehydrogenase -2.75 9.97 7.89E-09
Amuc_1654 leucyl-tRNA synthetase -2.28 10.72 1.38E-08
Amuc_0422
3,4-dihydroxy-2-butanone 
4-phosphate synthase -2.40 9.47 3.21E-08
Amuc_0616
protein serine/threonine 
phosphatase 3.31 7.53 4.94E-08
Amuc_0485 50S ribosomal protein L27 -2.61 9.02 2.19E-07
Amuc_2111
ErfK/YbiS/YcfS/YnhG 
family protein -2.13 8.55 2.56E-07
Amuc_0573 3'-5' exonuclease -2.47 9.20 2.67E-07
Amuc_1612
NADH dehydrogenase 
(quinone) -1.81 9.50 3.25E-07
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Amuc_0534
phosphoribosylformylgly
cinamidine synthase II -2.02 9.89 5.40E-07
Amuc_0426
radical SAM enzyme, Cfr 
family -2.08 9.11 7.06E-07
Amuc_1694
cytochrome d ubiquinol 
oxidase, subunit II 2.43 7.89 8.05E-07
Amuc_0469 N-acetyltransferase GCN5 2.64 9.19 1.71E-06
Amuc_1089 FeoA family protein -2.20 10.61 5.91E-06
Amuc_1965 aspartate kinase -1.95 8.72 6.30E-06
Amuc_1609 4Fe-4S ferredoxin -1.96 8.26 7.61E-06
Amuc_1300 adenylylsulfate reductase -2.06 10.95 1.62E-05
Amuc_1090 FeoA family protein -1.95 9.40 2.76E-05
Amuc_1653
Ribulose-phosphate 3-
epimerase -2.04 7.03 3.22E-05
Amuc_0213
glutamyl-tRNA(Gln) 
amidotransferase subunit 
B -1.83 10.08 3.57E-05
Amuc_0983 YD repeat protein 1.96 10.61 5.16E-05
Amuc_0425
signal recognition 
particle-docking protein 
FtsY -2.09 7.16 5.49E-05
Amuc_0955 ribosome-binding factor A 1.93 9.67 6.45E-05
Amuc_1693
2-oxoglutarate 
dehydrogenase, E1 
subunit 1.79 9.86 0.000112
Amuc_1250
carbamoyl-phosphate 
synthase small subunit -1.53 8.16 0.00015
Amuc_0424
NusB antitermination 
factor -1.97 7.61 0.000152
Amuc_1299
sulfate 
adenylyltransferase 
subunit 2 -1.95 10.38 0.000317
Amuc_1295
binding-protein-
dependent transporters 
inner membrane 
component -1.56 10.95 0.000418
Amuc_0291 valyl-tRNA synthetase -1.35 9.58 0.00063
Amuc_1960
PA14 domain-containing 
protein 1.71 6.57 0.000742
Amuc_1177 lipocalin family protein 1.71 6.30 0.001103
Amuc_0270 shikimate kinase 1.16 8.84 0.002179
Amuc_0436
HAD-superfamily 
hydrolase 1.30 8.51 0.002239
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Amuc_1692
2-oxoglutarate 
dehydrogenase, E2 
subunit, dihydrolipoamide 
succinyltransferase 1.49 7.77 0.002355
Amuc_1298
sulfate 
adenylyltransferase, large
subunit -1.38 10.75 0.003355
Amuc_0423
6,7-dimethyl-8-
ribityllumazine synthase -1.55 6.91 0.003563
Amuc_0962 4Fe-4S ferredoxin 1.12 7.65 0.003785
Amuc_0868
beta-N-
acetylhexosaminidase 1.18 7.30 0.003817
Amuc_0038 glutaminase 1.57 8.96 0.003836
Amuc_0850
RNA methyltransferase, 
TrmA family -1.26 7.96 0.00386
Amuc_0888
MerR family 
transcriptional regulator 1.49 6.50 0.004756
Amuc_1310 17 kDa surface antigen 0.95 9.37 0.008482
Amuc_1222 oligopeptide transporter 0.90 8.70 0.009872
Amuc_0445
GTP-binding protein 
YchF -1.13 8.62 0.010741
Amuc_1297
substrate-binding protein 
of aliphatic sulfonate ABC 
transporter -1.18 10.15 0.013182
Amuc_1537
outer membrane 
autotransporter barrel 
domain-containing protein 1.09 11.03 0.013917
Amuc_1922 ferredoxin -0.97 11.10 0.019463
Amuc_1321
alkyl hydroperoxide 
reductase 1.12 10.64 0.027838
Amuc_0175
PDZ/DHR/GLGF 
domain-containing protein 0.77 8.84 0.045832
Amuc_1517
ECF subfamily RNA 
polymerase sigma-24
subunit 0.76 7.62 0.050143
Amuc_1309 aldose 1-epimerase 0.79 8.76 0.062443
Amuc_1757
phosphotransferase 
system, phosphocarrier 
protein HPr 0.83 9.97 0.064148
Amuc_1291 surface layer protein 0.82 7.30 0.065961
Amuc_0787 rhomboid family protein 0.80 9.19 0.072646
Amuc_2129
nickel-dependent 
hydrogenase large subunit 0.68 9.01 0.097101
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Amuc_1030 cupin -0.86 5.46 0.13556
Amuc_2148
beta-N-
acetylhexosaminidase 0.61 7.60 0.13709
Amuc_2072 rubrerythrin -0.60 9.01 0.140012
Amuc_1211
N-acetylmuramoyl-L-
alanine amidase family 2 
protein 0.59 7.14 0.145489
Amuc_1408 chaperonin GroEL 0.54 12.13 0.148913
Amuc_1972 HhH-GPD family protein -0.70 7.25 0.150375
Amuc_0642
tRNA delta(2)-
isopentenylpyrophosphate 
transferase 0.82 5.47 0.176493
Amuc_0463
Phosphopantothenoylcyst
eine decarboxylase -0.49 7.31 0.236391
Amuc_1777
von Willebrand factor 
type A 0.48 12.16 0.273026
Amuc_2131
hydrogenase maturation 
protease 0.47 6.69 0.384665
Amuc_0876
heavy metal translocating 
P-type ATPase -0.38 8.46 0.421573
Amuc_0337 prephenate dehydrogenase -0.26 6.99 0.512197
Amuc_0865 rubrerythrin 0.30 9.28 0.546694
Amuc_2130 cytochrome B561 0.24 8.71 0.546999
Amuc_0775 thioesterase -0.33 7.59 0.556213
Amuc_2176
excinuclease ABC subunit 
A -0.20 8.76 0.598361
Amuc_0650
S-adenosyl-
methyltransferase MraW -0.16 9.02 0.622332
Amuc_0988
TatD-related 
deoxyribonuclease 0.18 7.02 0.625398
Amuc_0489 SufBD protein -0.18 9.24 0.628164
Amuc_0556
FmdB family regulatory 
protein 0.22 5.24 0.685003
Amuc_1187 Alpha-galactosidase 0.14 9.83 0.732847
Amuc_0059 ATPase AAA -0.10 11.23 0.783478
Amuc_2136
Glycoside hydrolase, 
family 20, catalytic core -0.10 10.14 0.78636
Amuc_0844
Phosphopyruvate 
hydratase -0.16 8.23 0.804343
Amuc_0488
FeS assembly protein 
SufB -0.09 9.43 0.814634
Amuc_0475 methyltransferase -0.09 6.78 0.843837
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Abstract
There is considerable attention for developing Akkermansia muciniphila as a new therapeutic 
microbe since it has shown to prevent diet-induced obesity and type 2 diabetes in mice. 
However, A. muciniphila is sensitive to gastric conditions such as low pH and oxygen. 
Therefore, we explored the possibility of encapsulating A. muciniphila in a water-in-oil-in-
water (W/O/W) double emulsion, to allow for protection during gastric passage and 
subsequent release in the small intestine. The bacteria were efficiently encapsulated in the 
inner emulsion droplets and remained entrapped during in vitro gastric digestion. The cells 
were then released in the simulated intestinal phase of the in vitro system. The viability of 
encapsulated cells was found to be higher when compared to cells dispersed in buffer, that 
had been subjected to similar mechanical process as the one conducted to prepare the 
emulsion systems. Surprisingly, the viability of the processed cells was even higher than that 
of the cells dispersed in buffer without processing, likely due to shear-induced stress 
tolerance. To conclude, encapsulation in a double emulsion seems to be a promising strategy 
to protect A. muciniphila during gastric passage in oral formulations. 
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Introduction
The influence of the gut microbiota on human health has been studied extensively during the 
past decades. Correlations have been found between microbiota composition and diseases, 
including but not limited to type 2 diabetes, metabolic syndrome and ulcerative colitis 
(Clemente, et al., 2012, Marchesi, et al., 2016). Recently, treatments aiming to change the 
microbiota composition were employed to fight infections. Faecal transplants by intubation 
were used to treat chronic infections caused by Clostridium difficile with high effectiveness 
(van Nood, et al., 2013). However, the mode of action of these treatments is poorly 
understood due to the undefined composition of the faecal matter (van Nood, et al., 2013).
In the last year, specific bacterial species from the microbiota have been identified as 
potential probiotics or even therapeutic microbes (Plovier, et al., 2016, Quevrain, et al., 2016, 
Udayappan, et al., 2016) that could be used to treat or prevent specific diseases. An important 
species is the gut bacterium Akkermansia muciniphila, the presence and abundance of which 
has been reported to inversely correlate with body weight, gut permeability and inflammation 
(Wang, et al., 2011, Everard, et al., 2013). This human mucus colonizer was found to be not 
only important for obesity development and associated metabolic disorders, but also for 
influencing the host’s general health and physiology. Recently, the administration of A. 
muciniphila by gavage was found to protect mice from diet-induced obesity (Everard, et al., 
2013, Plovier, et al., 2016). Moreover, A. muciniphila was found to be safe for use in humans 
(Plovier, et al., 2016). Incorporating this functional microbe in food products or medicine 
could be the starting point for obesity and type 2 diabetes prevention; however, the 
application of A. muciniphila may be challenged by its sensitivity to low pH, shear, and 
oxygen (Derrien, et al., 2004, Ouwerkerk, et al., 2016). Besides, survival or growth of A. 
muciniphila in the presence of bile salts has not been documented yet. 
To protect A. muciniphila during gastric passage, an effective encapsulation system is 
needed. Probiotics have commonly been encapsulated in various ways to increase shelf life, 
viability and targeted delivery (Anal and Singh, 2007), although many of these techniques 
impose high stress on the bacteria. For example, spray drying causes high osmotic pressure, 
and exposure to oxygen. Additionally, the high temperatures used in spray drying could either 
reduce bacterial viability and denature proteins that are of importance in probiotic efficacy 
(Plovier, et al., 2016). Extrusion is used for encapsulation in alginate beads, resulting in 
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were then released in the simulated intestinal phase of the in vitro system. The viability of 
encapsulated cells was found to be higher when compared to cells dispersed in buffer, that 
had been subjected to similar mechanical process as the one conducted to prepare the 
emulsion systems. Surprisingly, the viability of the processed cells was even higher than that 
of the cells dispersed in buffer without processing, likely due to shear-induced stress 
tolerance. To conclude, encapsulation in a double emulsion seems to be a promising strategy 
to protect A. muciniphila during gastric passage in oral formulations. 
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Introduction
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understood due to the undefined composition of the faecal matter (van Nood, et al., 2013).
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Udayappan, et al., 2016) that could be used to treat or prevent specific diseases. An important 
species is the gut bacterium Akkermansia muciniphila, the presence and abundance of which 
has been reported to inversely correlate with body weight, gut permeability and inflammation 
(Wang, et al., 2011, Everard, et al., 2013). This human mucus colonizer was found to be not 
only important for obesity development and associated metabolic disorders, but also for 
influencing the host’s general health and physiology. Recently, the administration of A. 
muciniphila by gavage was found to protect mice from diet-induced obesity (Everard, et al., 
2013, Plovier, et al., 2016). Moreover, A. muciniphila was found to be safe for use in humans 
(Plovier, et al., 2016). Incorporating this functional microbe in food products or medicine 
could be the starting point for obesity and type 2 diabetes prevention; however, the 
application of A. muciniphila may be challenged by its sensitivity to low pH, shear, and 
oxygen (Derrien, et al., 2004, Ouwerkerk, et al., 2016). Besides, survival or growth of A. 
muciniphila in the presence of bile salts has not been documented yet. 
To protect A. muciniphila during gastric passage, an effective encapsulation system is 
needed. Probiotics have commonly been encapsulated in various ways to increase shelf life, 
viability and targeted delivery (Anal and Singh, 2007), although many of these techniques 
impose high stress on the bacteria. For example, spray drying causes high osmotic pressure, 
and exposure to oxygen. Additionally, the high temperatures used in spray drying could either 
reduce bacterial viability and denature proteins that are of importance in probiotic efficacy 
(Plovier, et al., 2016). Extrusion is used for encapsulation in alginate beads, resulting in 
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particles of 2 to 5 mm; the most important limitation of extrusion being susceptibility of the 
alginate beads to damage (Krasaekoopt, et al., 2003, Solanki, et al., 2013).
In the current study we used W/O/W emulsions for encapsulation (Su, et al., 2008), which 
are oil globules, containing small aqueous droplets that are dispersed in an aqueous 
continuous phase (Leal-Calderon, et al., 2012). The internal aqueous droplets can serve as an 
entrapping reservoir for A. muciniphila because of its small size of ~1 µm. Besides, dedicated 
emulsification was preferred for A. muciniphila because of the rather mild process conditions. 
Encapsulation of A. muciniphila in the inner droplets of double water-in-oil-in-water 
(W/O/W) emulsions may give protection from adverse external conditions, and also allow
targeted delivery in the intestine, as was found for the probiotic Lactobacillus rhamnosus that 
had a higher relative viability (10-100 fold) after gastric digestions compared to the control 
(Shima, et al., 2006, Pimentel-Gonzalez, et al., 2009). However, L. rhamnosus has a high 
acid resistance and can survive an acidity of pH 2.5 (Corcoran, et al., 2005), whereas A. 
muciniphila is unable to grow at a pH below 5.5 (Derrien, et al., 2004), and needs to be better 
protected.
The application of W/O/W emulsions is challenging due to the many factors that can 
contribute to their physical instability. They often consist of large and polydisperse droplets 
that have a strong tendency for flocculation, creaming and coalescence (Benichou, et al., 
2004, van der Graaf, et al., 2005). In addition, it is difficult to retain the encapsulated matter 
within the water phase; release may occur as a result of concentration gradients and osmotic 
pressure difference (Benichou, et al., 2004), especially during storage. Bacteria-sized 
particles can even be expelled by coalescence of the inner water phase with the outer water 
phase. So, localisation of the entrapped bacteria in the W/O/W emulsion during gastric 
simulation and stabilization of the emulsion itself is imperative. Furthermore, an oil-based 
emulsion is needed to allow for the release of bacteria after gastric passage, because the oil 
is degraded by bile upon entering the small intestine. 
In this study, we encapsulated A. muciniphila (or fluorescently-labelled particle analogues) 
in the inner water droplets of double W/O/W emulsions produced via a mild homogenization 
technique developed in our labs. First, the morphology and physical stability of the emulsions 
were assessed. Subsequently, we investigated the localisation of bacteria analogues within 
                                   Encapsulation of the therapeutic microbe Akkermansia muciniphila      
175
the emulsions, and finally the survival rate of A. muciniphila, when emulsions were subjected 
to storage and simulated gastrointestinal conditions.
Materials and Methods
Media preparation of A. muciniphila
Liquid culture of A. muciniphila MucT (CIP 107961T) was prepared in anoxic basal media as 
described previously (Derrien, et al., 2004). The basal media was supplemented with 20 g/L 
tryptone (Oxoid Ltd, UK) and 4 g/L L-threonine (Sigma-Aldrich, USA). A mixture of 250 
mM glucose (D(+)-glucose monohydrate, Merck, Germany) and N-acetyl-D-glucosamine 
(purity ≥99%, Sigma-Aldrich, USA) was added by 10% v/v as the carbon source. Media were 
filled into serum bottles sealed with butyl-rubber stoppers and aluminium crimp caps under 
anaerobic conditions provided by a gas phase of 182 kPa (1.5 atm) N2/CO2.
For the total viable count (TVC), Brain Heart Infusion (BHI) mucin agar was prepared 
containing 10 g agar (bacteriological agar no. 1), Oxoid Ltd, UK), 37 g BHI (Becton, 
Dickinson & Co, Belgium), 0.5 g L-cysteine hydrochloride monohydrate (Sigma-Aldrich, 
USA), 1 mL rezasurin, and 5 g commercial hog gastric mucin (Type III ; Sigma, Saint Louis, 
USA) per litre medium. BHI mucin agar was kept in 2 anaerobic atmosphere generation bags 
(AnaeroGen™, Oxoid Ltd, UK) at minimum one day before use and one fresh bag was used 
during incubation.
Cultivation and preparation of concentrated glycerol stocks of A. muciniphila
Cultivation of A. muciniphila liquid culture was done in anoxic medium by inoculating 1% 
v/v of 2 days pre-culture. Incubation was done at 37 °C for 2-3 days until late exponential 
phase. Cells were harvested by centrifugation at 10,000 g for 10 minutes and washed twice 
in buffer A (Phosphate Buffered Saline (PBS), 10 mM pH 7.4 with additional NaCl: 0.2 g/l 
KCl, 0.23 g/L KH2PO4, 2 g/L NaCl, 1.15 g/L Na2HPO4). The harvested cells were then added 
by 1:1 (v/v) ratio to anaerobic vials containing 50% v/v glycerol in water. Cells were 
preserved at -80 °C until use. One vial was thawed and counted by TVC as the reference 
concentration for all other experiments. For the use at non-microbiological laboratory, the 
cells were pasteurised at 68 °C in a water bath for 30 minutes prior to use, to render them 
inactive. 
6Chapter 6. 
174
particles of 2 to 5 mm; the most important limitation of extrusion being susceptibility of the 
alginate beads to damage (Krasaekoopt, et al., 2003, Solanki, et al., 2013).
In the current study we used W/O/W emulsions for encapsulation (Su, et al., 2008), which 
are oil globules, containing small aqueous droplets that are dispersed in an aqueous 
continuous phase (Leal-Calderon, et al., 2012). The internal aqueous droplets can serve as an 
entrapping reservoir for A. muciniphila because of its small size of ~1 µm. Besides, dedicated 
emulsification was preferred for A. muciniphila because of the rather mild process conditions. 
Encapsulation of A. muciniphila in the inner droplets of double water-in-oil-in-water 
(W/O/W) emulsions may give protection from adverse external conditions, and also allow
targeted delivery in the intestine, as was found for the probiotic Lactobacillus rhamnosus that 
had a higher relative viability (10-100 fold) after gastric digestions compared to the control 
(Shima, et al., 2006, Pimentel-Gonzalez, et al., 2009). However, L. rhamnosus has a high 
acid resistance and can survive an acidity of pH 2.5 (Corcoran, et al., 2005), whereas A. 
muciniphila is unable to grow at a pH below 5.5 (Derrien, et al., 2004), and needs to be better 
protected.
The application of W/O/W emulsions is challenging due to the many factors that can 
contribute to their physical instability. They often consist of large and polydisperse droplets 
that have a strong tendency for flocculation, creaming and coalescence (Benichou, et al., 
2004, van der Graaf, et al., 2005). In addition, it is difficult to retain the encapsulated matter 
within the water phase; release may occur as a result of concentration gradients and osmotic 
pressure difference (Benichou, et al., 2004), especially during storage. Bacteria-sized 
particles can even be expelled by coalescence of the inner water phase with the outer water 
phase. So, localisation of the entrapped bacteria in the W/O/W emulsion during gastric 
simulation and stabilization of the emulsion itself is imperative. Furthermore, an oil-based 
emulsion is needed to allow for the release of bacteria after gastric passage, because the oil 
is degraded by bile upon entering the small intestine. 
In this study, we encapsulated A. muciniphila (or fluorescently-labelled particle analogues) 
in the inner water droplets of double W/O/W emulsions produced via a mild homogenization 
technique developed in our labs. First, the morphology and physical stability of the emulsions 
were assessed. Subsequently, we investigated the localisation of bacteria analogues within 
                                   Encapsulation of the therapeutic microbe Akkermansia muciniphila      
175
the emulsions, and finally the survival rate of A. muciniphila, when emulsions were subjected 
to storage and simulated gastrointestinal conditions.
Materials and Methods
Media preparation of A. muciniphila
Liquid culture of A. muciniphila MucT (CIP 107961T) was prepared in anoxic basal media as 
described previously (Derrien, et al., 2004). The basal media was supplemented with 20 g/L 
tryptone (Oxoid Ltd, UK) and 4 g/L L-threonine (Sigma-Aldrich, USA). A mixture of 250 
mM glucose (D(+)-glucose monohydrate, Merck, Germany) and N-acetyl-D-glucosamine 
(purity ≥99%, Sigma-Aldrich, USA) was added by 10% v/v as the carbon source. Media were 
filled into serum bottles sealed with butyl-rubber stoppers and aluminium crimp caps under 
anaerobic conditions provided by a gas phase of 182 kPa (1.5 atm) N2/CO2.
For the total viable count (TVC), Brain Heart Infusion (BHI) mucin agar was prepared 
containing 10 g agar (bacteriological agar no. 1), Oxoid Ltd, UK), 37 g BHI (Becton, 
Dickinson & Co, Belgium), 0.5 g L-cysteine hydrochloride monohydrate (Sigma-Aldrich, 
USA), 1 mL rezasurin, and 5 g commercial hog gastric mucin (Type III ; Sigma, Saint Louis, 
USA) per litre medium. BHI mucin agar was kept in 2 anaerobic atmosphere generation bags 
(AnaeroGen™, Oxoid Ltd, UK) at minimum one day before use and one fresh bag was used 
during incubation.
Cultivation and preparation of concentrated glycerol stocks of A. muciniphila
Cultivation of A. muciniphila liquid culture was done in anoxic medium by inoculating 1% 
v/v of 2 days pre-culture. Incubation was done at 37 °C for 2-3 days until late exponential 
phase. Cells were harvested by centrifugation at 10,000 g for 10 minutes and washed twice 
in buffer A (Phosphate Buffered Saline (PBS), 10 mM pH 7.4 with additional NaCl: 0.2 g/l 
KCl, 0.23 g/L KH2PO4, 2 g/L NaCl, 1.15 g/L Na2HPO4). The harvested cells were then added 
by 1:1 (v/v) ratio to anaerobic vials containing 50% v/v glycerol in water. Cells were 
preserved at -80 °C until use. One vial was thawed and counted by TVC as the reference 
concentration for all other experiments. For the use at non-microbiological laboratory, the 
cells were pasteurised at 68 °C in a water bath for 30 minutes prior to use, to render them 
inactive. 
Chapter 6. 
176
Preparation and characterisation of double emulsions 
Before use, both rotor-stator homogenizer and premix emulsification system were cleaned 
and filled with 1% halamid (Chloramine-T, Boom B.V., The Netherlands) solution for 10 
minutes. The system was emptied and refilled with sterile water to wash the remaining 
halamid. Water-in-oil (W1/O) emulsion (3:7, v/v) was firstly prepared by combining a freshly 
prepared solution of 109 CFU/mL A. muciniphila in PBS 10 mM + 2 g/L NaCl with 1% w/v 
PGPR (Givaudan, Switzerland) in sunflower oil (C1000, The Netherlands) in 50 mL conical 
centrifuge tube. The glycerol stocks used throughout the project were thawed only once and 
were not refrozen. The water and oil mixture was homogenized with a rotor-stator 
homogenizer (Ultraturrax T-18, IKA, Germany) at 4400 RPM for 6 minutes with manual up-
and-down moving every minute to ensure uniform homogenization.
Afterward, the resulting primary emulsion was added to the outer water phase containing 1% 
w/v sodium caseinate (sodium caseinate S 80% purity, DMV international, The Netherlands) 
in PBS 10 mM + 2 g/L NaCl that had been stirred overnight. The volume fraction of W1/O 
emulsion was 10% of the total double emulsion volume. A coarse double emulsion was first 
made with the rotor-stator homogenizer at 3400 RPM for 6 minutes, prior to emulsification 
with a premix column at 4 bar (pressurized CO2) for 5 passes. The procedure was similar to 
that used in previous work (Sahin, et al., 2014), except that it was carried out without nickel 
sieve and glass beads. The obtained double emulsion was kept in a 1 L bottle sealed with 
butyl-rubber stoppers and aluminium screw cap under anaerobic condition. A total volume 
of 300 mL double emulsions was made per batch. 
All preparations were done in triplicate; the primary and double emulsions were characterized 
for droplet morphology and droplet size distribution. Droplet morphology was observed 
using bright field confocal microscope at 400X magnification. A volume of 4 μL sample was 
used for all microscopy preparations throughout the project unless stated otherwise. For each 
sample, the droplet size distribution was measured in triplicate using a light scattering 
instrument (Mastersizer 2000, Malvern, UK) with the values indicated in Table S1 
(Supplementary materials and methods). The window glass pair was cleaned with soap and 
ethanol air every 3 to 4 measurements to ensure accurate detection.
In case of measurement of double emulsions containing living bacteria, measurement was 
done using 15 microscopy images processed by automated image analysis software (ImageJ 
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1.49o) and MS. Excel 2010 (Supplementary material). All values of droplet size were 
expressed as volume-weighted mean diameter (D [4, 3]). The following formula (Eq. 1) was 
used for the calculation of D [4, 3] in MS. Excel: 
D(4,3) = ∑����4
∑����
3 (1)
where ni is expressed as the number of particles in each size-class per unit volume of 
emulsion, while di is the diameter of the particles in each size-class. The width of the 
distribution (Span) was determined as follows (Eq. 2):
���� = �(0.9)−�(0.1)
�(0.5) (2)
where d(0.1), d(0.5) and d(0.9) are the sizes below which 10%, 50% and 90% of the particles 
are counted, respectively. 
Alternatively, the program ImageJ was used to analyse 15 microscopy images. First, the 
image was converted to black and white, after which the threshold was adjusted to show the 
desired droplets. Additionally, outliers were removed to exclude small primary emulsion 
droplets. Finally, the particles with a radius of 10 µm to infinity and a circularity of 0.50 –
1.00 were analysed. The output was used to calculate the D [4, 3] according to equation (1).
The osmotic pressure on the droplets exerted by the outer water phase was calculated by 
using the Van ‘t Hoff equation:
� = � × � × � × � (3)
In which Π is the osmotic pressure, T in Kelvin, R the gas constant, C the concentration of 
the compounds, and n the amount of dissociated compounds. 
Bacterial viability and emulsion stability during storage
A freshly prepared double emulsion loaded with bacteria was stored in anaerobic serum 
bottles with a N2/CO2 headspace and in aerobic conical centrifugation tubes. The same was 
done with an equal amount of bacteria in 10 mM PBS buffer as a control. Each bottle 
contained 10 mL of liquid. After these treatments, the samples were kept in the fridge at 4˚C 
and samples were taken at 0, 2 , 24 , 48 and 72 hours. At each time point, 0.5 mL sample of 
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the experimental group and the control group were taken under sterile conditions. To count 
the viable cells, the double emulsions underwent centrifugation steps (10,000 g for 10 min) 
to break down the emulsion and fully separate the oil layer and water layer (water phases 1 
and 2). The complete sample was mixed with a vortex agitator for 10 seconds to suspend the 
bacteria. Serial dilutions (10-1 to 10-7) were made of each sample in PBS. Spots of 2 µL were 
made from each dilution on BHI-mucin-agar plates, prepared as described above. The plates 
were incubated for two days at 37 ˚C.
The droplet size distribution, morphology, and encapsulation efficiency were set as standards 
to evaluate the physical properties of the double emulsion systems. The double emulsions 
were stored at 4 °C for 96 hours for the stability tests, and samples were taken at 0, 1, 2, 4, 
24, 48, and 96 hours. The whole set of experiments was conducted twice and each experiment 
contained two parallel cultures for each condition. 
Localisation and encapsulation efficiency of bacteria and fluorescent particles
Double emulsions were prepared with hydrophilic fluorescent particles (FluoSpheres® 1 µm 
F-13081, maximum emission wavelength 505 nm, ThermoFisher Scientific, USA) or 
pasteurized biomass which was labelled by 0.3% v/v of 3.34 mM SYTO9 (λem 608 nm, 
ThermoFisher Scientific, USA). The double emulsions were subjected to simulated digestion 
(see detailed procedure below) and samples were observed under fluorescence microscope. 
Green light (λ = 540 nm) was used for the excitation.
The encapsulation efficiency was calculated based on the average of 30 random microscopic 
images (400x magnification) from samples stored for different time periods. 
The encapsulation efficiency was calculated as follows (Eq. 4):
Encapsulation efficiency (%) = 1
30
∑ ��
30
�=1 = 130 (a1 + a2 +⋯+ a�) (4)
where 
a� = number of fluorescent particles entrapped in inner water dropletstotal number of fluorescent particles in view (5)
                                   Encapsulation of the therapeutic microbe Akkermansia muciniphila      
179
Simulated digestion test 
The international consensus of standardized static in vitro digestion method by Minekus et 
al. (Minekus, et al., 2014) was applied with some modifications (Table S2 Supplementary 
material). The tests were done in chemostat bioreactors (DASGIP® Parallel Bioreactor 
System, Eppendorf, Germany), each with a total volume of 500 mL. The gastric test was 
done at pH 3.0, 37 °C, 2 hours, and 100 RPM agitation with 0.2% w/v pepsin (from porcine 
gastric mucosa 3200–4500 U mg-1 protein, Sigma, USA), diluted in simulated gastric fluid 
(SGF) pH 6.0 (Table S3 Supplementary material). The intestinal test was done at pH 7.0, 37 
°C, 2 hours, and 100 RPM agitation with 0.48% w/v porcine bile extract (B8631, Sigma-
Aldrich, USA) and 0.22% w/v pancreatin (from porcine pancreas, 8X USP specification, 
Sigma-Aldrich, USA). 
Potassium hydroxide (3 M) and sulfuric acid (0.5 M) were used to control the pH during the 
experiment. Dissolved oxygen was programmed for gradual decrease during 2 hours gastric 
test until anaerobic conditions were reached and maintained during the intestinal phase. Pure 
nitrogen was used to alter the atmospheric composition in the vessels. Samples were taken 
before and after each digestion stage, kept on ice and observed by phase contrast confocal 
microscopy at 400x. Each microscope slide was prepared just before observation to keep 
droplets intact. For viable cell counts, the double emulsions were disrupted by centrifugation 
at 10,000 g for 10 minutes prior to TVC plating on BHI mucin.
All equipment and materials were sterilized except the enzyme solutions. Additional 
antibiotics were added with final concentration of 5 μg/mL vancomycin hydrochloride (>900 
μg/mg, AcrosOrganics, Belgium) and 50 μg/mL kanamycin sulfate (Sigma–Aldrich, USA) 
during the digestion test and in BHI-mucin-agar to avoid contamination and growth of 
undesired cells. Both processed and unprocessed cells dispersed in PBS were tested as 
control. In the former case, a bacterial suspension in PBS buffer was subjected to the same 
mechanical treatment as applied for preparing the double emulsions, i.e., 2 treatments with 
the rotor-stator homogenizer, followed by the premix column emulsification step.
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All equipment and materials were sterilized except the enzyme solutions. Additional 
antibiotics were added with final concentration of 5 μg/mL vancomycin hydrochloride (>900 
μg/mg, AcrosOrganics, Belgium) and 50 μg/mL kanamycin sulfate (Sigma–Aldrich, USA) 
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Further analysis and blanks
Zeta potential of sodium-caseinate-stabilized droplets at different pH 
In order to assess the effect of pH changes on the behaviour of oil droplets coated with sodium 
caseinate, additional (simple O/W) emulsions were prepared by mixing sunflower oil (10% 
volume fraction) with 1% sodium caseinate in PBS + 2 g/L NaCl, which was set at different 
pH values (1, 3, 5, 7, and 9). The mixture was homogenized at 6000 RPM for 10 minutes. 
The charge of the resulting emulsion droplets was analysed using Malvern Zetasizer Nano S 
(Malvern, UK). Prior to analysis, samples were diluted 10 times with deionized water. The 
measurement was done 3 times for each sample with an equilibration time of 300 s.
Utilization and resistance of bile extract 
Pre-culture of A. muciniphila was added at 1% v/v to anoxic tryptone media containing 
different concentration of porcine bile extract (0.05%, 0.1%, 0.5% and 1%, Bile extract 
porcine, Sigma-Aldrich, USA) . All media were supplemented with 10% v/v of a 125 mM n-
acetylglucosamine and 125 mM glucose solution. Each treatment was done in duplicate. The 
culture was incubated at 37 °C and optical density at 600 nm was measured. Anoxic tryptone 
medium with sugars was used as the positive control.
Statistical analyses 
The cell survival during digestion tests for both treatments (i.e., encapsulated bacteria and 
control) was analysed using two-way ANOVA on SPSS Statistics (version 23, IBM). One-
way ANOVA was used to compare the protection in the gastric test. A Student’s t-test in 
Microsoft Excel 2010 was used to compare the methods to measure droplets size. The 
analysis of cell release was also done using a paired t-test. Significant differences were 
considered at the level of p≤ 0.05. Standard errors of means were obtained and are shown as 
error bars in figures and tables.
Results and Discussion
Droplet size characterisation
An important prerequisite for developing the double emulsion delivery system was that the 
inner water droplets should be large enough to allow encapsulation of A. muciniphila cells, 
which have a size of 0.6 – 1.0 μm (Derrien, et al., 2004). Therefore, the preparation conditions 
for the primary (W/O) emulsions were chosen such that water droplets (W1) of around 3.5 
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μm (Table 1 and Figure 1) were obtained, which is suitable to accommodate single or paired 
cells of A. muciniphila.
Table 1 Average volume weighted mean diameter (D[4,3]) of inner water droplets (W1) and oil droplets (O) over 4-
day storage at 4° C.
Droplets W1 O
Time (h) 0 0 24 48 96
Average 
D[4,3] (μm)
3.50±0.30 15.11±0.6 24.00±0.9 24.74±1.3 25.13±1.5
Span 1.33±0.12 1.50±0.04 1.73±0.06 1.60±0.01 1.62±0.07
The fraction of primary emulsion in the total emulsion was chosen such that a high load of 
bacteria per gram of emulsion was obtained as presented in Table S4. Quite remarkably, the 
oil droplet diameter increased in 24 hours from 15 μm to a stable value of around 24-25 μm 
(Table 1). The diameter increased by a 1.6 factor, which is equivalent to a 4.6 swelling factor 
(defined as the ratio of droplet volume at time t to droplet volume at t=0). This swelling was 
consistently observed in various trials of the present study (See Supplementary data Figure 
S1 and Figure S2). The shift of the distribution of droplet size diameter can be seen in Figure 
1. All distributions were overall monomodal and normal. 
Figure 1. Droplet size distribution of inner water droplets (W1) in the primary W/O emulsion, and of oil droplets (O) 
in the double emulsion over 4 day storage at 4 °C.
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Both coalescence of oil droplets or water diffusion from outer to inner water phase (swelling) 
would result in larger droplet diameters. Such a diffusion process was previously shown to 
occur in comparable double emulsions (Eisinaite, et al., 2016). Although swelling has been 
shown to be one of the main challenges for the application of double emulsions, it can 
sometimes be used on purpose to, e.g., increase the emulsion’s viscosity post-preparation 
(Leal-Calderon, et al., 2012, Bahtz, et al., 2015). According to Yan and Pal (Yan and Pal, 
2001), water transfer from the external to the internal water phase is mainly caused by 
osmotic pressure differences that cause rapid swelling. In the present work, the inner and 
outer water phases were formulated from the same PBS buffer (A); the only differences being 
sodium caseinate (1% w/v) added to the outer water phase, while the inner water phase 
contained glycerol stock of bacteria. Based on the following assumptions: final concentration 
of glycerol in W1 phase approximately 85.5 mM, sodium related to caseinate was 1.3%, and 
bacterial cells having the same osmotic pressure as the used buffer, the total osmotic pressure 
difference was calculated to be 1.96 × 102 Pa. Following Leal-Calderon et al. (Leal-Calderon, 
et al., 2012), we calculated an induced swelling of a factor or 1.2, while we experimentally 
determined 4.6 from the oil droplet size. This indicates that also coalescence occurred, and 
that both effects contributed to the observed increase in droplet size over 24 h. 
Encapsulation efficiency and viability
Encapsulation efficiency of double emulsions
The encapsulation efficiency of bacteria was emulated by the use of 1 µm fluorescent 
particles and calculated with Eq. 4. We found a high initial particle encapsulation efficiency 
of 97.5%, which decreased to 89.6% after 4 days. As such relatively large hydrophilic 
particles are unlikely to migrate through the oil phase, the observed decrease was most 
probably caused by release of inner droplets (W1) into the outer water phase (W2), but please 
note that encapsulation efficiency remained high, and particle release was minimal. When 
using non-labelled cells, it was found that colonies on BHI-mucus plates were only observed 
after breaking the emulsion with centrifugation. If the emulsion was not broken, no colonies 
were observed. This indicates that all viable cell were encapsulated. 
Viability during storage 
Double emulsions loaded with cells were stored for 3 days in both anaerobic and aerobic 
conditions. For both conditions, a control was included, consisting of cells simply dispersed 
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in PBS. After one day, only cells stored anaerobically and dispersed in PBS showed no 
decrease in viability. After two days, the viability decreased in all conditions, but the viability 
in the PBS buffer remained high under anaerobic conditions (Figure 2). For the conditions 
used, no statistical differences were found between any of the end points (p>0.12).
Figure 2. The viability of A. muciniphila during storage while encapsulated in a double emulsion or freely dispersed 
in PBS (DEE = Double Emulsion Encapsulated, PBS = free dispersed in PBS, An = anaerobic, Ae= aerobic). The 
data were normalised to the viability after two hours. Only the bacteria stored anaerobically in PBS show no decrease 
in viability over 72h, but the differences were not significant, p=0.12.
Digestive tests
Emulsion morphology during in vitro gastric digestion
Droplet morphology changes in each stage of the simulated digestion, shown in Figure 3. In 
this series of experiments, the double emulsions had an initial diameter of 17.7 ± 0.3 μm. The 
microscopic appearance of the double emulsions just after preparation is shown in Figure 3a. 
When brought into contact with pepsin and electrolytes, the droplets flocculated, which can 
be seen in Figure 3b. To be complete, immediately after sample addition the pH of the 
simulated gastric fluid (SGF) increased from pH 3.0 to pH 4.9-5.5, before the system went 
back to a pH value of 3.0, and this can explain the immediate occurrence of droplet 
flocculation (as also further explained in the supporting material, Figure S3). Briefly, at pH 
5 the zeta potential is low, and electrostatic repulsion between droplets is minimal. Besides, 
the presence of calcium and other metal ions in the gastric fluid may enhance droplet 
flocculation through electrostatic screening (Parker and Dalgleish, 1981, Hunt and Dalgleish, 
p=0.12
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1996, Dickinson, 2010), and calcium bridges may form at low pH with the phosphoseryl 
residues of α-casein and β-casein. Furthermore, porcine pepsin will hydrolyse caseinate 
leading to destabilization and coalescence of the double emulsions, since the smaller peptides 
have a different affinity for the interface (Nik, et al., 2010). After 2 hours exposure to gastric 
fluid, large oil droplets were present with various morphology as can be seen in Figure 3c, 
with inner water droplets still present. 
At the end of the gastric test, the digestion was shifted to intestinal conditions, and emulsion 
droplets having a diameter of 10 μm could barely be seen after 2 h (Figure 3d); the few 
remaining oil droplets seemed nearly depleted from inner droplets. The disappearance of oil 
droplets was expected, since 70-90% of the fat is hydrolysed in the small intestine of the 
human body (Maldonado-Valderrama, et al., 2008). Bile salts aid lipolysis by competitively 
displacing protein emulsifier (Vinarov, et al., 2012), and thus allowing lipase and colipase to 
adsorb on the lipid surface and carry out lipolysis (Maldonado-Valderrama, et al., 2011),
irrespective of droplet size (Begley, et al., 2005).
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Figure 3. Double emulsion droplet morphology in stages of the simulated gastrointestinal digestion observed at 
400X magnification using phase contrast microscopy (a) before digestion (b) flocculation after immediate contact 
with gastric fluid, (c) after 2 hours gastric conditions (d) after 2h intestinal condition. Bar is 10 μm. 
Localisation of entrapped particles and A. muciniphila cells during gastric passage
To investigate localisation within the double emulsion when subjected to digestive 
conditions, a test was done using fluorescently-labelled bacteria (Figure 4). Right after 
preparation, cells were observed in the inner water phase (Figure 4a), and during the gastric 
phase (see Figure 4b), the cells remained there even though the oil globules were coalescing. 
In this phase, contact of bacterial cells and gastric fluid was minimized, which is very 
important to create a protective effect (see encapsulation section). The oil droplets that appear 
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as opaque spheres during the intestinal phase (Figure 4c), did not contain labelled bacteria 
but the continuous phase of the digested emulsion did. 
Figure 4. Double emulsions with fluorescence-labelled cells during each stage of simulated digestion (a) before 
digestion (b) after gastric phase (c) after intestinal phase. The bar represents 20 μm. Cells were observed as white 
dots. Oil globules that don’t contain cells show up as opaque spheres.
The release of cells was confirmed by total viable cell counting of samples obtained after the 
intestinal phase (with and without breaking the emulsion), and the total numbers of bacteria 
were shown to be similar (p > 0.05; Figure 5). This also indicates that most cells were released 
at the end of the intestinal phase, given their sensitivity to the digestive conditions used.
Figure 5. The viability of released A. muciniphila after in vitro digestion. The total amount of cells was obtained by 
breaking the emulsion, the released fraction by directly plating the digestate. There is no observed difference (p = 
0.74) between the total amount and released bacteria. 
Increased viability of encapsulated A. muciniphila during gastric passage
A. muciniphila survival was tested throughout simulated digestion using double emulsions 
and appropriate controls (freely dispersed cells in PBS buffer that have received the same 
processing as the double emulsion or are only dispersed (Figure 6). The relative viability of 
the non-encapsulated bacteria in the gastric juice (2 hours) decreased by more than 100-fold, 
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and only 0.4% of the control bacteria survived. The non-processed bacteria showed an even 
higher loss of viability in the gastric phase since only 0.02% survived. On the other hand, the 
bacteria encapsulated in the double emulsion were more resistant to the gastric phase, leading 
to an equivalent survival of 6.6%. All differences are significant (p<0.05), also after the 
intestinal phase during which the viability increased for both controls in PBS, but further 
decreased for the encapsulated bacteria. This could be due to the delayed exposure to bile 
that may stimulate the growth of A. muciniphila (see Figure S4). 
Figure 6. The normalised survival of A. muciniphila after 2 hours incubation in gastric juice and subsequent 2 hours 
incubation in intestinal fluid. Bacteria encapsulated in a double emulsion (DE, full line) had a higher survival than 
bacteria that were mechanically processed in PBS (dashed line). The lowest survival was obtained for bacteria that 
were only dispersed in PBS (dotted line). Error bars indicate standard deviation, only positive values are indicated. 
Other researchers have reported the use of double emulsion microencapsulation for probiotic 
species. Similar results were observed with Lactobacillus acidophilus (Shima, et al., 2006)
in which encapsulation at inner phase volume ratios between 0.03 and 0.45 resulted in 10-
100 times higher survival after 2 hours gastric testing. Double emulsion encapsulation of L. 
rhamnosus (Pimentel-Gonzalez, et al., 2009) also exhibited approximately 100 times higher 
survival difference compared to control. However, this higher survivability cannot be directly 
compared to those of A. muciniphila, mainly due to different sensitivity to dissolved oxygen 
(Jyoti, et al., 2004, Talwalkar and Kailasapathy, 2004), (Ouwerkerk, et al., 2016). It is known 
that oxygen, other gases and small non-electrolyte solutes can diffuse through oil and 
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membranes (Walter and Gutknecht, 1986), and the resulting stress may have induced 
tolerance in the cells which could explain the difference between processed and non-
processed cells dispersed in PBS (den Besten, et al., 2010, Abee, et al., 2011).
Conclusion
We have shown that the viability of A. muciniphila after passage through an in vitro gastric 
system is enhanced by its encapsulation in a double emulsion. Upon addition of the emulsion 
to gastric conditions, the oil droplets flocculate, but the bacteria remain entrapped inside the 
inner water phase. Upon the introduction of intestinal liquid, the emulsion is digested and the 
bacteria are released. Hence, double emulsions seems to be promising systems for 
encapsulation and targeted intestinal delivery of health-promoting bacteria. 
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membranes (Walter and Gutknecht, 1986), and the resulting stress may have induced 
tolerance in the cells which could explain the difference between processed and non-
processed cells dispersed in PBS (den Besten, et al., 2010, Abee, et al., 2011).
Conclusion
We have shown that the viability of A. muciniphila after passage through an in vitro gastric 
system is enhanced by its encapsulation in a double emulsion. Upon addition of the emulsion 
to gastric conditions, the oil droplets flocculate, but the bacteria remain entrapped inside the 
inner water phase. Upon the introduction of intestinal liquid, the emulsion is digested and the 
bacteria are released. Hence, double emulsions seems to be promising systems for 
encapsulation and targeted intestinal delivery of health-promoting bacteria. 
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Table S1 Optical index values used in droplets size distribution measurement
Emulsion Refractive index of dispersed 
phase
Absorption index of 
dispersed phase
Refractive index of 
dispersant
W1/O 1.333 0.01 1.469
W1/O/W2 1.465 0.01 1.333
Table S2 Conditions and components of simulated digestion model. Composition of SGF and SIF is given in Table 
S3
Example
Phase Conditions Solutions Stock concentration
Vol. 
Stock
Conc. 
In 
SGF
Gastric
pH 3, 37˚C, 
mixed, 
gradual 
oxygen 
decrease to 
0%
Simulated Gastric 
Fluid (SGF)*
1.25x 187.5 mL 1x
SGF:emulsion 
= 1:1
Double emulsion - 250 mL -
Porcine pepsin 0.1 g/mL 40 mL 0.8%
CaCl2 (add to 
pepsin)
0.3 M 125 µL
0.075 
mM
H2SO4 0.5M -
Equiv. 
pH3.0
water - 17.5 mL -
Total volume reactions 500 mL
Stopping Incubated on ice, 10 min NaOH 0.5 M
Equiv. 
pH 
6.5-7
For gastric 
phase sampling
Intestinal
pH 7, 37˚C, 
mixed, 
anaerobic
Simulated 
Intestinal Fluid 
(SIF)*
1.25x 137.5 mL 1x
SIF:emulsion= 
1:1
Gastric chyme - 250 mL -
NaOH 3 M -
Equiv. 
pH 7.0
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Porcine pancreatin 8 mg/mL 62.5 mL
1 
mg/mL
Porcine bile 68.75 mg/mL 31.25 mL 10 mM
CaCl2 (add to bile) 0.3 M 250 µL
0.3 
mM
water - 16.5 mL
Total volume reaction 500 mL
Stopping Incubate on ice, 10 min
Table S3 Composition of SGF and SIF
Stock SGF (pH 3) SIF (pH 7)
Constituent Stock Concentration Vol. of stock Conc. in SGF Vol. of 
stock
Conc. in SIF
(g/L) (mol/L) (mL) (mmol/L) (mL) (mmol/L)
KCl 37.3 0.5 25.875 6.9 17 6.8
KH2PO4 68 0.5 3.375 0.9 2 0.8
NaHCO3 84 1 46.875 25 106.25 85
NaCl 117 2 44.25 47.2 24 38.4
MgCl2(H2O)6 30.5 0.15 1.5 0.1 2.75 0.33
(NH4)2CO3 48 0.5 1.875 0.5 - -
NaOH 1 - - - -
HCl 6 4.875 15.6 1.75 8.4
        Water Make up to 1500 ml Make up to 1000mL
Supplementary Results
A. muciniphila load in double emulsions
Table S4 Calculation of A. muciniphila load and inner water droplets per gram of double emulsions with different 
fractions of dispersed phase (with loading 109 A. muciniphila/ml in W1). The bacterial load increases with the 
increase of fraction of primary emulsion.
Fraction of W1 in 
primary emulsion
Fraction of primary 
emulsion in double 
emulsion
Number of 
Akkermansia/g double 
emulsion
Number of inner water 
droplets/g double 
emulsion
25 10 2.5 x 106 7.5 x 108
30 10 3.0 x 106 9.0 x 108
30 30 9.0 x 106 2.7 x 109
40 30 1.2 x 107 3.6 x 109
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Morphology and droplet sizes of double emulsions 
Figure S1. Morphology and droplet sizes of double emulsions at t=0
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Morphology and droplet sizes of double emulsions 
Figure S1. Morphology and droplet sizes of double emulsions at t=0
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Figure S2. Morphology and droplet sizes of double emulsions after 24 hours and 48 hours
Emulsion stability under changing pH conditions 
The stability of protein-stabilized emulsions is heavily influenced by the droplet surface 
charge (Xu, Wu, & Xu, 2007), and often ±30 mV is accepted as the threshold for stable 
emulsions (Everett, 1988). The emulsion is subjected to a low pH in the gastric system, 
therefore the physical stability of oil droplets was investigated by measuring the zeta potential 
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of sodium caseinate-stabilized simple emulsions at various pH. As can be seen in Figure S3,
sodium caseinate can contribute to stable emulsions when the pH values are above 6.0. Below 
pH 6.0, the zeta potential increased and reached 0 mV at the isoelectric point (IEP = pH 4.5) 
which is close to the IEP of native casein (pH 4.6) (Liu, Cui, Mao, & Guo, 2012). The zeta 
potential then became positive below the IEP, but it never reached higher than +30 mV in the 
measured pH range, therefore below pH 6.0 flocculation of oil droplets could be expected.
Figure S3. Zeta potential of oil droplets stabilized by sodium caseinate. Values are mean ± standard deviations from 
triple measurements. The areas highlighted in grey indicate stable conditions.
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Growth of A. muciniphila on bile
Figure S4 Growth of A. muciniphila on medium supplemented with 0.1%, 0.5% and 1% porcine bile extract. Normal 
growth was observed in the medium without supplemented bile extract (dashed line – no bile added), while growth 
was increased by porcine bile extract (full lines). No growth was observed in the negative controls (dotted line – no 
A. muciniphila cells added).
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General Discussion
This thesis describes detailed studies on the growth, metabolism and application of 
Akkermansia muciniphila, a symbiont colonizing the human gut. The aims of this thesis were 
to investigate the growth requirements of A. muciniphila for the development of a minimal 
medium, a synthetic medium free from animal components and viable delivery to the host. 
These aims were defined based on the need  for a detailed physiological characterization of 
A. muciniphila and developing mechanistic insight into interactions between A. muciniphila 
and the host.
Causality and using genome-scale metabolic models in gut microbiota research
The bacterial composition in our gut has been subjected to many studies over the past decade, 
showing a great variety of correlations between bacterial groups and parameters of health 
(De Vos and De Vos, 2012). It has been well established that the intestinal bacteria can 
influence food digestion as well as affect immune and metabolic regulation. On the other 
hand, the intestinal bacterial composition and activity can be modulated by diet as well as 
medication (Actis, et al., 2014, Lee and Ko, 2014, Roopchand, et al., 2015, Zoetendal and 
Vos, 2014). It is expected that more research will focus on establishing the causality and 
molecular details of the bacteria-host interactions by thorough mechanistic and human 
interventions studies. Detailed studies of cultured representatives of bacteria involved in the 
correlations with health and disease is  among the first prerequisites, as described in chapter 
2 (van der Ark, et al., 2017).
To obtain unambiguous causative relations and detailed mechanistic insight in bacteria-host 
interactions, several microbiota-based therapies are currently applied. The least specific 
interventions are exploiting faecal microbiota transplantations (FMT) or influencing the 
abundance of bacterial species by prebiotic and other dietary compounds (Anhe, et al., 2015, 
Gibson, et al., 2017, Gupta, et al., 2016, Roopchand, et al., 2015). Recent insights and 
developments allow more specific interventions, which can result in mechanistic insights. 
These studies include the administration of cultured bacteria or derivatives in human subjects 
or patients. Another way is the specific suppression or inactivation of bacteria by the use of 
bacteriophages. The different therapies may have variable efficacies in clinical trials. It has 
been widely established that dietary interventions can change the microbiota (Cotillard, et 
al., 2013, Dao, et al., 2016), but have not been found to cure diseases (Vieira, et al., 2016).
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In some cases, the use of presently known probiotic bacteria has found to provide a positive 
influence on the prevention or development of a disease or metabolic disorders but 
convincing and robust evidence is lacking (Vieira, et al., 2016). These cases included studies 
using specific probiotic strains (Derrien and van Hylckama Vlieg, 2015), including 
bifidobacteria (Tojo, et al., 2014) and lactobacilli (Wang, et al., 2015). The use of other 
potential beneficial bacteria in intervention studies is limited to mouse models and include 
members of the natural microbiota and possible therapeutic microbes, such as Eubacterium 
hallii (Udayappan, et al., 2016), Faecalibacterium prausnitzii (Rossi, et al., 2015),
Butyricicoccus pullicaecorum (Eeckhaut, et al., 2014), Clostridium butyricum (Kanai, et al., 
2015), and A. muciniphila (Everard, et al., 2013, Plovier, et al., 2017). From all different 
intervention studies, only FMT has shown to be functional in curing several diseases, 
including recurrent Clostridium difficile infection (de Vos, 2013, van Nood, et al., 2013).
Next to these preclinical studies, cause-effect studies in human are essential to further 
advance the field and provide the necessary basis for performing mechanistic studies. For 
this purpose, cultured bacteria are needed that can be used in human interventions. 
In chapter 2 we provide a thorough description on predicting growth medium parameters of 
bacteria based on their genomes, providing insight on how pure cultures can be optimally 
grown. Based on whole genome sequences, predictions can be made on organism 
autotrophies for example by identifying the synthesis pathways for e.g. amino acids that are 
present and absent. The genome sequences can also be used to create genome-scale metabolic 
models (GEMs). These GEMs can be used to study the metabolic capacities of a bacterium 
and thereby aid in defining a minimal medium. Based on these minimal media, a systems 
cycle can be initiated to improve the GEM: predictions by the GEM can be validated using 
the minimal medium, after which the new discoveries can be implemented in the GEM again,
resulting in altered predictions and an improved GEM. The GEM can subsequently be used 
to generate new hypotheses.  Moreover, with an improved GEM, novel phenotypes can be 
better predicted. The possible phenotypes combined with data on niche composition,
including bacterial communities, can be used to predict in vivo functionality. It is worth 
notifying that the present predictions are limited to interactions based on metabolites, and do 
not include immunomodulation by proteins.
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The GEMs have various limitations, including their dependence on (appropriate) annotation, 
the inability to include proteins or peptides, and the failure to predict immunomodulation that 
all could underestimate the role of bacteria in gut health. Multiple studies have found 
interactions between bacterial species and the host, including A. muciniphila and F.
prausnitzii (Plovier, et al., 2017, Quevrain, et al., 2016).
In spite of the above-described shortcomings, GEMs are still a valuable tool in helping to 
understand the role of the microbiota. Also without the incorporation of immunomodulation 
in GEMs, it was recently shown that GEMs can be used to design dietary interventions in 
humans (Shoaie, et al., 2015). As described above, the host diet has influence on the microbial 
composition and the degradation of dietary components by bacteria has influence on host 
health. Such research is possible only by understanding the behaviour of the microbes.
The use of the A. muciniphila GEM to design a minimal medium
An initial GEM for A. muciniphila was constructed based on the full genome annotation and 
validated using non-defined media (Ottman, et al., 2017). This GEM was updated and used 
in chapter 3 to support the design of a minimal and synthetic medium for the effective growth 
of A. muciniphila. We confirmed the prediction of L-threonine essentiality for the growth of 
A. muciniphila, whereas the sugar-degrading capabilities were generally predicted correctly. 
However the model required optimization to fully understand the metabolism of A. 
muciniphila. To discover misinterpretations of metabolism by the model, it is important to 
also understand the steps taken in the construction of the model. One of the important steps 
in creating a functional model is the use of gap-filling algorithms (Henry, et al., 2010, Orth 
and Palsson, 2010). These algorithms, as the name suggests, fill gaps in the metabolic 
pathways that are not predicted in the initial draft model. These gaps can be caused by wrong 
annotation of genes or the absence of annotated genes with the assumption that the 
functionality should be present. In case of such an incorrect annotation, or assumed presence 
of functionality, the gap filling does not result in mistakes in the model, but just fill gaps. 
However, if the filled gaps represent reactions that are really absent in the genome of the 
organism, it leads to erroneous predictions. The latter was the case for the wrongly filled gap 
in the conversion of fructose-6-phosphate (Fru6P) to glucosamine-6-phosphate (GlcN6P), 
mediated by the enzyme GlcN6P synthase GlmS in the A. muciniphila GEM. The filling of 
this gap led to the prediction that glucose could be used as carbon source and converted into 
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GlcN6P via Fru6P. We showed in chapter 3 that is was not the case, because the only enzyme 
mediating the conversion between Fru6P and GlcN6P in A. muciniphila, named NagB, was 
found to prefer the reaction in the direction of Fru6P. Hence, it was discovered that N-
acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc) cannot be synthesized de
novo from glucose and hence are essential for the growth of A. muciniphila, and thus need to 
be present in the growth medium. The composition of the developed media was therefore 
mainly based on the supplementation of GlcNAc or GalNAc.
The genome of A. muciniphila predicts the presence of peptidoglycan and recently it was 
demonstrated that A. muciniphila does produce this important cell-wall component using 
chemical microbiology (T Sminia PhD thesis: Probing the bacterial cell wall with chemical 
biology tools - 2017). The absence of GlmS is unique for bacteria that produce peptidoglycan 
and its precursor uridine diphosphate (UDP)-GlcNAc (Figure 1) (Barreteau, et al., 2008). The 
constant availability of GlcNAc and GalNAc provided by the host resulted in an effective 
way of UDP-GlcNAc synthesis. The synthesis of UDP-GlcNAc usually involves the 
subsequent phosphorylation, amination and acetylation of glucose to yield the same end 
product. This normally requires one glutamine for amination and one acetyl-CoA for
acetylation. Both steps require ATP, one for the synthesis of glutamine for amination of 
Fru6P (Harper, et al., 2010), and one for the synthesis of acetyl-CoA (Kumari, et al., 2000)
(Figure 1). In the case of A. muciniphila, GlcNAc is readily provided by the host via the 
produced mucus. This makes the synthesis of GlcN6P a redundant function in A. muciniphila, 
which could have resulted in the loss of the gene or its function. The shortcut in UDP-GlcNAc 
synthesis reduces the need of approximately 2 ATP per UDP-GlcNAc synthesized, which 
gives A. muciniphila a competitive advantage over other mucolytic bacteria that need to 
synthesize UDP-GlcNAc via GlcN6P (Figure 1). 
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Figure 1. Overview of GlcNAc, glucose, glucosamine and GalNAc utilization and the conversion from GlcN6P to 
Fru6P. The peptidoglycan shortcut is indicated by blue arrows. Enzymes and transporter between [ ] and co-
metabolites are indicated only when required. Dotted arrows indicate multiple reactions. A red dot indicates the 
consumption of 1 ATP for the production of this substrate at the indicated reaction. 
Besides the growth on GlcNAc, we also found similar growth on GalNAc and limited growth
on glucosamine (GlcN). Both GlcN and GalNAc degradation were not predicted by the initial 
model, but observed upon the addition to the minimal medium. Apparently, GalNAc can 
replace GlcNAc in the minimal medium and hence we assigned an epimerase (UDP-glucose 
4-epimerase encoded by the gene on locus Amuc_1125 or Amuc_0029) that potentially 
mediated the reaction (Figure 1). The degradation of GlcN is predicted to be possible with 
the addition of a transport reaction, which is not yet annotated in the A. muciniphila genome. 
Therefore, the inability to reach high growth rates and optical densities on this sugar is likely 
due to limited transport.
The use of GlcNAc directly for peptidoglycan synthesis is mediated by the formation of 
UDP-GlcNAc. The subsequent use of UDP-GlcNAc for peptidoglycan synthesis is common 
in all peptidoglycan-forming bacteria (Barreteau, et al., 2008). The conversion between 
GlcNAc-1P and UDP-GlcNAc is mediated by the uridyltransferase GlmU, encoded by the 
gene on locus Amuc_0814. The preceding phosphorylation of GlcNAc could be mediated by 
N-acetylhexosamine 1-kinase, encoded by the gene on locus Amuc_0030, directly adjacent 
to one of the genes for UDP-glucose 4-epimerase on locus Amuc_0029. These genes indicate 
the direct use of GlcNAc in peptidoglycan formation (Uehara and Park, 2004). The operon-
like structure of the genes for N-acetylhexosamine 1-kinase and UDP-glucose 4-epimerase 
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could be a lead for the incorporation of GalNAc residues in the cell wall. The use of GalNAc
in cell wall polysaccharides has been described before (Leoff, et al., 2008).
The minimal medium was composed based on the previously described CP mineral medium, 
with the omission of ammonium (Plugge, 2005). To sustain growth for A. muciniphila, only 
GlcNAc (or GalNAc) and L-threonine need to be added. The omission of ammonium 
indicates that either L-threonine of GlcNAc could serve as nitrogen source. Vitamins, 
including B12, were added during the experiments. It was described before that vitamin B12 
is an important cofactor in the methylmalonyl pathway for the conversion of succinate to 
propionate (Ottman, et al., 2017). Although not essential for growth, vitamin B12 is important 
for propionate production, and thereby optimal utilization of the provided sugars in terms of 
energy gain.
The growth of A. muciniphila on minimal medium is approximately 0.08 h-1, depending on 
the applied combination of sugars. This is around 20% of the growth rate obtained for A.
muciniphila grown on mucus, which has a doubling time of around 1.5 h (equals a growth 
rate of 0.46 h-1). Enrichment of the minimal medium with glucose, as predicted by the GEM 
and shown in vitro, increases the growth rate 1.5 fold, from ~0.08 h-1 on GlcNAc only to 
~0.12 h-1 on GlcNAc with the addition of glucose. We expect that the development of this 
medium paved the road for future physiological studies of A. muciniphila and its application 
as therapeutic microbe. 
Combining the GEM with the minimal medium would allow the prediction and verification 
of physiological properties and phenotypes of A. muciniphila. This includes the production 
of γ-aminobutyric acid (GABA) and the reaction to oxygen as discussed below, but also 
predictions on interspecies interactions. It was shown that A. muciniphila is a keystone 
species in gut microbiota composition (Arumugam, et al., 2011, Shetty, et al., 2017). This 
data can be used to determine the co-occurrence of this species with other bacterial species 
(Shetty, et al., 2017). A function we expect to find in species correlated with the presence of 
A. muciniphila is sulphate reduction. This is expected because of the presence of a dozen 
sulfatase genes in the genome of A. muciniphila (van Passel, et al., 2011), the described 
sulfatase activity in the supernatant (Derrien, et al., 2004), and presence of sulfate on mucins 
(Johansson, et al., 2011). The release of sulfate by A. muciniphila could be used by sulfate-
reducing bacteria (SRB), such as Desulfovibrio piger to produce hydrogen sulfide. Hydrogen 
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sulfide is a mediator in the gut-brain axis (Schicho, et al., 2006). Finally, it could be possible 
for A. muciniphila to use the hydrogen sulfide to produce cysteine, which in turn is used to 
reduce oxygen. Even though we were not able to prove this hypothesis in vitro, such 
interactions are common in the gut, and are an important contributor to the microbiota 
composition. 
The capacity of A. muciniphila to utilize mucus-derived components and its physiological 
characteristics are indicative of a high degree of adaptation of this microbe to the mucosal 
environment. The oxygen respiration (discussed below) and the use of GlcNAc in anabolism 
and catabolism results in the efficient use of available compounds. There are more microbes 
that show mucolytic capabilities, such as Bacteroides fragilis. This anaerobic bacterium is 
also able to reduce oxygen (Baughn and Malamy, 2004), and can degrade mucus, but is not 
associated to health in the same way as A. muciniphila. Like A. muciniphila, B. fragilis is 
also able to remove sialic acid residues from human derived polysaccharides (Godoy, et al., 
1993). However, B. fragilis was found to be associated with the onset of colorectal cancer in 
rats and with colorectal cancer development in human (Boleij, et al., 2015, Wu, et al., 2009).
From all Bacteroides species, B. fragilis is most commonly associated with adverse effects 
(Wexler, 2007). The outcome of competition in the mucus layer between species can be 
determined by differences in the composition of the mucus layer (Li, et al., 2015). Imposing 
the conditions found the in mucus layer on GEMs of mucolytic bacteria could be used to 
predict the outcome of the competition, and ultimately interventions to steer the bacterial 
composition and diversity of the mucus layer. 
Growing A. muciniphila for therapeutic applications 
The anaerobic preparations of A. muciniphila used for the first mouse trials have been 
described recently (Ouwerkerk, et al., 2017). Further development of the medium and growth 
conditions for A. muciniphila building on an improved GEM for clinical trials is discussed in 
chapter 4 of this thesis. The minimal medium was supplemented with soy peptone and 
glucose to increase the growth yield and growth rate. During the medium development, we 
also investigated the growth on casein digests. We found that the addition of a tryptic digest 
of casein yield the highest growth rate. As discussed above, the growth rate of A. muciniphila
on non-mucus medium could be improved by enriching the medium. This was indeed the 
case after the addition of more complex nitrogen sources. The growth rate on medium 
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supplemented with soy or casein protein digests reaches the same rate as on mucus medium, 
~0.3-0.8 h-1, depending on the type of peptide and sugars present in the medium. 
The good growth of A. muciniphila on glucose with high concentrations of only tryptone, as 
described previously (Ottman, et al., 2017a) could be due to the presence of glycosylated 
casein fractions that may serve as a glycan substrates for growth. These casein glycans 
contain, like mucosal glycans, different sugar residues, including GalNAc, mannose and 
galactose in mucin (Johansson, et al., 2011) and galactose and GalNAc in kappa-casein 
(Neelima, et al., 2013) and GlcNAc, GalNAc, galactose, fucose and mannose in lactoferrin 
(O'Riordan, et al., 2014). The increased yield and growth rate on casein-derived tryptone can 
be explained by the presence of these glycans. Combined with the knowledge about growth 
on different sugars described in chapter 3 and in previous studies (Derrien, et al., 2004, 
Ottman, et al., 2017a), we hypothesise that the addition of different types of monosaccharides 
can further increase growth rate and yield. These sugars could include fucose and galactose 
besides the already used glucose, GlcNAc and GalNAc. 
The comparison of growth rate and yield between mucus medium, tryptone medium and soy 
medium is complicated by the changes in morphology of the bacteria and the opacity of 
mucus medium. Due to the elongated cell morphology in especially soy medium, the relation 
between cell number and optical density changes. In general, larger cell scatter more light 
increasing the optical density and thereby increasing the perceived growth rate of the soy 
medium (Volkmer and Heinemann, 2011). The suspension of mucus in medium invokes a 
starting optical density (OD600) of around 0.7, while the other medium types generally not 
exceed an OD600 of 0.1. Therefore, the measurement of the net increase of OD600 for mucus 
medium might underestimate the actual growth yield and rate. This is then caused by the 
supposed degradation of mucus. To determine the real increase of cell density, quantitative 
PCR or determination of CFUs could be applied. 
We showed that the changes in growth medium have no significant effect on therapeutic 
efficacy in mice. The expression profile of genes involved in cell shape and division 
suggested that the cells were not dividing normally, which could result in cell death, as 
discussed in chapter 4. Impaired growth of the bacteria could have an influence on the 
colonisation properties of the bacteria, resulting in reduced long-term effects. These effects 
are not incorporated in the study design, because mice are sacrificed at the end of the trial, 
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and supplemented with bacteria each day during the trial. Therefore, long-term effect studies 
are required for optimal use of A. muciniphila potential. The growth medium would need to 
be adjusted to decrease cell size if the therapeutic potential is impaired indeed. This could be 
done by studying the influence of different sugar compositions in the medium, to mimic the 
glycan composition of mucin. It remains to be established how the changed cellular 
morphology affects the metabolic impact and colonization capacity of A. muciniphila in mice 
or human.
A. muciniphila oxygen reduction capacities
The niche adaptation of A. muciniphila is not only manifested in the GlcNAc-mediated mucin 
dependency, but also in the oxygen tolerance of A. muciniphila, as discussed in chapter 5. 
While initially A. muciniphila has been described as a strict anaerobe, we observed that this 
bacterium is capable of reducing low amounts of oxygen and use it for respiration. The 
mechanism that is employed by A. muciniphila to reduce oxygen resembles the mechanism 
used by E. coli at low oxygen tensions (Belevich, et al., 2005). It uses cytochrome bd to 
mediate the transfer of electrons to oxygen, and also utilizes oxygen detoxification systems, 
such as catalase and oxygen dismutase to reduce excess of oxygen and other reactive oxygen 
species (ROS). The need for heme as a cofactor for respiratory growth was only found after 
the growth on mucus-free medium to which haemin was added, which shows the importance 
of the development of defined media for the study of bacterial physiology. The knowledge 
on oxygen resistance has been used in the preparation of bacteria for intervention studies. We 
found that the reduction of viability was not significant in the first 24 hours of exposure to 
ambient oxygen pressure, and therefore the collection and formulation of the bacteria did not 
require strictly anaerobic conditions to maintain a high viability.  
The discovery of oxygen reduction and respiration redefines A. muciniphila not to be strict 
anaerobic bacterium. However, A. muciniphila does also not fit in the category of facultative 
aerobic bacteria, because it cannot tolerate ambient oxygen levels. A. muciniphila is also not 
an microaerophilic bacterium, because that would hold that a dissolved oxygen concentration 
below 2-10% is a prerequisite for growth (Willey, 2008). This is not the case with A. 
muciniphila. The growth of A. muciniphila is not impaired in the absence of oxygen. 
Therefore, we would like to classify A. muciniphila as a facultative microaerophilic 
bacterium. 
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Oxygen resistance or reduction by cytochromes is a widespread trait among probiotics and 
gut bacteria. In the genus of Bifidobacteria, there is a wide distribution in oxygen sensitivity. 
B. adolescentis had no observed viability after 48 hours exposure to oxygen in ambient air, 
while 91% of B. bifidum cells survived the exposure (Andriantsoanirina, et al., 2013). Oxygen 
reduction in a range of lactic acid bacteria has been found to involve a heme-containing 
cytochrome bd complex and menaquinones (Brooijmans, et al., 2009). The mucus-degrading 
Bacteroides fragilis also employs a cytochrome bd containing electron transport chain very 
similar to A. muciniphila, which also is likely to utilize quinones (Baughn and Malamy, 
2004). Also other presumed strictly anaerobic gut bacteria show some mechanism of oxygen 
resistance or reduction. For example, an external electron shuttle has described to be used by 
F. prausnitzii to reduce oxygen (Khan, et al., 2012).
The oxygen concentrations in the gut show a steep decrease starting at the epithelial barrier 
towards the centre of the gut (Albenberg, et al., 2014, Espey, 2013). This oxygen gradient is 
important in shaping the gut microbiota, but is not constant over time (Espey, 2013). The 
presence of oxygen and reactive oxygen species (ROS) in the gut is also influenced by gut 
health. Upon damage or inflammation of the epithelial cells, more ROS and oxygen diffuse 
into the gut, and the production of ROS increases upon the entry of polymorphonuclear 
neutrophils (PMNs) on the inflamed site (Mittal, et al., 2014). Loss of gut barrier function 
also inhibits the secretion of mucus, reducing the nutrient availability for A. muciniphila.
Distortion of the gut ecosystem by inflammation results in changes of the microbiota 
composition (Boulange, et al., 2016, Ijssennagger, et al., 2015, Turner, 2009), which might 
explain widespread correlations found between colonic inflammations and gut microbiota. 
Characterization of cultured microbiota in terms of oxygen tolerance is therefore important 
to understand the influence of the host on the microbiota composition and vice versa. 
Many of the characterized gut bacteria show some adaptation to the presence of oxygen. It is 
generally assumed that the anaerobic bacteria account for over 90% of the microbiota 
(Eckburg, et al., 2005, Maier, et al., 2014). The presence of oxygen in the host and the leakage 
of oxygen into the gut (Figure 2), and its isolation from other anaerobic ecosystems, make it 
favourable for bacteria to have some degree of oxygen tolerance to survive and colonize this 
ecosystem. 
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Figure 2. Overview of the niche of A. muciniphila (green ovals). Upon inflammation, increased amounts of oxygen 
and ROS enter the gut from the blood stream. This inhibits the growth of oxygen sensitive bacteria, and changes the 
bacterial composition, allowing pathogens to enter the blood stream (purple). Polymorphonuclear neutrophils 
(PMNs) produce more ROS to counter infection. Oxygen concentrations as percentage of saturation after (Espey, 
2013).
The first steps in genetic modification of A. muciniphila 
The need for detailed physiological studies of intestinal bacteria in general and A. muciniphila
in specific has been well recognized. To study the physiology and its impact on molecular 
mechanisms, it is helpful to be able to modify the genetic content. In studying A. muciniphila-
host interactions, deletion or overexpression of the Amuc_1100 gene would provide final 
proof of its signalling function (Ottman, et al., 2017b, Plovier, et al., 2017), and deletion of 
the cytochrome bd subunits should yield an oxygen sensitive strain. Mucus utilization could 
be studied by deleting the glycosidases and sulfatases, and growth of A. muciniphila on 
glucose could be achieved by expressing a functional GlmS gene. This gene is missing in the 
synthesis pathway of GlcN6P, as discussed above.
Hence, we have studied the options to make A. muciniphila genetically accessible. Firstly, 
we utilized random transposon insertion, as described previously for the species 
Verrucromicrobium spinosum (Domman, et al., 2011). The use of this technique relied on 
the simultaneous transformation of a genetic element, the transposon, with the required 
protein to insert the genetic element, the transposase. This method did not yield any modified 
colonies of A. muciniphila.
The challenges in developing a genetic toolbox for A. muciniphila are numerous. Firstly, the 
limited amount of applicable antibiotics is limited due to the resistance of A. muciniphila. 
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Secondly, it was a challenge to determine whether the applied transformation protocols 
would allow the translocation of DNA over the cell membrane. Thirdly, after successful 
translocation of DNA, it is unknown whether the plasmid is replicated inside the cell. 
We investigated the availability of antibiotics for transformation to be able to use selection 
markers. The selected markers used in the experiments should invoke resistance against 
tetracycline and chloramphenicol, used at 10 µg/mL and 25 µg/mL respectively. These 
antibiotic concentrations in agar fully inhibited growth of A. muciniphila, in contrast to what 
was described before, possibly due to application of the antibiotics inside the agar instead of 
diffusion from a strip on top of the agar plates. (Ouwerkerk, 2016). The promoters used for 
these antibiotic resistance genes are optimized for use in E. coli, so they might not confer 
resistance to A. muciniphila. To determine the translocation of DNA over the cell membrane, 
we transformed fluorescently labelled plasmids and traced these plasmids upon 
transformation by electroporation (see Figure 3). The technique showed the successful 
translocation of plasmid DNA into the cell. Hence, the first two of the three above-mentioned 
problems were addressed, which will help in the further development of a genetic system. 
The lack of knowledge on plasmid replication could be solved by gene insertion into the 
genome by homologous recombination.  
Recombination of DNA can be inhibited by the degradation of DNA upon entry in the cell. 
A. muciniphila codes for several restriction modification systems that are able to degrade 
foreign DNA (van Passel, et al., 2011). Additionally, A. muciniphila encodes a CRISPR-Cas 
system, which could be employed for genetic modification (Selle and Barrangou, 2015), but 
also degrades the DNA upon entry into the cell when the right spacer sequence is present in 
the translocated DNA. Characterisation of the protospacer adjacent motif would be required 
for the prevention of DNA degradation or utilization of the system for genetic modification 
(Jiang, et al., 2013).
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Figure 3. Image of labelled plasmids in A. muciniphila traced after electroporation. The bacteria were visualised 
(left) after which the location of fluorescence was determined (middle) and tracked over time (right). (Image 
obtained in collaboration with Jan Groen, Sharon Geerlings and Marnix Vlot, Microbiology, Wageningen University 
and Research, 2017).
Alternatively, we approached the issue from the ecological perspective. We assumed that A. 
muciniphila, like other bacteria, can be infected by bacteriophages. In fact, the A. muciniphila
genome contains several prophages or remnants thereof, indicating the presence of 
bacteriophages in this gut symbiont. Such bacteriophages, by definition, are able to transfer 
their genetic content, either DNA or RNA, into the bacterial cell. By using the inherent 
infecting capabilities of bacteriophages, it would be possible to modify the genetic content 
of A. muciniphila. The isolated bacteriophage should be sequenced and characterized to 
identify possible functions such as integrases to develop possible vectors for transformation 
or transfection (Oram, et al., 2007). Subsequent modification of the phage DNA could lead 
to specific knock-ins or recombinant deletions from the A. muciniphila genome. A 
prerequisite for using the phage for genetic engineering, is the presence of an in vitro 
packaging system or a second host, which is genetically accessible. The bacteriophage DNA 
can be adjusted and used to transform the second host, after which the second host can 
produce new phage particle. These particles could be used to modify the A. muciniphila 
genome.  
To obtain bacteriophages, we filtered faecal samples that were previously shown to have a 
high relative abundance of A. muciniphila, because a high relative abundance increases the 
chance of the presence of a bacteriophage for the target species (Manrique, et al., 2017, 
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Weinbauer, 2004). Subsequent plaque assays and enrichment of potential bacteriophage in 
liquid medium resulted in the discovery of a potential bacteriophage for A. muciniphila,
which was only observed using electron microscopy, see Figure 4.
Figure 4. Electronmicrographs of potential bacteriophages isolated from faecal samples and enriched in A. 
muciniphila cultures. A single phage-like particle with 100 nm scale (left) and a phage-like particle attached to an 
A. muciniphila cell with 1 µm scale (right). (Image obtained in collaboration with Sharon Geerlings and Yifan Zhu, 
Microbiology, Wageningen University and Research, 2017). 
Potential health-promoting functions of A. muciniphila
Different modes of interaction between A. muciniphila and the host have been described. A. 
muciniphila produces the SCFA acetate and propionate (Derrien, et al., 2004). These 
compounds are known to fuel enterocytes and are involved in immune and metabolic 
signalling (Andoh, 2016). Propionate is known to increase the gut transit speed, while acetate 
decreases this (Kolmeder and de Vos, 2017). Propionate also decreases satiety (Kolmeder 
and de Vos, 2017). As described in chapters 3, 4 and 5 of this thesis, the ratio between acetate 
and propionate is influenced by the sugars present in the medium, the addition of oxygen and 
the presence of vitamin B12. An increase of glucose in the medium also increases the 
production of propionate. The presence of oxygen also increases the production of 
propionate. The reduction of oxygen also decreases the toxicity of this compound for other 
bacteria and increases fermentative conditions, which could lead to butyrate production. 
The production of SCFA is the result of mucin degradation. It is expected that the degradation 
of mucin by A. muciniphila would decrease the thickness of the mucus layer. This layer forms 
a barrier between the colonic content and the host and thereby prevents infections (Hansson, 
2012). However, the presence of A. muciniphila was found to be associated with an increased 
7Chapter 7. 
212
Figure 3. Image of labelled plasmids in A. muciniphila traced after electroporation. The bacteria were visualised 
(left) after which the location of fluorescence was determined (middle) and tracked over time (right). (Image 
obtained in collaboration with Jan Groen, Sharon Geerlings and Marnix Vlot, Microbiology, Wageningen University 
and Research, 2017).
Alternatively, we approached the issue from the ecological perspective. We assumed that A. 
muciniphila, like other bacteria, can be infected by bacteriophages. In fact, the A. muciniphila
genome contains several prophages or remnants thereof, indicating the presence of 
bacteriophages in this gut symbiont. Such bacteriophages, by definition, are able to transfer 
their genetic content, either DNA or RNA, into the bacterial cell. By using the inherent 
infecting capabilities of bacteriophages, it would be possible to modify the genetic content 
of A. muciniphila. The isolated bacteriophage should be sequenced and characterized to 
identify possible functions such as integrases to develop possible vectors for transformation 
or transfection (Oram, et al., 2007). Subsequent modification of the phage DNA could lead 
to specific knock-ins or recombinant deletions from the A. muciniphila genome. A 
prerequisite for using the phage for genetic engineering, is the presence of an in vitro 
packaging system or a second host, which is genetically accessible. The bacteriophage DNA 
can be adjusted and used to transform the second host, after which the second host can 
produce new phage particle. These particles could be used to modify the A. muciniphila 
genome.  
To obtain bacteriophages, we filtered faecal samples that were previously shown to have a 
high relative abundance of A. muciniphila, because a high relative abundance increases the 
chance of the presence of a bacteriophage for the target species (Manrique, et al., 2017, 
                                                                           General Discussion
213
Weinbauer, 2004). Subsequent plaque assays and enrichment of potential bacteriophage in 
liquid medium resulted in the discovery of a potential bacteriophage for A. muciniphila,
which was only observed using electron microscopy, see Figure 4.
Figure 4. Electronmicrographs of potential bacteriophages isolated from faecal samples and enriched in A. 
muciniphila cultures. A single phage-like particle with 100 nm scale (left) and a phage-like particle attached to an 
A. muciniphila cell with 1 µm scale (right). (Image obtained in collaboration with Sharon Geerlings and Yifan Zhu, 
Microbiology, Wageningen University and Research, 2017). 
Potential health-promoting functions of A. muciniphila
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signalling (Andoh, 2016). Propionate is known to increase the gut transit speed, while acetate 
decreases this (Kolmeder and de Vos, 2017). Propionate also decreases satiety (Kolmeder 
and de Vos, 2017). As described in chapters 3, 4 and 5 of this thesis, the ratio between acetate 
and propionate is influenced by the sugars present in the medium, the addition of oxygen and 
the presence of vitamin B12. An increase of glucose in the medium also increases the 
production of propionate. The presence of oxygen also increases the production of 
propionate. The reduction of oxygen also decreases the toxicity of this compound for other 
bacteria and increases fermentative conditions, which could lead to butyrate production. 
The production of SCFA is the result of mucin degradation. It is expected that the degradation 
of mucin by A. muciniphila would decrease the thickness of the mucus layer. This layer forms 
a barrier between the colonic content and the host and thereby prevents infections (Hansson, 
2012). However, the presence of A. muciniphila was found to be associated with an increased 
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thickness of the mucus layer (Everard, et al., 2013), and possibly increase the gut barrier 
function (Reunanen, et al., 2015, Schneeberger, et al., 2015). This could be caused by the 
increase of mucin-producing goblet cells upon administration of A. muciniphila (Shin, et al., 
2014).
The direct interaction of A. muciniphila with the host is not only mediated by secreted 
compounds, but also by an immunomodulation protein. This protein was identified to be 
Amuc_1100*, a pili-like protein that induces a the NF-κB pathway via the induction of TLR-
2 and TLR-4 signalling in vitro (Ottman, et al., 2017b). The efficacy of this protein was 
confirmed in an intervention study in mice. The protein showed to have a similar effect as 
the administration of viable or pasteurized A. muciniphila (Plovier, et al., 2017). In addition 
to the interpretations and predictions of the GEM described in this thesis and the above 
described interactions, some other observations can be made regarding the possible 
functionality of A. muciniphila. Recent observations considering the gut-brain axis indicate 
that the compound γ-aminobutyric acid (GABA) is an important signalling molecule in this 
trans-host connection (Dinan, et al., 2013). In humans, GABA is an inhibitory 
neurotransmitter, which presence has influence on epileptic episodes (Petroff, 2002), anxiety 
and depression (Dinan, et al., 2013, Schousboe and Waagepetersen, 2007). The effect of 
GABA is counteracted by glutamate from which it is synthesized (Petroff, 2002). The 
bacterial GABA synthesis pathway is used for deacidification of the cytosol (Feehily and 
Karatzas, 2013). In this pathway, glutamate is converted to GABA by glutamate 
decarboxylase (GAD) with pyridoxal-5’-phosphate (PLP) as cofactor (Dhakal, et al., 2012).
In this reaction, a proton is bound to glutamate and exported over the cell membrane with 
GABA, see Figure 5 (Dhakal, et al., 2012). The genes in this pathway are also annotated in 
the genome of A. muciniphila, including the required transporter and glutamate 
decarboxylase encoded by genes on locus amuc_0037 and amuc_0372, respectively. GABA 
production by A. muciniphila has not yet been shown in vitro but could be tested by the 
addition of glutamate and PLP to the minimal medium. Interestingly, correlations have been 
shown between A. muciniphila abundance, anxiety and GABA receptor upregulation in mice 
(Burokas, et al., 2017).
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Figure 5. Overview of the GABA production pathway. Dashed lines indicate cell membrane. The enzyme glutamate 
decarbocylase (GAD) is indicated between [ ], cofactor pyridoxal-5’-phosphate (PLP) is indicated between ( ).
For the host, GABA has a completely different function, as it can be detected by specific 
GABA receptors. It functions as a neurotransmitter and relieves anxiety. Combining the 
potential GABA production by A. muciniphila, an increased relative abundance in mice that
have a reduced anxiety upon addition of GOS/FOS, with increased expression of GABA 
receptors in mice, it could be speculated that A. muciniphila is one of the undiscovered 
psychobiotics (Dinan, et al., 2013).
Administration of viable A. muciniphila
In chapter 6 we described the application of a double emulsion system for the viable delivery 
of A. muciniphila to the small intestine. We used an in vitro digestive model simulating the 
stomach and first part of the small intestine with the addition of bile. In this system, we 
showed that A. muciniphila has a significant higher survival rate when encapsulated in a 
double emulsion than the control of non-encapsulated bacteria in PBS. A challenge in 
encapsulating bacteria is the available space for bacteria in the inner water phase. As shown 
in chapter 6, the size of A. muciniphila varies in the different media that were used. Therefore, 
we used a medium based on a tryptic digest of casein for the cultivation of bacteria for 
encapsulation, instead of the clinical applicable soy medium. The casein medium showed 
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smaller cells compared to soy medium, which allowed encapsulation in the inner water 
droplets that have an average size of 5 µm. The decrease of viability during simulated 
digestion with the encapsulation in a double emulsion is about 100-fold. This could be 
improved by enhancing the buffer capacity of the inner water phase to increase the protection 
against the acid in the stomach. Additionally, a boost can be given to the bacteria upon release 
by co-encapsulating nutrients that are required for growth. This could be a cocktail of 
mucosal sugars, especially including GlcNAc. The supplementation of nutrients could also 
be achieved by incorporating glycoproteins in the emulsification process, although that might
influence the stability of the emulsion itself. For enhanced protection during formulation and 
gastric passage, it might be beneficial to add cysteine as antioxidant in the encapsulation 
procedure as previously employed for F. prausnitzii (Khan, et al., 2014).
The importance of viable delivery of A. muciniphila is debatable, because pasteurized cells 
and A. muciniphila protein Amuc_1100* have a similar effect in preclinical mouse trials 
(Plovier, et al., 2017). All treatments reduced the effect of a high fat diet on the metabolism 
of the mice, including fat mass gain and weight gain. The application of the bacteria, both 
viable and pasteurized, and purified proteins in this preclinical trial was done by gavage. This 
implies that the applied treatments were not exposed to saliva and the full volume of the 
treatment is added to the stomach at once, possibly resulting in a lower acidity. The exposure 
to bile is also different in mice compared to humans. Therefore, it might be worthwhile 
investigating also the delivery of pasteurized cells and proteins encapsulated in a double 
emulsion. The low acidity in the stomach can have a destabilizing influence on the protein 
Amuc_1100*. Additionally, it is vulnerable for degradation by active proteases and 
peptidases, which are secreted throughout the GI tract (Antalis, et al., 2007). When the 
efficacy of protein Amuc_1100*, viable bacteria and pasteurized bacteria in mice was tested, 
the above discussed similar results were obtained for the mediation of diet induced obesity 
and associated biomarkers and gut barrier function. However, longitudinal effects and effects 
on other non-metabolic diseases were not tested. Also the long-term effect of A. muciniphila
colonisation by live bacteria was not studied, although persistent strain colonisation after 
FMT or probiotic ingestion is not always shown and differs between studies (Li, et al., 2016, 
Segers and Lebeer, 2014). A combination of A. muciniphila strains might increase the 
colonization efficiency and therapeutic efficacy, as was also described for various probiotics 
(Timmerman, et al., 2004).
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The mode and matrix for administration have influence on the functionality of probiotics 
(Ranadheera, et al., 2010). In the presented research, we only studied the application of a 
single type of double emulsion system based on sunflower oil. Alternative encapsulation 
methods have been applied for probiotic lactic acid bacteria, as briefly discussed in chapter
6. Many other administration matrices can be considered, such as ingestion of lyophilized 
bacteria, frozen bacteria in glycerol or formulation in food products. The two most important 
challenges in encapsulating probiotics are the shear imposed during processing, and 
upscaling of the process itself. Besides emulsification, there is one other technique which has 
been employed for the encapsulation of probiotics and that lives up to both challenges, which 
is extrusion (Solanki, et al., 2013). For this purpose, mainly alginate is used to form the 
extruded particles containing bacteria. This technique could be tested for A. muciniphila as 
well, but it is not possible to predict to what extent it will protect this bacterium and what the 
influence of the final product will be. A possible drawback of using extrusion is the sensory 
mouthfeel if the product particles exceed 100 µm and the low cfu/g material (Iravani, et al., 
2015, Kailasapathy, 2009, Khosravi Zanjani, et al., 2014). In the end, A. muciniphila should
also taste good. 
Bile resistance of A. muciniphila
In the chapter 6 on the delivery in a double emulsion system, we found that A. muciniphila
viability increased with the incubation in porcine bile extract. The viability of non-
encapsulated bacteria increased during the incubation in the intestinal phase, where bile is 
present. We further investigated the bile resistance of A. muciniphila, and found that the 
resistance on the used porcine bile extract is not replicated for ox bile or purified bile salts 
(Figure 6). For porcine bile, there was no inhibition found with the addition of 1% (w/v). 
Both ox bile and purified bile salts show inhibition with the addition of 0.5% (w/v). This can 
be caused by the differences in extraction methods, purification and composition of the bile 
extract used. 
The used bile salts (Sigma, Bile salts for Microbiology) are a mixture of purified cholic acid 
sodium salt and deoxycholic sodium salt (Noriega, et al., 2004). The Ox-bile (Sigma, Ox bile, 
dehydrated, purified for microbiology) used in the experiment is a dehydrated form of bile, 
therefore also containing more impurities. The porcine bile extract (Sigma, Bile extract 
porcine) is suggested to be used for the determination of bile acid resistance by the 
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manufacturer. The differences of composition between bovine and porcine bile have been 
described to be mainly in the hydroxylation of the glycine conjugates and tauro conjugates 
(Coleman, et al., 1979).
Figure 6. Growth of A. muciniphila grown in soy medium with the addition of porcine bile extract, ox bile extract 
or purified bile salts at 0%, 0.1%, 0.5% and 2% (w/v). Data shown are averages of duplicates. Symbols in legend 
account for all bile types. 
The mechanism of protection against bile is not known for A. muciniphila. A putative bile 
acid transporter gene is annotated in the genome on locus Amuc_0139, and if expressed could 
be involved in export of bile acid, thereby reducing the effects inside the cell, but not on the 
cell wall. Alternatively, an external polysaccharide layer could protect against the effect of 
bile, as previously described in Lactobacillus and Bifidobacterium (Fanning, et al., 2012, 
Ruiz, et al., 2013).
Conclusion and future expectations for applications of A. muciniphila 
In this thesis we have shown that A. muciniphila can be cultivated for human applications. 
We have also improved the GEM of this microbe and found that L-threonine and either 
GlcNAc or GalNAc are essential ingredients for growth, which can be applied in medical 
applications. We have shown that A. muciniphila is a facultative microaerophilic bacterium 
that can use oxygen as electron acceptor. Finally, we have ensured that it can be applied in a 
double emulsion to improve viable delivery to the gut. 
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Mouse intervention and human correlation studies have resulted in the hypothesis that A. 
muciniphila could have a positive effect on human health. The mechanism by which A. 
muciniphila confers it beneficial properties are described to vary from immunomodulation 
by Amuc_1100* (Ottman, et al., 2017b, Plovier, et al., 2017), the production of SCFA (Belzer 
and de Vos, 2012, Ottman, et al., 2017a) and maybe GABA production as hypothesized 
above. The genome of A. muciniphila also contains over 600 genes with unknown function. 
Each of these genes could represent a possible mediator between humans and A. muciniphila.
If the modification of the genome becomes possible, it could be possible to make a random 
transposon library (van Opijnen and Camilli, 2013). This library can be used for intervention
study for in vivo study of functional genes.  
Besides applying bacteria, or parts of it, the abundance of A. muciniphila could also be 
increased in the host by food additives. The addition of a GOS/FOS mixture to mice has 
shown to increase the relative abundance of A. muciniphila in mice (Burokas, et al., 2017).
For the growth of A. muciniphila in humans, it could be helpful to identify additional food 
additives that increase the abundance, on top of previously described polyphenols and 
capsaicin (Baboota, et al., 2014, Roopchand, et al., 2015). These additives should be 
indigestible fibres that contain GlcNAc residues, which may be combined with glutamate 
and PLP for GABA production. 
Before GABA production can be induced in vivo, it should be produced in vitro. Using the 
minimal medium developed for A. muciniphila will prove to be critical in this study and in 
further elucidating the physiology of A. muciniphila. 
The final challenges in applying A. muciniphila as therapeutic agent are correct dosing, 
population wide application and long term safety. The research described in this thesis, 
especially the development of suitable growth media, has made these type of clinical studies 
possible. If A. muciniphila is the therapeutic microbe it promises to be, we expect to receive 
confirmation soon as a human trial is ongoing (Plovier et al., 2017; see clinicaltrials.gov).
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Summary
In chapter 1 of this thesis, we provide background knowledge about the gut microbiota in 
general and A. muciniphila specifically. The gut harbors a complex ecosystem in which many 
bacteria, both beneficial and pathogens, thrive. These bacteria have a profound influence on 
host health, but their presence is in turn influenced by the host. Factors that influence 
microbial composition are diet, host health, age, gender, and environment in general. The 
mucosal niche that A. muciniphila lives in is characterized by its close proximity to the host 
epithelial cells. The mucus secreted by the host cells can serve as the sole carbon and nitrogen 
source for this bacterium. The potential importance of A. muciniphila as a member of the
intestinal microbiota comes from the fact that A. muciniphila is reversely correlated with 
several diseases and reduce the fat mass gain of mice fed a high fat diet. 
In chapter 2 we describe the use of genome-scale metabolic models to further understand the 
genetic and metabolic potential of microbiota members, as well as potential phenotypes and 
influence on the host. We emphasize the importance of culturing bacteria and provide an 
outline in which GEMs are used to aid in the development of minimal culture media. GEMs 
have been instrumental in the development of minimal media for microbiota members 
including Faecalibacterium prausnitzii and probiotic lactic acid bacteria. When it is possible 
to grow bacteria in pure cultures, it is also possible to study the phenotype of these bacteria. 
GEMs can be used to predict the phenotypes of bacteria under changing conditions. This 
includes the interaction with other bacteria, which makes it possible to make multispecies 
models. The construction and interpretation of these models is complicated, but not 
impossible. Multispecies GEMs have been successfully employed to predict the influence of 
diet on the host and of complex bacterial communities on the health of the host. 
The use of GEMs for the development of minimal media was applied in chapter 3. The 
minimal medium described in this chapter was developed based on a previously defined 
GEM. We found that the essential components of A. muciniphila medium are L-threonine 
and either N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc). The GEM 
accurately predicted the essentiality of L-threonine for A. muciniphila growth. However, it 
did not predict the essentiality of GlcNAc or GalNAc. We found that the enzyme mediating 
the reaction between fructose-6-phosphate and glucosamine-6-phostphate, an important first 
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to grow bacteria in pure cultures, it is also possible to study the phenotype of these bacteria. 
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models. The construction and interpretation of these models is complicated, but not 
impossible. Multispecies GEMs have been successfully employed to predict the influence of 
diet on the host and of complex bacterial communities on the health of the host. 
The use of GEMs for the development of minimal media was applied in chapter 3. The 
minimal medium described in this chapter was developed based on a previously defined 
GEM. We found that the essential components of A. muciniphila medium are L-threonine 
and either N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc). The GEM 
accurately predicted the essentiality of L-threonine for A. muciniphila growth. However, it 
did not predict the essentiality of GlcNAc or GalNAc. We found that the enzyme mediating 
the reaction between fructose-6-phosphate and glucosamine-6-phostphate, an important first 
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step in peptidoglycan formation. The enzyme annotated for this function, NagB, was 
characterized and found to prefer the deaminating reaction. This finding was incorporated in 
the GEM, which resulted in the correct prediction of GlcNAc essentiality as well. 
The composition of the minimal medium was used to develop an animal component free 
medium as described in chapter 4. The addition of soy derived peptides increased the growth 
rate an yield, and the omission of animal components makes the cultured bacteria applicable 
in humans. We observed morphology changes upon cultivation with soy peptides with light 
and scanning electron microscopy. The cells were significantly longer when compared to the 
mucus grown. To identify changes of A. muciniphila cultured on soy enriched medium 
compared to mucus medium, we applied transcriptome analysis. We found that there were 
changes in the expression of genes involved in the determination of cell shape and cell 
division, including the rod shape determining protein MreB. Upregulation of this gene is 
generally associated with cell elongation. We also analyzed the expression of the gene 
Amuc_1100, which was found to be involved in host signaling previously. There was no 
significant alteration in the expression of this genes, or genes in the associated gene cluster. 
To confirm the applicability of the soy medium to grow A. muciniphila for medical 
applications, we applied both mucus medium grown and soy medium grown bacteria in a
preclinical mouse trial. We found no significant differences in the efficacy of both groups on 
the fat mass gain and general weight gain of mice fed a high fat diet. 
In chapter 5 we zoom in on the oxygen tolerance of the anaerobic bacterium A. muciniphila.
We discovered that A. muciniphila is able to tolerate ambient air for 24 hours. Subsequently, 
we investigated influence of small amounts of oxygen on A. muciniphila growth. The 
addition of oxygen increased the growth rate and yield, with small changes in the 
acetate:propionate ratio. This indicated that the oxygen was used as electron acceptor. By 
using transcriptome analysis we identified a candidate cytochrome bd, which could mediate 
respiration with oxygen as electron acceptor. We expressed the two subunits of this 
cytochrome in the cytochrome deficient Escherichia coli ECOM4. The metabolism of this 
transgenic E. coli ECOM4-Cytbd was changed, resembling the native metabolism of E. coli. 
Finally, we proved that the oxygen reduction was at least partly heme dependent. With the 
addition and omission of heme in a heme deprived synthetic medium, we observed the partial 
loss of oxygen reduction capacity. 
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In chapter 6 of this thesis, we describe a method for protecting A. muciniphila during 
ingestion. We encapsulated the cell in a water in oil in water double emulsion. We determined 
the changes of the emulsion during simulated digestion tests. The emulsion coagulated into 
large oil droplets in the low pH phase simulating the stomach. During coagulation, the cell 
remained entrapped inside the emulsion. Upon entry of the intestinal phase with the presence 
of bile and pancreatic extracts, we observed digestion of the emulsion and release of the 
bacteria. We determined the survival of bacteria encapsulated in the double emulsion and 
compared it with the survival of cells freely dispersed in PBS. We found a 100 fold higher 
survival of the encapsulated cells. We concluded that the double emulsion could be an 
effective matrix for the viable delivery of A. muciniphila.
To conclude this thesis, we discussed all the findings in chapter 7. The application of A. 
muciniphila has been made possible by the development of the media described in this thesis. 
This allows detailed study of this bacterium in vitro and in vivo. The in vivo intervention 
studies are especially important in moving from correlations to causalities and mechanistic 
insight in the microbiome. We also provide a preview of what can be expected in future A. 
muciniphila research. A hypothesis is described for the production of the neurotransmitter γ-
aminobutyric acid (GABA), based on the A. muciniphila GEM. GABA is a potential mediator 
in the gut-brain axis, which is currently being investigated intensely. We show the first steps 
that were taken in the development of a genetic system for A. muciniphila, with the possible 
isolation of a bacteriophage. The final steps required for the application of A. muciniphila as 
therapeutic microbe are described shortly, and are all within reach. 
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Samenvatting
In hoofdstuk 1 van deze thesis wordt de huidige kennis van de darmflora geïntroduceerd, 
gevolgd door de kennis over Akkermansia muciniphila. Het maagdarmstelsel is een complex 
ecosysteem waarin zowel goede als ziekteverwekkende bacteriën leven. Deze bacteriën 
hebben sterke invloed op de gezondheid van de gastheer, die op zijn beurt de samenstelling 
van de bacteriën beïnvloed. Factoren die invloed hebben op de microbiële compositie zijn 
dieet, gezondheid van de gastheer, leeftijd, geslacht, en de omgeving in het algemeen. De 
slijmlaag of mucus laag waar A. muciniphila leeft wordt gekenmerkt door de nabijheid van 
de darmcellen van de gastheer. De mucus dat wordt geproduceerd door de gastheer voorziet 
deze bacterie van zowel koolstof als stikstof. Het potentiele belang van A. muciniphila als 
onderdeel van de darmflora wordt veroorzaakt door de lage aanwezigheid van deze bacterie 
in mensen met verschillende ziektes. Daarnaast worden muizen die met een vetrijk dieet 
minder dik als ze A. muciniphila krijgen toegediend. 
In hoofdstuk twee beschrijven we het gebruik van metabole modellen voor de studie van de 
genetische en metabole potentie van de darmflora soorten en fenotypen die invloed hebben 
op de gastheer. We benadrukken het belang van het groeien van bacteriën en voorzien in een 
kader waarbinnen de modellen gebruikt kunnen worden voor de ontwikkeling van minimale 
groei media. Metabole modellen zijn belangrijk geweest in de ontwikkeling van minimale 
media voor Faecalibacterium prausnitzii, en probiotische melkzuurbacteriën. Als het 
mogelijk is om bacteriën in reincultuur te groeien, is het ook mogelijk de fenotypen in 
verschillende condities te bestuderen. Dit maakt het ook mogelijk de interacties tussen 
soorten te bestuderen, waardoor metabole modellen met meerdere soorten gemaakt kunnen 
worden. Deze complexe modellen hebben succesvol bijgedragen aan het voorspellen van de 
invloed van dieet op de gastheer en op de darmflora.
Het gebruik van metabole modellen voor de ontwikkeling van minimaal groeimedium is 
toegepast in hoofdstuk 3. Het minimale medium dat in dit hoofdstuk beschreven wordt is 
gebaseerd op een bestaand metabool model. We ontdekten dat de suikers n-
acetylglucosamine (GlcNAc) of n-acetylgalactosamine (GalNAc) en het aminozuur L-
threonine de essentiële ingrediënten zijn voor de groei van A. muciniphila. Het metabole 
model voorspelde de noodzaak van L-threonine, maar niet de noodzaak van GlcNAc of 
GalNAc. We ontdekten dat een enzym ontbrak dat de omzetting van fructose-6-fosfaat naar 
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glucosamine-6-fostfaat mogelijk zou maken. Deze omzetting is een belangrijke stap in de 
synthese van peptidoglycaan. Het enige enzym dat deze functie zou kunnen vervullen, NagB, 
bleek een voorkeur te hebben voor de deaminerende richting van de reactie. Deze ontdekking 
was toegevoegd aan het metabole model, wat resulteerde in de correcte voorspelling voor de 
noodzaak van GlcNAc.
De samenstelling van het minimale medium is gebruikt voor de ontwikkeling van een 
groeimedium wat geen dierlijke componenten bevat, zoals beschreven in hoofdstuk 4. De 
toevoeging van soja eiwitten zorgde voor de toename van groei snelheid en opbrengst, en de 
omissie van dierlijke componenten maakt het medium geschikt voor de toepassing in mensen. 
We observeerden veranderingen in de morfologie van de bacteriën met lichtmicroscopie en 
elektronenmicroscopie. De cellen waren significant langer in vergelijking met bacteriën die 
gegroeid waren in mucus medium. Om te achterhalen waardoor deze verandering veroorzaakt 
wordt, hebben we transcriptie analyse toegepast. We ontdekten dat genen die betrokken zijn 
in de bepaling van de bacterie vorm anders tot expressie kwamen. Eén van deze genen was 
de staafvormig bepalend gen MreB. Een hogere expressie van dit gen wordt geassocieerd 
met een langere cel vorm. We hebben ook de expressie van het gen Amuc_1100 
geanalyseerd, omdat dit gen belangrijk is in de communicatie met de gastheer. We ontdekten 
geen significante verschillen in de expressie van dit gen. Om te bevestigen dat het soja 
medium gebruikt kan worden voor medische toepassingen, hebben we de verschillen tussen 
bacteriën gegroeid in mucus medium en soja medium getest in muizen. We hebben geen 
significante verschillen gevonden tussen de muizen in de toename van vetmassa en 
lichaamsgewicht. 
In hoofdstuk 5 beschrijven we de zuurstoftolerantie van de anaerobe bacterie A. muciniphila.
We ontdekten dan A. muciniphila 24 uur lang zuurstof kan tolereren. Daarna onderzochten 
we de invloed van kleine hoeveelheden zuurstof op A. muciniphila groei. De toevoeging van 
zuurstof zorgt voor een toename van groei snelheid en opbrengst, met kleine verschillen in 
de acetaat:propionaat ratio. Dit wijst erop dat zuurstof wordt gebruikt als elektronen acceptor. 
Door gebruikt te maken van transcriptie analyse ontdekten we dat cytochroom bd gebruikt 
kan worden in de respiratie van zuurstof. We brachten de twee onderdelen van cytochroom 
bd tot expressie in Escherichia coli ECOM4. Het metabolisme van transgene E. coli ECOM4-
Cytbd veranderde en leek meer op het originele E. coli metabolisme. Tot slot hebben we 
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bewezen dat de reductie van zuurstof ten minste deels afhankelijk is van haem. Met de 
toevoeging en omissie van haem in een synthetisch medium ontdekte we het gedeeltelijke 
verlies van de capaciteit om zuurstof te reduceren. 
In hoofdstuk 6 van deze thesis beschrijven we een methode om A. muciniphila te beschermen 
tijden ingestie. We verpakten de bacteriën in een water in olie in water dubbele emulsie. We 
bepaalden de veranderingen van de emulsie tijdens een gesimuleerde vertering. De emulsie 
coaguleerde in grotere oliedruppels in de lage pH fase waarin de maag gesimuleerd werd. 
Tijdens deze fase bleven de cellen in de binnenste water fase van de emulsie. Nadat de 
emulsie werd blootgesteld aan gal en alvleesklier extracten, observeerden we de afbraak van 
de emulsie en de vrijlating van de cellen. We bepaalden de overleving van verpakte bacteriën 
in vergelijking met bacteriën in PBS. We ontdekten dat er 100 keer meer van de verpakte 
bacteriën de vertering overleefden. We concluderen dat een dubbele emulsie een effectieve 
matrix kan zijn voor de toepassing van A. muciniphila.
Om deze thesis af te sluiten bespraken we alle ontdekkingen on hoofdstuk 7. De toepassing 
van A. muciniphila is mogelijk gemaakt door de ontwikkeling van de groei media die 
beschreven zijn in deze thesis. Dit maakte het mogelijk deze bacterie in detail te bestuderen, 
zowel in vivo als in vitro. De in vivo interventiestudies zijn van speciaal belang voor de 
bepaling van causaliteit en verkrijgen van mechanistisch inzicht in de darmflora. We 
beschrijven ook wat er verwacht kan worden van onderzoek naar A. muciniphila in de 
toekomst. We hypothetiseren dat de neurotransmitter γ-aminobutyric acid (GABA) 
geproduceerd kan worden door A. muciniphila. GABA speelt een rol in de verbinding tussen 
de darmen en de hersenen, waar tegenwoordig veel onderzoek naar gedaan wordt. We 
beschrijven de eerste stappen die we genomen hebben in de genetische modificatie van A.
muciniphila, met de mogelijke isolatie van een bacteriofaag. De laatste stappen die nog nodig 
zijn voor de toepassing van A. muciniphila zijn kort beschreven, en zouden op korte termijn 
realiseerbaar moeten zijn. 
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